<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004530.pub4" GROUP_ID="INFECTN" ID="843203041723070271" MERGED_FROM="" MODIFIED="2011-10-14 16:11:21 +0100" MODIFIED_BY="Emmanuel Effa" NOTES="&lt;p&gt;&lt;span modified=&quot;2011-06-17 17:05:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;What does complicated mean?? How does this differ from severe?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-10-14 16:11:21 +0100" NOTES_MODIFIED_BY="Emmanuel Effa" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-10-12 21:39:28 +0100" MODIFIED_BY="Emmanuel Effa">
<TITLE MODIFIED="2011-04-14 18:50:56 +0100" MODIFIED_BY="[Empty name]">Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)</TITLE>
<CONTACT>
<PERSON ID="14281" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Zulfiqar</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Bhutta</LAST_NAME>
<SUFFIX/>
<POSITION>Professor and Chair</POSITION>
<EMAIL_1>zulfiqar.bhutta@aku.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Women and Child Health</DEPARTMENT>
<ORGANISATION>Aga Khan University Hospital</ORGANISATION>
<ADDRESS_1>Stadium Road</ADDRESS_1>
<ADDRESS_2>PO Box 3500</ADDRESS_2>
<CITY>Karachi</CITY>
<ZIP>74800</ZIP>
<REGION>Sindh</REGION>
<COUNTRY CODE="PK">Pakistan</COUNTRY>
<PHONE_1>+92 21 3486 4782</PHONE_1>
<PHONE_2/>
<FAX_1>+92 21 3493 4294</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-10-12 21:39:28 +0100" MODIFIED_BY="Emmanuel Effa">
<PERSON ID="6169979C82E26AA2011EF9F6C43FD8A8" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Emmanuel</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Effa</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Registrar</POSITION>
<EMAIL_1>emmanueleffa@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Calabar Teaching Hospital</ORGANISATION>
<ADDRESS_1>PMB 1278</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calabar</CITY>
<ZIP/>
<REGION>Cross River State</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="682E3A2282E26AA201066D885A9F3794" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Zohra</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Lassi</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Instructor - Research</POSITION>
<EMAIL_1>zohra.lassi@aku.edu</EMAIL_1>
<EMAIL_2>zohra.lassi@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Women and Child Health</DEPARTMENT>
<ORGANISATION>Aga Khan University Hospital</ORGANISATION>
<ADDRESS_1>Stadium Road</ADDRESS_1>
<ADDRESS_2>PO Box 3500</ADDRESS_2>
<CITY>Karachi</CITY>
<ZIP>74800</ZIP>
<REGION/>
<COUNTRY CODE="PK">Pakistan</COUNTRY>
<PHONE_1>+92 21 34864981</PHONE_1>
<PHONE_2/>
<FAX_1>+92 21 4934294</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19574" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Critchley</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Epidemiology</POSITION>
<EMAIL_1>J.A.Critchley@newcastle.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Health and Society</DEPARTMENT>
<ORGANISATION>Newcastle University</ORGANISATION>
<ADDRESS_1>William Leech Building</ADDRESS_1>
<ADDRESS_2>The Medical School</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>NE2 4HH</ZIP>
<REGION>Tyne and Wear</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 191 222 5100</PHONE_1>
<PHONE_2/>
<FAX_1>+44 191 222 8211</FAX_1>
<FAX_2>+44 191 222 6461</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7492" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Garner</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>pgarner@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 705 3201</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 705 3364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="795C7A7F82E26AA2016E721201F60C88" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sinclair</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>sinclad@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17054" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Piero</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Olliaro</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>olliarop@who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)</DEPARTMENT>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>1211 Geneva 27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 22 791 3734</PHONE_1>
<PHONE_2/>
<FAX_1>+41 22 791 4774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14281" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Zulfiqar</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Bhutta</LAST_NAME>
<SUFFIX/>
<POSITION>Professor and Chair</POSITION>
<EMAIL_1>zulfiqar.bhutta@aku.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Women and Child Health</DEPARTMENT>
<ORGANISATION>Aga Khan University Hospital</ORGANISATION>
<ADDRESS_1>Stadium Road</ADDRESS_1>
<ADDRESS_2>PO Box 3500</ADDRESS_2>
<CITY>Karachi</CITY>
<ZIP>74800</ZIP>
<REGION>Sindh</REGION>
<COUNTRY CODE="PK">Pakistan</COUNTRY>
<PHONE_1>+92 21 3486 4782</PHONE_1>
<PHONE_2/>
<FAX_1>+92 21 3493 4294</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-10-05 14:05:08 +0100" MODIFIED_BY="Anne-Marie Stephani">
<UP_TO_DATE>
<DATE DAY="1" MONTH="2" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2011-10-05 14:08:20 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 14:08:20 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Amendment made to acknowledgements</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-10-05 14:08:01 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-10-05 14:08:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>A new search was conducted and the structure of the review altered. In previous versions the different types of  fluoroquinolone were combined in the meta analyses in spite of their dissimilarity. In this revision, we have analysed them separately with the intention of highlighting the effectiveness of different fluoroquinolones. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-06-04 07:52:21 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-06-04 07:52:21 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-06-04 07:51:16 +0100" MODIFIED_BY="[Empty name]">
<NAME>University of Calabar Teaching Hospital, Calabar</NAME>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-06-04 07:52:21 +0100" MODIFIED_BY="[Empty name]">
<NAME>Nigeria branch of South African Cochrane centre</NAME>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-10-14 16:11:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-09-01 11:50:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-04-14 18:51:54 +0100" MODIFIED_BY="[Empty name]">Fluoroquinolones for treating enteric fever</TITLE>
<SUMMARY_BODY MODIFIED="2011-09-01 11:50:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Researchers in The Cochrane Collaboration conducted a review of the effect of fluoroquinolone antibiotics in people enteric fever. After searching for relevant studies, they identified 26 studies involving 3033 patients. Their findings are summarized below.</B>
</I>
</P>
<P>
<B>What is enteric fever and how might fluoroquinolones work?</B>
</P>
<P>Enteric fever is a common term for two similar clinical illnesses known individually as typhoid fever and paratyphoid fever. These are most common in low- and middle-income countries where water and sanitation may be inadequate.</P>
<P>Enteric fever typically causes fever and headache with diarrhoea, constipation, abdominal pain, nausea and vomiting, or loss of appetite. In left untreated some people can develop serious complications and can be fatal.</P>
<P>The fluoroquinolones are a large family of antibiotic drugs, which are commonly used for a variety of infectious diseases. In the past, enteric fever responded extremely well to fluoroquinolones, but drug resistance has become a major public health problem in many areas especially Asia.</P>
<P>
<B>What the research says</B>
</P>
<P>Effect of using fluoroquinolones:</P>
<P>Generally, fluoroquinolones are effective in typhoid.</P>
<P>Policy makers and clinicians will need to consider local antibiotic resistance when considering treatment options for enteric fever.</P>
<P>One relatively new fluoroquinolone, gatifloxacin, seems to remain effective in some regions where resistance to older fluoroquinolones has developed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-09-04 15:36:55 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-08-24 09:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>Typhoid and paratyphoid are febrile illnesses, due to a bacterial infection, which remain common in many low- and middle-income countries. The World Health Organization (WHO) currently recommends the fluoroquinolone antibiotics in areas with known resistance to the older first-line antibiotics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-09 05:41:55 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate fluoroquinolone antibiotics for treating children and adults with enteric fever.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-04-19 12:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane Infectious Disease Group Specialized Register (February 2011); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (2011, Issue 2); MEDLINE (1966 to February 2011); EMBASE (1974 to February 2011); and LILACS (1982 to February 2011). We also searched the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) in February 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-08-24 09:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials examining fluoroquinolone antibiotics, in people with blood, stool or bone marrow culture-confirmed enteric fever.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-08-24 09:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed the trial's methodological quality and extracted data. We calculated risk ratios (RR) for dichotomous data and mean difference for continuous data with 95% confidence intervals (CI).</P>
<P>Comparative effectiveness has been interpreted in the context of; length of treatment, dose, year of study, known levels of antibiotic resistance, or proxy measures of resistance such as the failure rate in the comparator arm.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-09-04 15:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-six studies, involving 3033 patients, are included in this review.</P>
<P>
<I>Fluoroquinolones versus older antibiotics (chloramphenicol, co-trimoxazole, amoxicillin and ampicillin)</I>
</P>
<P>
<I> </I>In one study from Pakistan in 2003-04, high clinical failure rates were seen with both chloramphenicol and co-trimoxazole, although resistance was not confirmed microbiologically. A seven-day course of either ciprofloxacin or ofloxacin were found to be superior. Older studies of these comparisons failed to show a difference (six trials, 361 participants).</P>
<P>In small studies conducted almost two decades ago, the fluoroquinolones were demonstrated to have fewer clinical failures than ampicillin and amoxicillin (two trials, 90 participants, RR 0.11, 95% CI 0.02 to 0.57).</P>
<P>
<I>Fluoroquinolones versus current second-line options (ceftriaxone, cefalexin, and azithromycin)</I>
</P>
<P>The two studies comparing a seven day course of oral fluoroquinolones with three days of intravenous ceftriaxone were too small to detect important differences between antibiotics should they exist (two trials, 89 participants).</P>
<P>In Pakistan in 2003-04, no clinical or microbiological failures were seen with seven days of either ciprofloxacin, ofloxacin or cefixime (one trial, 139 participants). In Nepal in 2005, gatifloxacin reduced clinical failure and relapse compared to cefixime, despite a high prevalence of NaR in the study population (one trial, 158 participants, RR 0.04, 95% CI 0.01 to 0.31).</P>
<P>Compared to a seven day course of azithromycin, a seven day course of ofloxacin had a higher rate of clinical failures in populations with both multi-drug resistance (MDR) and nalidixic acid resistance (NaR) enteric fever in Vietnam in 1998-2002 (two trials, 213 participants, RR 2.20, 95% CI 1.23 to 3.94). However, a more recent study from Vietnam in 2004-05, detected no difference between gatifloxacin and azithromycin with both drugs performing well (one trial, 287 participants).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-09-04 15:36:03 +0100" MODIFIED_BY="[Empty name]">
<P>Generally, fluoroquinolones performed well in treating typhoid, and maybe superior to alternatives in some settings. However, we were unable to draw firm general conclusions on comparative contemporary effectiveness given that resistance changes over time, and many studies were small. Policy makers and clinicians need to consider local resistance patterns in choosing a fluoroquinolone or alternative.</P>
<P>There is some evidence that the newest fluoroquinolone, gatifloxacin, remains effective in some regions where resistance to older fluoroquinolones has developed. However, the different fluoroquinolones have not been compared directly in trials in these settings.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-10-14 16:11:21 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-09-01 14:38:55 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-08-26 16:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>Enteric fever is a common term to encompass two similar clinical illnesses, caused by different serotypes of the bacterium <I>Salmonella enterica</I>. Typhoid fever (due to <I>Salmonella typhi</I>) is generally more common, and more severe, but recent reports suggest that the relative frequency of paratyphoid fever (due to <I>Salmonella paratyphi</I>) may be increasing (<LINK REF="REF-Chandel-2000" TYPE="REFERENCE">Chandel 2000</LINK>; <LINK REF="REF-Ahmad-2002" TYPE="REFERENCE">Ahmad 2002</LINK>; <LINK REF="REF-Butt-2005" TYPE="REFERENCE">Butt 2005</LINK>; <LINK REF="REF-Ochiai-2005" TYPE="REFERENCE">Ochiai 2005</LINK>; <LINK REF="REF-Jesudason-2005" TYPE="REFERENCE">Jesudason 2005</LINK>; <LINK REF="REF-Woods-2006" TYPE="REFERENCE">Woods 2006</LINK>; <LINK REF="REF-Maskey-2008" TYPE="REFERENCE">Maskey 2008</LINK>). In the year 2000, there were an estimated 21.6 million cases of typhoid fever, with 210,000 deaths, and 5.4 million cases of paratyphoid fever (<LINK REF="REF-Ochiai-2008" TYPE="REFERENCE">Ochiai 2008</LINK>; <LINK REF="REF-Crump-2004" TYPE="REFERENCE">Crump 2004</LINK>).</P>
<P>The symptoms of enteric fever are generally non-specific and can vary among different populations (<LINK REF="REF-Parry-2002" TYPE="REFERENCE">Parry 2002</LINK>). Common symptoms include fever, headache, and gastrointestinal complaints; such as diarrhoea, constipation, abdominal pain, nausea and vomiting, or loss of appetite (<LINK REF="REF-Lee-2000" TYPE="REFERENCE">Lee 2000</LINK>; <LINK REF="REF-Richens-2000" TYPE="REFERENCE">Richens 2000</LINK>). Severe disease occurs in 10 to15% of people, and complications such as; intestinal perforation, intestinal bleeding, shock, pancreatitis (inflammation of the pancreas), pneumonia, myocarditis (inflammation of the heart muscles), meningitis (inflammation of the covering of the brain), or psychosis (altered mental state) can occur, typically after the illness has lasted more than two weeks (<LINK REF="REF-Parry-2002" TYPE="REFERENCE">Parry 2002</LINK>).</P>
<P>The bacteria may be shed in the faeces during the acute illness, during convalescence, and occasionally for prolonged periods when the person is labelled a 'chronic carrier' (defined as excretion of the bacterium in the stool or urine for more than one year (<LINK REF="REF-Bhan-2005" TYPE="REFERENCE">Bhan 2005</LINK>)). Infection occurs when food or water contaminated with faeces harbouring the bacteria are ingested. The organisms then penetrate the intestinal lining, multiply in lymphoid tissues, and are released into the blood stream from where they spread throughout the body to various organs; most commonly the liver, spleen, bone marrow, and gall bladder (<LINK REF="REF-Lesser-2001" TYPE="REFERENCE">Lesser 2001</LINK>).</P>
<P>The enteric fevers remain a major health problem in low- and middle-income countries where water and sanitation services may be inadequate. They are endemic throughout Asia (with the highest incidence in South and Southeast Asia), the Middle East, Africa, and South and Central America (<LINK REF="REF-Ivanoff-1995" TYPE="REFERENCE">Ivanoff 1995</LINK>; <LINK REF="REF-Crump-2004" TYPE="REFERENCE">Crump 2004</LINK>). In high-income countries, most cases occur in travellers returning from these endemic areas (<LINK REF="REF-McNabb-2008" TYPE="REFERENCE">McNabb 2008</LINK>). The highest incidence has been reported in children between five and 10 years of age (<LINK REF="REF-Lin-2000" TYPE="REFERENCE">Lin 2000</LINK>; <LINK REF="REF-Siddiqui-2006" TYPE="REFERENCE">Siddiqui 2006</LINK>; <LINK REF="REF-Sur-2006" TYPE="REFERENCE">Sur 2006</LINK>), and in those under five years of age (<LINK REF="REF-Sinha-1999" TYPE="REFERENCE">Sinha 1999</LINK>; <LINK REF="REF-Saha-2001" TYPE="REFERENCE">Saha 2001</LINK>; <LINK REF="REF-Saha-2003" TYPE="REFERENCE">Saha 2003</LINK>; <LINK REF="REF-Brooks-2005" TYPE="REFERENCE">Brooks 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Diagnosis and treatment</HEADING>
<P>The diagnosis of enteric fever can be difficult due to the non specific nature of the symptoms. A definitive diagnosis is possible when the organisms are isolated from blood, bone marrow or other body fluids. Blood cultures are typically positive in 60 to 80% of cases, while bone marrow cultures are more sensitive with 80 to 95% positive, even after prior antibiotic therapy (<LINK REF="REF-Parry-2002" TYPE="REFERENCE">Parry 2002</LINK>). Serological tests, such as the Widal reaction, have been widely used but these are non-specific, giving false positive results, and can be difficult to interpret. More recently, there has been interest in the use of DNA probes and polymerase chain reaction (PCR) testing , but these are not widely available in enteric fever endemic areas (<LINK REF="REF-Parry-2002" TYPE="REFERENCE">Parry 2002</LINK>).</P>
<P>Untreated the disease last 3 to 4 weeks with fever, septicaemia, and a 10-30% mortality. Treatment is with antibiotics and most patients are managed as outpatients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antibiotic resistance</HEADING>
<P>Resistance of <I>S. typhi</I> and <I>S. paratyphi</I> to commonly used antibiotics has become problematic. Resistance to the highly effective chloramphenicol in the 1970's was associated with simultaneous resistance to sulfonamides, tetracycline, and streptomycin; this led to the use of alternative agents such as co-trimoxazole and amoxicillin (<LINK REF="REF-Parry-2002" TYPE="REFERENCE">Parry 2002</LINK>). Subsequently, multi-drug resistant (MDR) strains (resistant to chloramphenicol, ampicillin, co-trimoxazole and streptomycin) emerged and are now prevalent in many parts of the world.</P>
<P>In the Indian subcontinent and China, the frequency of MDR strains ranges from 50% to 80% of all <I>S. typhi</I> isolates and has reached 100% during outbreaks (<LINK REF="REF-Lee-2000" TYPE="REFERENCE">Lee 2000</LINK>). In sub-Saharan Africa, MDR <I>S. typhi</I> has been found in 61% and 82.4% of isolates in Nigeria and Kenya, respectively (<LINK REF="REF-Akinyemi-2005" TYPE="REFERENCE">Akinyemi 2005</LINK>;<LINK REF="REF-Kariuki-2004" TYPE="REFERENCE">Kariuki 2004</LINK>). Surveillance studies can show considerable geographic differences in the proportion of MDR isolates within the same region; MDR <I>S. typhi</I> is far more common in India, Pakistan and Vietnam than in areas of China and Indonesia (<LINK REF="REF-Ochiai-2008" TYPE="REFERENCE">Ochiai 2008</LINK>). Longitudinal studies have also shown that the proportion of MDR strains can decrease over time following changes in antibiotic use (<LINK REF="REF-Lakshmi-2006" TYPE="REFERENCE">Lakshmi 2006</LINK>; <LINK REF="REF-Maskey-2008" TYPE="REFERENCE">Maskey 2008</LINK>). Indeed several areas have reported a re-emergence of strains susceptible to first-line antibiotics such as chloramphenicol (<LINK REF="REF-Takkar-1995" TYPE="REFERENCE">Takkar 1995</LINK>; <LINK REF="REF-Sood-1999" TYPE="REFERENCE">Sood 1999</LINK>; <LINK REF="REF-Wasfy-2002" TYPE="REFERENCE">Wasfy 2002</LINK>; <LINK REF="REF-Rodrigues-2003" TYPE="REFERENCE">Rodrigues 2003</LINK>; <LINK REF="REF-Butt-2005" TYPE="REFERENCE">Butt 2005</LINK>; <LINK REF="REF-Walia-2005" TYPE="REFERENCE">Walia 2005</LINK>; <LINK REF="REF-Mohanty-2006" TYPE="REFERENCE">Mohanty 2006</LINK>; <LINK REF="REF-Gupta-2009" TYPE="REFERENCE">Gupta 2009</LINK>).</P>
<P>Infection with resistant strains can lead to higher treatment failure rates, an increased risk of complications, and an increased potential for transmission due to prolonged faecal carriage (<LINK REF="REF-Coovadia-1992" TYPE="REFERENCE">Coovadia 1992</LINK>; <LINK REF="REF-Bhutta-1996" TYPE="REFERENCE">Bhutta 1996</LINK>; <LINK REF="REF-Mermin-1999" TYPE="REFERENCE">Mermin 1999</LINK>; <LINK REF="REF-Rupali-2004" TYPE="REFERENCE">Rupali 2004</LINK>; <LINK REF="REF-Walia-2005" TYPE="REFERENCE">Walia 2005</LINK>; <LINK REF="REF-Crump-2008" TYPE="REFERENCE">Crump 2008</LINK>).</P>
<P>The isolates that respond less well clinically to fluoroquinolones are usually nalidixic acid resistant (NaR) by disc susceptibility testing and have high minimum inhibitory concentrations (MICs) although their breakpoints remain within the range set by the Clinical and Laboratory Standard Institute (CLSI). Using current CLSI disk breakpoints (<LINK REF="REF-CLSI-2007" TYPE="REFERENCE">CLSI 2007</LINK>) means that fluoroquinolones may continue to be used inappropriately thereby increasing the risks of treatment failure. A key consideration now is the suggested need to redefine breakpoints for isolates with reduced susceptibility to fluoroquinolones in order to identify these strains, offer appropriate therapy and stem the emergence of more resistant organisms (<LINK REF="REF-Crump-2003" TYPE="REFERENCE">Crump 2003</LINK>, <LINK REF="REF-Parry-2010" TYPE="REFERENCE">Parry 2010</LINK>, <LINK REF="REF-BSAC-2011" TYPE="REFERENCE">BSAC 2011</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2011-09-01 14:38:55 +0100" MODIFIED_BY="[Empty name]">
<P>The fluoroquinolones are a large family of anti-infective drugs, synthesized around a quinolone core, that possess a broad spectrum of antibacterial activity (<LINK REF="REF-Congeni-2002" TYPE="REFERENCE">Congeni 2002</LINK>).</P>
<P>Nalidixic acid, the prototype quinolone, was first introduced into clinical use in 1962. Four generations of fluoroquinolones have subsequently been developed, classified according to their spectrum of antibacterial activity, and used to treat a range of urinary tract, respiratory, gastrointestinal, and sexually transmitted infections (<LINK REF="REF-Oliphant-2002" TYPE="REFERENCE">Oliphant 2002</LINK>):</P>
<UL>
<LI>second generation; eg ciprofloxacin, ofloxacin, pefloxacin, norfloxacin; broad gram-negative cover but limited activity against gram-positive bacteria;</LI>
<LI>third generation; eg levofloxacin, sparfloxacin, gatifloxacin, moxifloxacin; improved activity against gram-positive bacteria;</LI>
<LI>fourth generation; eg trovafloxacin, gemifloxacin; improved activity against anaerobic bacteria.</LI>
</UL>
<P>Subsequently, several of these products have been withdrawn from clinical use (<LINK REF="REF-Committee-2006" TYPE="REFERENCE">Committee 2006</LINK>), and norfloxacin is not generally recommended for the treatment of enteric fever due to its poor bioavailability (<LINK REF="REF-Miller-2000" TYPE="REFERENCE">Miller 2000</LINK>; <LINK REF="REF-Hooper-2000" TYPE="REFERENCE">Hooper 2000</LINK>).</P>
<P>
<B>Adverse events</B>
</P>
<P>Fluoroquinolones generally have few adverse effects. The most common are mild and self-limiting symptoms affecting either the gastrointestinal system (nausea, vomiting or diarrhoea), or the central nervous systems (headaches and dizziness) (<LINK REF="REF-Bertino-2000" TYPE="REFERENCE">Bertino 2000</LINK>; <LINK REF="REF-Oliphant-2002" TYPE="REFERENCE">Oliphant 2002</LINK>). Rare and serious adverse effects have been linked to specific fluoroquinolone compounds and several have subsequently been withdrawn from clinical use: prolongation of the corrected QT (QTc) interval with grepafloxacin, liver toxicity with trovafloxacin, and anaphylaxis, haemolytic anaemia and renal failure with temafloxacin.(<LINK REF="REF-Bertino-2000" TYPE="REFERENCE">Bertino 2000</LINK>; <LINK REF="REF-Fish-2001" TYPE="REFERENCE">Fish 2001</LINK>)</P>
</INTERVENTION>
<THEORY MODIFIED="2011-08-24 10:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>In the past, enteric fevers responded extremely well to the fluoroquinolones, but quinolone resistant strains of <I>S. typhi</I>, especially in Asia, have become a major public health problem (<LINK REF="REF-Chuang-2009" TYPE="REFERENCE">Chuang 2009</LINK>; <LINK REF="REF-Parry-2010" TYPE="REFERENCE">Parry 2010</LINK>; <LINK REF="REF-Smith-2010" TYPE="REFERENCE">Smith 2010</LINK>; <LINK REF="REF-Parry-2010" TYPE="REFERENCE">Parry 2010</LINK>).The susceptibility of <I>S. typhi</I> to the fluoroquinolones can be divided into three categories:</P>
<UL>
<LI>fully susceptible; susceptible to both nalidixic acid and ciprofloxacin;</LI>
<LI>reduced susceptibility: NaR, but susceptible to ciprofloxacin (<LINK REF="REF-Threlfall-1999" TYPE="REFERENCE">Threlfall 1999</LINK>; <LINK REF="REF-Ackers-2000" TYPE="REFERENCE">Ackers 2000</LINK>; <LINK REF="REF-Crump-2003" TYPE="REFERENCE">Crump 2003</LINK>); or</LI>
<LI>resistant: both NaR and ciprofloxacin resistant (<LINK REF="REF-Rupali-2004" TYPE="REFERENCE">Rupali 2004</LINK>; <LINK REF="REF-Parry-2006" TYPE="REFERENCE">Parry 2006</LINK>; <LINK REF="REF-Kownhar-2007" TYPE="REFERENCE">Kownhar 2007</LINK>).</LI>
</UL>
<P>However, not all strains with reduced susceptibility to fluoroquinolones are NaR suggesting the likelihood of a new mechanism of resistance unrelated to the principal mechanisms of resistance already known (<LINK REF="REF-Threlfall-2003" TYPE="REFERENCE">Threlfall 2003</LINK>; <LINK REF="REF-Cooke-2006" TYPE="REFERENCE">Cooke 2006</LINK>). There are emerging reports of isolates with absolute fluoroquinolone resistance (<LINK REF="REF-Harish-2004" TYPE="REFERENCE">Harish 2004</LINK>; <LINK REF="REF-Adachi-2005" TYPE="REFERENCE">Adachi 2005</LINK>; <LINK REF="REF-Renuka-2005" TYPE="REFERENCE">Renuka 2005</LINK>; <LINK REF="REF-Ahmed-2006" TYPE="REFERENCE">Ahmed 2006</LINK>; <LINK REF="REF-Mohanty-2006" TYPE="REFERENCE">Mohanty 2006</LINK>; <LINK REF="REF-Walia-2006" TYPE="REFERENCE">Walia 2006</LINK>; <LINK REF="REF-Joshi-2007" TYPE="REFERENCE">Joshi 2007</LINK>). To date, fluoroquinolone resistance has been reported in several countries including India (<LINK REF="REF-Renuka-2005" TYPE="REFERENCE">Renuka 2005</LINK>,<LINK REF="REF-Gaind-2006" TYPE="REFERENCE">Gaind 2006</LINK>, <LINK REF="REF-Kownhar-2007" TYPE="REFERENCE">Kownhar 2007</LINK>), Vietnam (<LINK REF="REF-Ahmed-2006" TYPE="REFERENCE">Ahmed 2006</LINK>), Kuwait (<LINK REF="REF-Dimitrov-2009" TYPE="REFERENCE">Dimitrov 2009</LINK>), South Africa (<LINK REF="REF-Keddy-2010" TYPE="REFERENCE">Keddy 2010</LINK>), UK (<LINK REF="REF-Cooke-2007" TYPE="REFERENCE">Cooke 2007</LINK>) and the USA (<LINK REF="REF-Medalla-2011" TYPE="REFERENCE">Medalla 2011</LINK>). Most of those reported in the UK and the USA have been imported from India, Vietnam and Bangladesh.</P>
<P>There is current interest in gatifloxacin, which has been found to be active against NaR strains. The alteration in its structure is such that it may hypothetically make the drug less susceptible to the mutations that caused resistance to the older fluoroquinolones (<LINK REF="REF-Fukuda-2001" TYPE="REFERENCE">Fukuda 2001</LINK>). Studies of gatifloxacin suggest that there may be fewer cardiac adverse effects than seen with older generation fluoroquinolones, but with a higher incidence of dysglycaemia (high or low blood sugar) (<LINK REF="REF-Frothingham-2005" TYPE="REFERENCE">Frothingham 2005</LINK>; <LINK REF="REF-Park_x002d_Wyllie-2006" TYPE="REFERENCE">Park-Wyllie 2006</LINK>), although some authorities state this may be confined to the elderly, and those with non-insulin dependent diabetes (<LINK REF="REF-Ambrose-2003" TYPE="REFERENCE">Ambrose 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-08-26 16:33:13 +0100" MODIFIED_BY="[Empty name]">
<P>This review aims to summarise trials comparing fluoroquinolones and other antibiotics in treating enteric fever. Interpreting trial data needs to take into account other factors, in particular the year and location of the study, as antibiotic resistance (and therefore efficacy), is dynamic and changes with time.</P>
<P>In the earlier version of this review, different generations of fluoroquinolones were combined in the analysis with sub groups according to the prevalence of NaR strains (<LINK REF="REF-Thaver-2008" TYPE="REFERENCE">Thaver 2008</LINK>). It was clear that there were important differences between the fluoroquinolones, and this update therefore seeks to group studies by each fluoroquinolone individually. As norfloxacin has poor bioavailability and is no longer a credible treatment option, studies evaluating this drug were excluded. </P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-06-18 14:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the fluoroquinolone antibiotics in the treatment of enteric fever in children and adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-10-14 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-10-14 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-12-20 09:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-12-22 18:41:27 +0100" MODIFIED_BY="[Empty name]">
<P>People diagnosed with typhoid or paratyphoid fever based on microbiological confirmation from blood, stool or bone marrow.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-10-14 16:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<P>Different fluoroquinolone antibiotics, excluding norfloxacin or other fluoroquinolones not currently in use</P>
<P>
<B>Control</B>
</P>
<P>Any non-fluoroquinolone antibiotic used to treat enteric fever; chloramphenicol, ampicillin, amoxicillin, cotrimoxazole, azithromycin or cephalosporins.</P>
<P>An alternative fluoroquinolone, or a different treatment duration of the same fluoroquinolone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-06-20 16:19:37 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-06-20 16:19:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical failure; defined as development of complications, requiring a change of antibiotic therapy, or remaining symptomatic beyond a time period specified by trial authors.</LI>
<LI>Microbiological failure; defined as a positive culture from blood, bone marrow, or any sterile anatomic site, beyond a time period specified by trial authors.</LI>
<LI>Relapse; defined as the recurrence of symptoms with a positive culture from blood or bone marrow or any sterile anatomic site, beyond a time period defined by trial authors.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-06-19 22:48:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Fever clearance time; defined as the time in hours/days taken to clear fever from the start of the intervention or control drug with the definition of fever clearance as specified by trial authors.</LI>
<LI>Length of hospital stay; defined as the time in days from entry into trial until discharge.</LI>
<LI>Convalescent faecal carriage; defined as a positive faecal culture detected at any time after the end of treatment up to one year of follow up.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events (as defined by trial authors)</HEADING>
<UL>
<LI>Serious adverse events; defined as adverse events leading to death, inpatient hospitalization, prolonged hospitalization, or life threatening, resulting in persistent or significant disability or incapacity, such as joint disease, tendonitis and tendon rupture, prolongation of QTc interval, seizures, nephrotoxicity, haematological reactions, or severe dermatologic reactions.</LI>
<LI>Other adverse events, such as nausea, diarrhoea, headache, dizziness, mild photosensitivity, hepatic enzyme elevations, and hypersensitivity reactions.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-08-26 17:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>Emmanuel Effa worked with Vittoria Lutje (Information Retrieval Specialist, Cochrane Infectious Diseases Group) to identify all relevant trials regardless of language or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-08-05 11:40:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases using the search terms and strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>: Cochrane Infectious Diseases Group Specialized Register (February 2011); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (2011, Issue 2); MEDLINE (1966 to February 2011); EMBASE (1974 to Febrary 2011); and LILACS (1982 to February 2011). We also searched the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) in February 2011 using the search term "(typhoid fever) NOT vaccine".</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-08-26 17:37:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Researchers</HEADING>
<P>We contacted Christiane Dolecek (in October, 2010) who provided information on unpublished and ongoing trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reference lists and review authors' personal collections</HEADING>
<P>We also checked the reference lists of all retrieved trials and searched the review authors' personal literature collections for relevant trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-09-01 14:39:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-06-22 10:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors, Emmanuel E Effa (EEE) and Zohra S Lassi (ZSL), independently assessed all the potential studies identified by the search strategy and applied the inclusion criteria. Any disagreements were resolved through discussion. The excluded studies, and the reason for their exclusion are included in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-08-26 17:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>For eligible studies, two review authors (EEE and ZSL) extracted the data using a pre-tested data extraction form. For dichotomous outcomes, such as clinical failure, we extracted the total number of participants and number of participants that experienced the event. For continuous outcomes, such as fever clearance time, we extracted the total number of participants, arithmetic means, and standard deviations. If the standard deviation was not reported, we attempted to use the confidence interval or P value to derive it. The extracted data were entered data into <LINK REF="REF-Review-Manager-5.1" TYPE="REFERENCE">Review Manager 5.1</LINK>. and cross-checked by a second author for accuracy.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-08-24 11:27:47 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (EEE and ZSL) independently assessed the risk of bias for each included trial using the Cochrane collaboration's 'Risk of bias' tool as described in the <I>Cochrane Handbook of Systematic Reviews of Intervention (</I>
<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>
<I>). </I>
</P>
<P>We followed the guidance to assess whether adequate steps were taken to reduce the risk of bias across six domains: sequence generation, allocation concealment, blinding (of participants, personnel and outcome assessors), incomplete outcome data, selective outcome reporting and other sources of bias. We have categorized our judgements as 'yes' (low risk of bias), 'no' (high risk of bias) or 'unclear'. We compared our entries and resolved disagreements by discussion.</P>
<P>The risk of bias judgements are displayed in a table and summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-08-24 11:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Dichotomous data are presented and compared using risk ratios (RR), and continuous data using a mean difference (MD). All results are presented with the corresponding 95% confidence interval (CI).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-06-21 11:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Trials including more than two comparison groups have been split and analysed as individual pair-wise comparisons. When conducting meta-analysis we have ensured that participants and cases in the placebo group are not counted more than once, by dividing the placebo cases and participants evenly between the intervention groups.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-06-17 18:03:22 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to conduct an intention-to-treat analysis on culture-positive cases since no further information was available for culture-positive participants who were lost to follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-08-24 11:32:12 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed for heterogeneity by visually inspecting the forest plots and by using the Chi<SUP>2</SUP> test for homogeneity, using a 10% level of statistical significance to indicate statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-06-21 11:21:57 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to assess for the presence of publication bias by looking for funnel plot asymmetry but this was not possible due to the low number of trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-09-01 14:39:38 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed data using <LINK REF="REF-Review-Manager-5.1" TYPE="REFERENCE">Review Manager 5.1</LINK>.</P>
<P>We analysed data using pair-wise comparisons. we compared the fluoroquinolones with each alternative antibiotic and subgrouped by the specific fluoroquinolone. The data are organised into four sections:</P>
<UL>
<LI>
<I>fluoroquinolones versus first-line antibiotics</I> <I>(chloramphenicol, co-trimoxazole, and ampicillin or amoxicillin)</I>;</LI>
</UL>
<UL>
<LI>
<I>fluoroquinolones versus second-line antibiotics (cefixime, ceftriaxone, azithromycin)</I>;</LI>
</UL>
<UL>
<LI>
<I>comparison of different fluoroquinolones and different durations of fluoroquinolones;</I>
</LI>
</UL>
<UL>
<LI>
<I>a summary of the evidence for gatifloxacin</I>
</LI>
</UL>
<P>Where there is no statistical heterogeneity we have used the fixed-effect model. Where statistical heterogeneity was detected, and we still considered it appropriate to pool the data, we used the random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-08-24 11:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to investigate heterogeneity by conducting subgroup analyses according to; drug dose; severe or complicated enteric fever (as defined by trialists) versus uncomplicated enteric fever; and different time points for outcome measurements. This was not possible due to the limited number of trials in each comparison. We have instead commented on these factors within the text where appropriate.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-06-21 11:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to assess the robustness of the data by performing a sensitivity analysis for each of the risk of bias assessment factors, but were again unable to do this due to the low number of trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-09-01 11:50:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-09-01 11:50:59 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-08-24 11:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed 72 trials for eligibility. Twenty-six were included and 36 excluded. Seven studies are awaiting classification and one trial is ongoing.</P>
<P>Among the seven trials awaiting classification; we were unable to retrieve full text copies for two (<LINK REF="STD-Flores-1991" TYPE="STUDY">Flores 1991</LINK>; <LINK REF="STD-Soewandojo-1992" TYPE="STUDY">Soewandojo 1992</LINK>), and four did not provide adequate information on the methodology for inclusion (<LINK REF="STD-Quintero-1988" TYPE="STUDY">Quintero 1988</LINK>; <LINK REF="STD-Weng-1996" TYPE="STUDY">Weng 1996</LINK>, <LINK REF="STD-Xiao-1991" TYPE="STUDY">Xiao 1991</LINK>, <LINK REF="STD-Yu-1998" TYPE="STUDY">Yu 1998</LINK>). (<I>See</I> the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-09-01 11:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>The 26 trials included 3033 participants. Most trials were small and lacked statistical power to detect differences between the treatment regimens. The smallest trial had 23 participants and the largest had 352 participants.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial setting</HEADING>
<P>Nine trials were conducted in Vietnam, two trials in each of Italy, Nepal and Pakistan, and one trial in each of Albania, Bahrain, Bangladesh, Egypt, Guatemala, Indonesia, Laos, Morocco and Turkey. We could not determine the location of one trial (<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>).</P>
<P>Twenty-two of the 26 trials were conducted on inpatients. <LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK> was conducted on both inpatients and outpatients. <LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK> was a community-based outpatient trial, while <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK> and <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK> recruited outpatients presenting to the outpatient or emergency department of the study hospital.</P>
<P>Twenty-two trial reports included data on the prevalence of MDR strains among trial participants, and 13 trial reports included data on the prevalence of NaR strains.</P>
<P>Of the 13 trials comparing fluoroquinolones with first-line antibiotics, MDR strains were only present in two trials (<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>; <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>), they were absent in seven trials, and four trials did not report it (<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>; <LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>; <LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>).</P>
<P>
<I>See</I> <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for further details on microbiological results and sensitivity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Three trials were exclusively in children (<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>; <LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>; <LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>). Seven trials included both children and adults (<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>; <LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>; <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>; <LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>;<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>; <LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>; <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>), 15 trials were exclusively in adults (<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>; <LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>; <LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>; <LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>; <LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>; <LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>; <LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>; <LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>; <LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>; <LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>; <LINK REF="STD-Kalo-1997-ALB" TYPE="STUDY">Kalo 1997 ALB</LINK>; <LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>; <LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>; <LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>; <LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>), and five trial reports did not mention the participants' age of which one used the keyword "adult" (<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>).</P>
<P>Eighteen trials were conducted specifically on participants with uncomplicated enteric fever or participants without major complications of enteric fever (<LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>; <LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>; <LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>; <LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>; <LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>; <LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>; <LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>; <LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>; <LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>; <LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>; <LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>; <LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>; <LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>; <LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>; <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>; <LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>; <LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>; <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK> ), and one included only participants with severe enteric fever (<LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>). The remaining trials did not provide this information.</P>
<P>Most trials used blood cultures, bone marrow cultures, or both, to confirm cases of enteric fever. In <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>, a rapid diagnostic test - Dot Enzyme immunosorbent Assay - was also used although all but one participant was culture positive.</P>
<P>Trials that included patients diagnosed clinically tended to report outcomes only for culture-confirmed cases of enteric fever and excluded culture-negative cases from their analysis, even if initially enrolled in the study. Only <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK> detailed analyses were done both reporting culture positive cases only and intention to treat which included patients randomized but who were culture negative..</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Nineteen trials compared fluoroquinolones with alternative antibiotics: chloramphenicol (eight trials), amoxicillin or ampicillin (two trials), co-trimoxazole (three trials), azithromycin (four trials), ceftriaxone (two trials), and cefixime (three trials). Seven trials compared different fluoroquinolone treatment durations: two days versus three days (three trials); three days versus five days (one trial), five days versus seven days (one trial); seven days versus 10 days (one trial); and 10 days versus 14 days (one trial).</P>
<P>Most trials comparing fluoroquinolones with a non-fluoroquinolone antibiotic treated the participants with the fluoroquinolone for seven (eight trials) or 10 days (six trials) (range: three to 15 days).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>There were considerable variations regarding the time points at which outcomes were measured, particularly microbiological failure (such as day two, the end of treatment, and some days after treatment) and relapse (such as during therapy or up to two months after treatment completion). The precise descriptions also varied considerably; for example, some trialists defined "relapse" as the recurrence of similar signs and symptoms with confirmation by blood and/or bone marrow culture (sterile site, as defined in protocol), and others as confirmed by positive stool cultures (non-sterile site) only. Some trialists did not explicitly state how they confirmed relapse in their trial (<I>see</I> <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> 'Definitions of outcomes'). A full summary of adverse events as stated in the papers is summarized in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
<P>Further details are presented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-08-24 11:38:42 +0100" MODIFIED_BY="[Empty name]">
<P>Of the excluded studies, five were excluded as they used norfloxacin (<LINK REF="STD-Nalin-1987" TYPE="STUDY">Nalin 1987</LINK>; <LINK REF="STD-Sarma-1991" TYPE="STUDY">Sarma 1991</LINK>; <LINK REF="STD-Huai-2000" TYPE="STUDY">Huai 2000</LINK>; <LINK REF="STD-Bai-1995" TYPE="STUDY">Bai 1995</LINK>; <LINK REF="STD-ZhongYang-1997" TYPE="STUDY">ZhongYang 1997</LINK>), and three involved fluoroquinolones no longer in clinical use (<LINK REF="STD-Abejar-1993" TYPE="STUDY">Abejar 1993</LINK>; <LINK REF="STD-Arnold-1993" TYPE="STUDY">Arnold 1993</LINK>; <LINK REF="STD-Tran-1994" TYPE="STUDY">Tran 1994</LINK>). (For further details <I>see</I> the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-08-24 11:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See summary of 'risk of bias' assessment in </I>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
<ALLOCATION MODIFIED="2011-06-21 17:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>The method used to generate the allocation sequence was at low risk of bias in sixteen trials, and unclear in ten.</P>
<P>Fourteen trials used an adequate method (sealed envelopes) to conceal allocation. The method used in the remaining 12 trials was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-04-04 09:32:32 +0100" MODIFIED_BY="[Empty name]">
<P>Three trials were described as "double blinded" and 22 trials were open; one trial did not mention use of placebo, but we assumed it was open (<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>). In one trial, blinding was unclear (<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-04-01 08:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>There were incomplete long term outcome data reported for four trials (<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>; <LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>; <LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>; <LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>). The reason for this was unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-04-01 08:14:58 +0100" MODIFIED_BY="[Empty name]">
<P>Most trials reported both efficacy and safety data. In one trial (<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>), there were no reports of adverse events while in another, the report was incomplete as only mortality and associated data for one participant were reported (<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-06-22 20:35:44 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials were stopped early. One because of a significant difference in the primary outcome (<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>), and one due to apparent lower efficacy in the control group, the cost of control drug and inconvenience of intravenous administration (<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>). Two trials were funded by pharmaceutical companies (<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>; <LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>)</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Fluoroquinolones versus first-line antibiotics (chloramphenicol, co-trimoxazole, and ampicillin or amoxicillin)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1. Fluoroquinolones versus chloramphenicol</HEADING>
<P>
<I>
<B>Overall, a seven-day course of any fluoroquinolone appears at least as effective as a 14-day course of chloramphenicol at reducing clinical and microbiological treatment failures (eight trials, 916 participants). In the most recent study, from Pakistan in 2003-04, high failure rates were seen with chloramphenicol, and the fluoroquinolones used (ciprofloxacin and ofloxacin) were superior. </B>
</I>
</P>
<P>Eight trials have compared four different fluoroquinolones with chloramphenicol: Four trials used ciprofloxacin as the comparator drug (<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>; <LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>; <LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>), four trials used ofloxacin (<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>; <LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>; <LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>), two used pefloxacin (<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>; <LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>), and one trial assessed gatifloxacin (<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>).</P>
<P>Two studies did not clarify the proportion of participants with MDR strains (<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>; <LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>), and seven did not report NaR data. The dosing of fluoroquinolones varied from trial to trial and is included in the forest plots as footnotes to aid interpretation.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>Only one three-arm study, from Pakistan in 2003-04, demonstrated a statistically significant benefit with fluoroquinolones compared to chloramphenicol (<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>). The incidence of clinical and microbiological failure with chloramphenicol was high in this trial (9/44) suggesting significant resistance, although this was not confirmed microbiologically. Clinical failures were lower with both ciprofloxacin (RR 0.05, 95% CI 0.00 to 0.81, 92 participants, one trial, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), and ofloxacin (RR 0.05, 95% CI 0.00 to 0.86, 89 participants, one trial, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Conversely, the largest trial to date found no significant difference between gatifloxacin and chloramphenicol in Nepal in 2006-08 (352 participants, one trial, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The remaining older trials were too small to detect clinically important differences between the treatment regimens should they exist.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse and convalescent faecal carriage</HEADING>
<P>The current trials have not shown a statistically significant difference in post-treatment relapses or fecal carriage with any fluoroquinolone compared to chloramphenicol ( participants, six trials, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The follow-up in the included trials varied from two weeks to six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever clearance time</HEADING>
<P>Fever clearance time was significantly longer with chloramphenicol compared with ciprofloxacin (MD -62.46, 95% CI -75.52 to -49.39, 147 participants, two trials, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and ofloxacin (MD -75.85, 95% CI -88.52 to -63.17, 140 participants, two trials, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of hospitalisation</HEADING>
<P>Participants who had chloramphenicol in <LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>, stayed a significantly longer number of days in hospital compared with ofloxacin (MD -9.90, 95% CI -11.42 to -8.38, 60 participants, one trial, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). However, we note that ofloxacin was given only for three days compared to the 14 days of chloramphenicol, so this is perhaps unsurprising.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No difference has been shown between ciprofloxacin and chloramphenicol (173 participants, two trials, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), or ofloxacin and chloramphenicol where no serious adverse events were recorded (50 participants, one trial, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>Non-serious adverse events were significantly lower following treatment with gatifloxacin than with chloramphenicol (RR 0.58, 95% CI 0.44 to 0.78, 844 participants, one trial, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). This data included all randomized participants including those who were culture negative. The events were mainly gastrointestinal in nature and the common ones included abdominal pains, diarrhoea, nausea and vomiting. Elevated blood sugar was more common in the gatifloxacin group between the second and seventh days of the study. There was no difference in the number of participants with low blood sugar for both groups.</P>
<P>The differences between the other fluoroquinolones and chloramphenicol did not reach statistical significance (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 2. Fluoroquinolones versus cotrimoxazole</HEADING>
<P>
<I>
<B>In one study, from an area of Pakistan in 2003-04, the fluoroquinolones used (ciprofloxacin and ofloxacin) were superior to co-trimoxazole. Two small trials done in the 1980s, in the absence of MDR strains, failed to show a difference with both drugs performing well.</B>
</I>
</P>
<P>Three trials have compared three different fluoroquinolones with cotrimoxazole: two trials used ciprofloxacin; <LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>, and one trial each assessed ofloxacin; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>, and pefloxacin; <LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>.</P>
<P>
<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK> and <LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK> both report the absence of MDR strains and <LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK> also records that there were no participants with NaR strains. <LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK> and <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK> do not report the presence or absence of NaR strains.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>Of the three trials, only <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK> reports any clinical failures at all. In this trial, from Pakistan in 2003-04, there was a high incidence of clinical and microbiological failure following treatment with co-trimoxazole (13/44) suggesting significant resistance, compared with no clinical failures following ciprofloxacin (RR 0.03, 95% CI 0.00 to 0.56, 92 participants, one trial, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) or ofloxacin (RR 0.04, 95% CI 0.00 to 0.59, 89 participants, one trial, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>The high failure rate with co-trimoxazole is the likely cause of the longer fever clearance time observed by <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK> (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse and convalescent faecal carriage</HEADING>
<P>Only <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK> assessed for relapses, and only <LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK> assessed for convalescent faecal carriage, but there were no events in either trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever clearance and duration of hospitalisation</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Serious adverse events were not reported.</P>
<P>No statistically significant difference in non-serious events has been shown between any individual fluoroquinolone and co-trimoxazole (219 participants, three trials, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). The events were mainly gastrointestinal in nature and were self limiting.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 3. Fluoroquinolones versus amoxicillin or ampicillin</HEADING>
<P>
<B>Two small studies conducted in the 1990s, found that ofloxacin given for 10 to 14 days reduced clinical and microbiological failures compared to a 10 to 14 day course of amoxicillin or ampicillin. The prevalence of antibiotic resistance was not reported.</B>
</P>
<P>One small trial has compared ofloxacin with ampicillin (<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>), and another compared ofloxacin with amoxicillin (<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>)</P>
<P>There was no indication as to the presence or not of MDR or NaR strains.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>The risk of clinical or microbiological failure was significantly lower in the ofloxacin group compared to ampicillin or amoxicillin (RR 0.11, 95% CI 0.02 to 0.57, 90 participants, two trials, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; RR 0.13; 95% CI 0.03 to 0.68, 90 participants, two trials, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> respectively). It should be noted that these two trials are almost 20 years old and may not be relevant today.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse and convalescent faecal carriage</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever clearance and duration of hospitalization</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events occurred in either of the studies. Non-serious events were significantly more following treatment with ofloxacin compared to amoxicillin (RR 0.27; 95% CI 0.09 to 0.86, 50 participants, one trial, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The reported events were mostly diarrhoea and skin rashes.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fluoroquinolones versus second-line antibiotics (cefixime, ceftriaxone, azithromycin)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 4. Fluoroquinolones versus cefixime</HEADING>
<P>
<I>
<B>In one study from Pakistan in 2003-04 no clinical or microbiological failures were seen with either ciprofloxacin, ofloxacin or cefixime. In Nepal in 2005, gatifloxacin reduced clinical failure and relapse compared to cefixime, despite a high prevalence of NaR in the study population.</B>
</I>
</P>
<P>Three trials have compared a fluoroquinolone with cefixime. One trial used ciprofloxacin as the comparator drug (<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>), two trials used ofloxacin (<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>) and one gatifloxacin (<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>).</P>
<P>In one trial, participants were mostly adults (<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>) while one trial had only child participants (<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>). The third trial included both adult and child participants (<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>). One trial (<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>) had a high proportion of NaR strains, but the other two trials did not report the presence of these strains ( <LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>). In <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>, because of its wholly out patient status, community medical auxiliaries conducted twice daily home-based assessments and provided directly observed treatment with study drugs. All participants were then compulsorily seen at the hospital on Day 10.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>Of the three tested fluoroquinolones, only gatifloxacin has demonstrated a statistically significant reduction in clinical failure compared to cefixime (RR 0.04, 95% CI 0.01 to 0.31, 158 participants, one trial, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Microbiological failures were too low across all three trials to demonstrate any significant differences for any of the comparisons (379 participants, three trials, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>
<B>Relapse and convalescent faecal carriage</B>
</P>
<P>Only gatifloxacin has demonstrated a statistically significant reduction in relapse (RR 0.20, 95% CI 0.04 to 0.93, 138 participants, one trial, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). There were no reported incidents of faecal carriage.</P>
<P>
<B>Fever Clearance and duration of hospital stay</B>
</P>
<P>Fever clearance time was significantly shorter for ofloxacin (MD -24.00, 95% CI -41.46 to -6.54, one trial, 91 participants, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). There was a statistically significant difference in the median time to fever clearance for gatifloxacin (92 hours vs 138 hours, P &lt;0.0001) and ofloxacin (105 hours vs 201 hours, P &lt;0.0001). This reductions for ofloxacin were also reflected in the shorter length of hospital stay in that group (MD -3.00, 95% CI -4.53 to -1.47, 80 participants, one trial, <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Serious adverse events were low in two trials comparing ofloxacin and gatifloxacin with cefixime but there was no significant difference between the comparisons (251 participants, two trials, <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
<P>Non-serious adverse events appear to be higher with gatifloxacin than with cefixime (RR 20.92, 95% CI 2.9 to 150.90, 169 participants, one trial, <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>). However it is not clear whether adverse events were completely reported in this trial. No difference has been shown between ciprofloxacin or ofloxacin and cefixime.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 5. Fluoroquinolones versus ceftriaxone</HEADING>
<P>
<I>
<B>Two studies, conducted almost 20 years ago, compared five to seven days of an oral fluoroquinolone with three days of intravenous ceftriaxone, and were too small to demonstrate important differences if they exist. The prevalence of NaR strains was either absent or unreported.</B>
</I>
</P>
<P>One trial has compared ciprofloxacin with ceftriaxone (<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>), and one trial compared ofloxacin (<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>).</P>
<P>In both trials, over half of participants had MDR strains. There were no participants with NaR strains in <LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK> whereas the proportion was not stated in <LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>. Sample sizes for these studies were quite small resulting in very wide confidence intervals.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>The proportion of clinical failures was lower with fluoroquinolones but the result was not statistically significant (89 participants, two trials, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Only one microbiological failure is reported in either group (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>
<B>Relapse and convalescent faecal carriage</B>
</P>
<P>The incidence of relapse and faecal carriage following treatment was very low with no differences between both groups (42 participants, one trial, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
<P>
<B>Fever clearance and duration of hospitalization</B>
</P>
<P>Only <LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK> reported adequate data for the fever clearance time which was significantly shorter with ofloxacin (MD -115.0; 95% CI -150.67 to -79.33, 47 participants, 1 trial, <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). In <LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>, mean fever clearance times for the ciprofloxacin and ceftriaxone groups were 4 and 5.2 days respectively. No standard deviation was reported but the P value was given as 0.04.</P>
<P>Similarly, only <LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK> reported the duration of hospitalization which averaged nine days (range: 6 to 13 days) in the ofloxacin group and 12 days (range: 7 to 23 days) in the ceftriaxone group. No values for standard deviation were reported but a P value was given as 0.01.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No serious adverse events were reported. Non-serious events were few, mild and self limiting in both groups in the only trial that recorded them (47 participants, 1 trial, <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 6. Fluoroquinolones versus azithromycin</HEADING>
<P>
<I>
<B>Azithromycin was superior to ofloxacin in reducing clinical failures and convalescent faecal carriage in populations with both MDR and NaR enteric fever in Vietnam.</B>
</I> <I>
<B>The most recent study, also from Vietnam, found no difference between gatifloxacin and azithromycin with both drugs performing well.</B>
</I>
</P>
<P>Four trials involving 564 participants made this comparison. One trial each compared ciprofloxacin with azithromycin (<LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>, 64 participants) and gatifloxacin with azithromycin (<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>, 287 participants). Two trials compared ofloxacin with azithromycin (<LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>, 88 participants and <LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>, 125 participants).</P>
<P>In <LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>, a third of participants were infected with MDR strains. The proportion of NaR strains was not reported. The other trials had varying proportions of participants with MDR and NaR strains.</P>
<SUBSECTION>
<HEADING LEVEL="5">Clinical and microbiological response</HEADING>
<P>Treatment with azithromycin resulted in a statistically significant decrease in clinical failures compared to ofloxacin (RR 2.20, 95% CI 1.23 to 3.94, 213 participants, two trials, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), but no difference has been shown between ciprofloxacin (64 participants, one trial, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), or gatifloxacin (287 participants, one trial, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>)</P>
<P>No statistically significant difference in microbiological failure has been seen in any of the trials comparing fluoroquinolones with azithromycin (564 participants, four trials, <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse and convalescent faecal carriage</HEADING>
<P>No statistically significant difference in relapse rate has been seen in any of the trials comparing fluoroquinolones with azithromycin (479 participants, 4 trials, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
<P>Convalescent faecal carriage was lower in the azithromycin group compared with ofloxacin (RR 13.52, 95% CI 2.64 to 69.36, 193 participants, 2 trials, <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>), but no difference has been shown between ciprofloxacin (64 participants, 1 trial, <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>), or gatifloxacin (268 participants, 1 trial, <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever clearance time</HEADING>
<P>No consistent statistically significant difference in fever clearance has been shown between any of the fluoroquinolones and azithromycin (564 participants, four trials, <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of hospitalization</HEADING>
<P>There was a statistically significant reduction in the duration of hospital stay in the ofloxacin group (RR 1.01, 95% CI 0.19 to 1.83, 213 participants, two trials, <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No significant difference in serious events has been seen between the ofloxacin with azithromycin groups (88 participants, 1 trial, <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>). Overall, non-serious adverse events were similar across all the trials (564 participants, four trials, <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Head to head comparisons of different fluoroquinolones or different durations of treatment</HEADING>
<P>
<I>
<B>Differences in efficacy between the different fluoroquinolones has not been demonstrated in head to head clinical trials.</B>
</I>
</P>
<P>The different fluoroquinolones have only been compared as part of multiple arm studies (<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>; <LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>). In these studies no clinical or microbiological failures, or relapses were seen in the fluoroquinolone treatment arms (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<I>
<B>None of the comparisons demonstrated one duration was superior to another for failure or relapse, even in the presence of MDR and NaR strains. Studies were generally too small to detect what might be important differences. </B>
</I>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 7. Fluoroquinolones for two days versus three days</HEADING>
<P>Three trials made this comparison: one in adults (<LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>) and two in children (<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>; <LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>). They were all ofloxacin trials. All three trials reported the percentage of participants with NaR and MDR strains. These were 2.5.% and 90% (<LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>), 5% and 79% (<LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>), and 13% and 84% (<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>), respectively.</P>
<P>There were no statistically significant differences for all the outcomes in either groups of the trials. There were no serious adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 8. Fluoroquinolones three days versus five days</HEADING>
<P>Only one trial (<LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>) with over 70% children compared three days with five days of ofloxacin. The majority of <I>S. typhi</I> isolates (91%) were MDR. Some participants had NaR strains, although the precise number of these participants was not available.</P>
<P>Fever clearance time was significantly shorter in the three day group compared with the five day group (MD -12.0; 95% CI -18.07 to -5.93,195 participants, one trial, <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>). There were no differences in the risk of relapse and adverse events in either groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 9. Fluoroquinolone five days versus seven days</HEADING>
<P>One trial made this comparison (<LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>) with pefloxacin. Thirteen percent of the strains were MDR. There was no report of the proportion with NaR strains.</P>
<P>There were no clinical failures in either arm, and we did not detect a statistically significant difference in microbiological failure, relapse and fever clearance time. Adverse events were not serious and they were similar in both groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 10. Fluoroquinolone seven days versus 10 or 14 days</HEADING>
<P>One trial compared pefloxacin for seven days with 10 days (<LINK REF="STD-Kalo-1997-ALB" TYPE="STUDY">Kalo 1997 ALB</LINK>) in a population wholly infected with ampicillin resistant <I>S. typhi </I>some of whom were MDR. The proportion of participants with NaR strains was not reported.</P>
<P>There was no statistically significant difference in microbiological failure. There were no clinical failures or convalescent faecal carriers. Adverse events were mild and self limiting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 11. Fluoroquinolone 10 days versus 14 days</HEADING>
<P>One trial, with 7% of the participants infected with NaR strains, made this comparison (<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>). There was no statistically significant difference in relapse or fever clearance time. There were no clinical or microbiological failures, or convalescent faecal carriers. Adverse events<B> </B>(gastrointestinal symptoms, headache and rashes in both arms, and one case of joint pain in the 14-day arm) were mild and self limiting.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of gatifloxacin comparisons</HEADING>
<P>In the light of the emerging interest in gatifloxacin, we have summarised the results in this section for this one drug.</P>
<P>One trial each compared gatifloxacin with chloramphenicol (<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>), cefixime (<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>) and azithromycin (<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>). All the trials had a majority of participants infected with NaR strains equally distributed between groups. In <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK> and <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>, MDR strains were negligible (0.58% and 0% respectively). All the trials were conducted in areas previously known to have a high prevalence of MDR and NaR salmonella isolates.</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 13. Gatifloxacin versus chloramphenicol</HEADING>
<P>No statistically significant difference has been shown in the risk of clinical or microbiological failure, or relapse, between a 7-day course of gatifloxacin and 14 days of chloramphenicol in Nepal (352 participants, one trial, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>). Treatment with gatifloxacin may however be associated with fewer adverse events (RR 0.58, 95% CI 0.44 to 0.78, 844 participants, one trial, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 14. Gatifloxacin versus cefixime</HEADING>
<P>Compared to 7-days of cefixime, a 7-day course of gatifloxacin was shown to produce a statistically significant reduction in clinical failure (RR 0.04; 95% CI 0.01 to 0.31, 158 participants, one trial, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>), and relapse (RR 0.2; 95% CI 0.04 to 0.93, 138 participants, one trial, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>) in Nepal. There was however no difference in microbiological failure assessed at day 10 (158 participants, one trial, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>). Gatifloxacin was associated with a statistically significant increase in adverse events (RR 19.25, 95% CI 2.66 to 139.30, 169 participants, one trial, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>). The events were mainly vomiting and in two cases, this was severe enough to require intravenous fluids.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 15. Gatifloxacin versus azithromycin</HEADING>
<P>No statistically significant difference has been shown in the risk of clinical or microbiological failure, or relapse, between a 7-day course of gatifloxacin and 7 days of azithromycin in Vietnam (287 participants, one trial, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). There is also no evidence of a difference in the incidence of adverse events (285 participants, one trial, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-10-12 21:47:03 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Fluoroquinolones versus older antibiotics</HEADING>
<P>In one study from Pakistan in 2003-04, high clinical failure rates were seen with both chloramphenicol and co-trimoxazole, although resistance was not confirmed microbiologically. A seven day course of either ciprofloxacin or ofloxacin was found to be superior. Older studies of these comparisons failed to show a difference.</P>
<P>In two small studies conducted almost two decades ago the fluoroquinolones were demonstrated to be more effective than ampicillin and amoxicillin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fluoroquinolones versus current second-line options</HEADING>
<P>The two studies comparing a seven day course of oral fluoroquinolones with three days of intravenous ceftriaxone were too small to detect important differences between antibiotics should they exist.</P>
<P>In Pakistan in 2003-04 no clinical or microbiological failures were seen with seven days of either ciprofloxacin, ofloxacin or cefixime. In Nepal in 2005, gatifloxacin reduced clinical failure and relapse compared to cefixime, despite a high prevalence of NaR in the study population.</P>
<P>Compared to a seven day course of azithromycin, a seven day course of ofloxacin had a higher rate of clinical failures in populations with both MDR and NaR enteric fever in Vietnam in 1998-2002. However, the most recent study, also from Vietnam in 2004-05, found no difference between gatifloxacin and azithromycin, with both drugs performing well.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fluoroquinolones versus alternative fluoroquinolones</HEADING>
<P>Differences in efficacy between the available fluoroquinolones, or between different durations of treatment with an individual fluoroquinolone, have not been demonstrated in head to head clinical trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Overall, the adverse event profiles were similar for the fluoroquinolone and non-fluoroquinolone antibiotics. They were mostly mild and self limiting.The risk of dysglycaemia with gatifloxacin has been reported in several studies (<LINK REF="REF-Frothingham-2005" TYPE="REFERENCE">Frothingham 2005</LINK>, <LINK REF="REF-Park_x002d_Wyllie-2006" TYPE="REFERENCE">Park-Wyllie 2006</LINK>). However, in the three studies included in this review which report on dysglycaemia ( <LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>; <LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>; <LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>), no difference was detected in the risk of hypoglycaemia or hyperglycaemia among those studied</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-24 13:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>Most of the included trials were conducted on inpatients and may not be representative of the majority of settings where most enteric fever is managed as outpatients. The data are likely to represent a subset of patients with more severe illness who may respond less favourably to conventional therapy.</P>
<P>The changing epidemiology of resistance patterns across various regions precludes any generalization of the results of the included studies. Indeed, some included studies are nearly two decades old and thus may not be useful in informing practice.</P>
<P>In addition, overall, there are too few studies in each comparison, and the studies themselves are too small, to make any firm conclusions on the prescience or absence of important differences between the different treatment options.</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2011-08-24 14:00:32 +0100" MODIFIED_BY="[Empty name]">
<P>Although we found several trials from China, and published in the Chinese language, we were unable to extract adequate details on the trial methodology to allow inclusion. These studies are listed in the 'Studies awaiting assessment' table. A recent study of over 30,000 apparent RCTs in China showed that only 6.8% were authentic RCTs (<LINK REF="REF-Wu-2009" TYPE="REFERENCE">Wu 2009</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-10-12 21:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>In our previous update (<LINK REF="REF-Thaver-2008" TYPE="REFERENCE">Thaver 2008</LINK>), different types of fluoroquinolone were combined in the meta analyses in spite of their dissimilarity. In this revision, we have analysed them separately with the intention of highlighting the effectiveness of different fluoroquinolones. We also considered the changing pattern of resistance across various regions over different times.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-10-14 16:11:21 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-10-14 16:11:21 +0100" MODIFIED_BY="[Empty name]">
<P>Generally, fluoroquinolones performed well in the treating typhoid. Generally, fluoroquinolones performed well in the treating typhoid, and maybe superior to alternatives in some settings. However, we were unable to draw firm general conclusions on comparative contemporary effectiveness given that resistance changes over time, and many studies were small. In choosing any fluoroquinolone, clinicians need to take into account current, local resistance patterns.</P>
<P>There is some evidence that the newest fluoroquinolone, gatifloxacin, remains effective in some regions where resistance to older fluoroquinolones has developed. However, the different fluoroquinolones have not been compared directly in head to head trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-09-01 11:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>The re-emergence of chloramphenicol sensitive strains in some regions may suggest a similar trend for other first line drugs which had been abandoned following prevalent MDR. Trials may therefore focus on re-examining these relatively inexpensive alternatives in robust comparisons with fluoroquinolones in appropriate endemic populations.</P>
<P>Most of the studies were small . Given the importance of the study question, we would recommend multi-centred, adequately powered trials, with robust methods and analytical design. Given the nature of the disease and the importance of accurate diagnoses, we would recommend the development of robust diagnostic tests and gold standards for defining disease and resistance patterns, based on molecular methods if possible. Rapid diagnostic tests for diagnosing enteric fever should be made more widely available in endemic areas; this will ensure more efficient participant recruitment in trials and avoid the problem of syndromic treatment. In addition, it will reduce the widespread abuse of antibiotics, especially the use of fluoroquinolones for suspected typhoid fever.</P>
<P>Definitions of outcomes and their measurement should also be standardized to make more effective comparisons and adaptability across regions.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-10-05 14:12:08 +0100" MODIFIED_BY="[Empty name]">
<P>Emmanuel Effa's fellowship to Liverpool School of Tropical Medicine, and the update of this review was supported by a grant from the World Health Organization. The Cochrane Infectious Diseases Group is funded by the UK Department for International Development (DFID) for the benefit of low- and middle-countries.</P>
<P>We acknowledge Vittoria Lutje, Trials Search Co-ordinator for the CIDG for assistance with the searches as well as staff of the CIDG for assistance during the process of updating the review.</P>
<P>The Contact Editor for this review was Dr Mical Paul.</P>
<P>Thanks to Durrane Thaver, who wrote the original and first update of this review. She is fondly remembered by all of us that knew her.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-06-17 16:57:47 +0100" MODIFIED_BY="[Empty name]">
<P>None known. Professor ZA Bhutta has been part of trials of treatment for typhoid therapy in children, none of which involved fluoroquinolones.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-08-26 17:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>Emmanuel Effa and Zohra Lassi , considered the new search, extracted and enter data, updated the risk of bias assessment and Dave Sinclair co-extracted data, assisted with restructuring and writing up of the review. Julia Critchley provided technical inputs and assisted with the restructuring of the review. Prof Zulfiquar Bhutta, Prof Paul Garner, and Piero Olliaro guided the restructuring, examined the data, provided technical direction and edited the manuscript. All authors contributed to the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-06-08 10:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>We changed the intervention from 'Fluoroquinolone antibiotic' to 'Different fluoroquinolone antibiotic excluding norfloxacin or other fluoroquinolones not currently in use'</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-09-01 14:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>The Contact Editor for this review was Dr Mical Paul.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-08-26 17:22:01 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-08-26 17:22:01 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-08-26 17:22:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alam-1995-BGD" MODIFIED="2011-01-11 11:48:05 +0100" MODIFIED_BY="[Empty name]" NAME="Alam 1995 BGD" YEAR="1995">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alam MN, Haq SA, Das KK, Baral PK, Mazid MN, Siddique RU, et al</AU>
<TI>Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug resistant salmonella</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>3</NO>
<PG>306-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arjyal-2011" MODIFIED="2011-08-26 17:22:01 +0100" MODIFIED_BY="[Empty name]" NAME="Arjyal 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-08-26 17:08:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C.</AU>
<TI>Gatifloxacin versus choramphenicol: An open, randomized controlled trial in the treatment of uncomplicated enteric fever</TI>
<SO>Lancet Infect Dis</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>6</NO>
<PG>445-454</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinh-1997-VNM" MODIFIED="2011-01-11 11:49:35 +0100" MODIFIED_BY="[Empty name]" NAME="Chinh 1997 VNM" YEAR="1997">
<REFERENCE MODIFIED="2010-12-20 05:52:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chinh NT, Solomon T, Mai XT, Nguyen TL, Nguyen TT, Wain J, et al</AU>
<TI>Short courses of ofloxacin for the treatment of enteric fever</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>3</NO>
<PG>347-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinh-2000-VNM" MODIFIED="2011-01-11 11:50:09 +0100" MODIFIED_BY="[Empty name]" NAME="Chinh 2000 VNM" YEAR="2000">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, et al</AU>
<TI>A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever</TI>
<SO>Antimicrobial agents and chemotherapy</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>7</NO>
<PG>1855-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cristiano-1995-ITA" MODIFIED="2011-01-11 11:50:46 +0100" MODIFIED_BY="[Empty name]" NAME="Cristiano 1995 ITA" YEAR="1995">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cirstiano P, Imparato L, Carpinelli C, Lauria F, Iovene MR, Corrado MF, et al</AU>
<TI>Pefloxacin versus chloramphenicol in the therapy of typhoid fever</TI>
<SO>Infection</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>2</NO>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolecek-2008-VNM" MODIFIED="2011-01-11 11:51:05 +0100" MODIFIED_BY="[Empty name]" NAME="Dolecek 2008 VNM" YEAR="2008">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolecek C, La TTP, Rang NN, Phuong LT, Tuan PQ, DU DC et al</AU>
<TI>A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid and paratyphoid fever in children and adults in Vietnam</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>5</NO>
<PG>e2188</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores-1994-MEX" MODIFIED="2011-01-11 11:51:27 +0100" MODIFIED_BY="[Empty name]" NAME="Flores 1994 MEX" YEAR="1994">
<REFERENCE MODIFIED="2010-12-15 06:31:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores GR, Dorantes F, Aviles J</AU>
<TI>Safety and efficacy of oral ofloxacin vs oral ampicillin in the management of typhoid</TI>
<SO>Investigacion Medica Internacional</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>2</NO>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasem-2003-IDN" MODIFIED="2011-01-11 11:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Gasem 2003 IDN" YEAR="2003">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gasem MH, Keuter M, Dolmans WM, Van Der Ven-Jongekrijg J, Djokomoeljanto R, Van Der Meer JW</AU>
<TI>Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2003</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1727-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girgis-1999-EGY" MODIFIED="2011-01-11 11:52:23 +0100" MODIFIED_BY="[Empty name]" NAME="Girgis 1999 EGY" YEAR="1999">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, Tribble D et al</AU>
<TI>Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance</TI>
<SO>Antimicrobial Agents And Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1441-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gottuzzo-1992-N_x002f_A" MODIFIED="2011-01-11 11:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Gottuzzo 1992 N/A" YEAR="1992">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Gottuzzo E, Carillo C</AU>
<TI>Typhoid fever. Evaluation of the efficacy and safety of ciprofloxacin in comparison with chloramphenicol</TI>
<SO>Use of quinolones in travel medicine. Second Conference on International Travel Medicine, Atlanta, Georgia 1991</SO>
<YR>1992</YR>
<PG>16-22</PG>
<ED>HL Dupont</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin, Germany</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hajji-1988-MAR" MODIFIED="2011-01-11 11:53:19 +0100" MODIFIED_BY="[Empty name]" NAME="Hajji 1988 MAR" YEAR="1988">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hajji M, el Mdaghri N, Benbachir M, el Filali KM, Himmich H</AU>
<TI>Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>361-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalo-1997-ALB" MODIFIED="2011-01-11 11:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kalo 1997 ALB" YEAR="1997">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalo T, Davachi F, Nushi A, Dedja S, Karapici L, Como N, et al</AU>
<TI>Therapeutic efficacy of perfloxacin in treatment of ampicillin-resistant typhoid fever in 7 days versus 10 days</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Limson-1989-PHL" MODIFIED="2011-01-11 11:54:28 +0100" MODIFIED_BY="[Empty name]" NAME="Limson 1989 PHL" YEAR="1989">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limson BM, Littaua RT</AU>
<TI>Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever</TI>
<SO>Infection</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>2</NO>
<PG>105-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morelli-1992-ITA" MODIFIED="2011-01-11 11:55:21 +0100" MODIFIED_BY="[Empty name]" NAME="Morelli 1992 ITA" YEAR="1992">
<REFERENCE MODIFIED="2010-12-15 06:15:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morelli G, Mazzoli S, Tortoli E, Simonetti MT, Perruna F, Postiglione A</AU>
<TI>Fluoroquinolones versus chloramphenicol in the therapy of typhoid fever: a clinical and microbiological study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1992</YR>
<VL>52</VL>
<NO>4</NO>
<PG>532-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandit-2007-NPL" MODIFIED="2011-01-11 11:55:45 +0100" MODIFIED_BY="[Empty name]" NAME="Pandit 2007 NPL" YEAR="2007">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pandit, A, Arjyal, A, Day JN, Paudyal B, et al</AU>
<TI>An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever</TI>
<SO>PLoS ONE</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>6</NO>
<PG>e542</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parry-2007-VNM" MODIFIED="2011-01-11 11:56:17 +0100" MODIFIED_BY="[Empty name]" NAME="Parry 2007 VNM" YEAR="2007">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al</AU>
<TI>Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever</TI>
<SO>Antimicrobial Agents Chemotherapy</SO>
<YR>2007</YR>
<VL>51</VL>
<NO>3</NO>
<PG>819-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phongmany-2005-LAO" MODIFIED="2011-01-11 11:56:34 +0100" MODIFIED_BY="[Empty name]" NAME="Phongmany 2005 LAO" YEAR="2005">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phongmany S, Phetsouvanh R, Sisouphone S, Darasavath C, Vongphachane P, Rattanavong O, et al</AU>
<TI>A randomized comparison of oral chloramphenicol versus ofloxacin in the treatment of uncomplicated typhoid fever in Laos</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>6</NO>
<PG>451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phuong-1999-VNM" MODIFIED="2011-01-11 11:56:27 +0100" MODIFIED_BY="[Empty name]" NAME="Phuong 1999 VNM" YEAR="1999">
<REFERENCE MODIFIED="2010-12-20 05:56:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phuong CXT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM</AU>
<TI>A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>3</NO>
<PG>245-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizvi-2007-PAK" MODIFIED="2011-01-11 11:57:29 +0100" MODIFIED_BY="[Empty name]" NAME="Rizvi 2007 PAK" YEAR="2007">
<REFERENCE MODIFIED="2011-01-03 16:55:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizvi Q</AU>
<TI>Effeciveness of anti-typhoid drugs currently used in Pakistan</TI>
<SO>Pakistan Journal of Surgery</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>1</NO>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1994-VNM" MODIFIED="2011-01-11 11:57:37 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1994 VNM" YEAR="1994">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, Diep TS, et al</AU>
<TI>Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>8</NO>
<PG>1716-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1995-VNM" MODIFIED="2011-01-11 11:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Tran 1995 VNM" YEAR="1995">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran TH, Bethell DB, Nguyen TT, Wain J, To SD, Le TP, et al</AU>
<TI>Short course of ofloxacin for treatment of multidrug-resistant typhoid</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>4</NO>
<PG>917-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unal-1996-TUR" MODIFIED="2011-01-11 11:58:46 +0100" MODIFIED_BY="[Empty name]" NAME="Unal 1996 TUR" YEAR="1996">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unal S, Hayran M, Tuncer S, Gur D, Uzun O, Akova M, et al</AU>
<TI>Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>12</NO>
<PG>2898-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinh-1996-VNM" MODIFIED="2011-01-11 11:58:58 +0100" MODIFIED_BY="[Empty name]" NAME="Vinh 1996 VNM" YEAR="1996">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinh H, Wain J, Vo TN, Cao NN, Mai TC, Bethell D, et al</AU>
<TI>Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>4</NO>
<PG>958-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinh-2005-VNM" MODIFIED="2011-08-24 14:55:47 +0100" MODIFIED_BY="[Empty name]" NAME="Vinh 2005 VNM" YEAR="2005">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinh H, Duong NM, Phuong lT, Truong NT, Bay PV, Wain J, et al</AU>
<TI>Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-1993-BHR" MODIFIED="2011-01-11 11:59:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wallace 1993 BHR" YEAR="1993">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, et al</AU>
<TI>Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>12</NO>
<PG>907-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yousaf-1992--PAK" MODIFIED="2011-01-11 12:00:29 +0100" MODIFIED_BY="[Empty name]" NAME="Yousaf 1992  PAK" YEAR="1992">
<REFERENCE MODIFIED="2010-12-15 05:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yousaf MH, Hasnain SS, Mohsin A, Ara N</AU>
<TI>A comparative study of efficacy and safety of three antimicrobials in the treatment of enteric fever</TI>
<SO>Pakistan Journal of Gastroenterology</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>2</NO>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-08-24 15:01:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abejar-1993" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Abejar 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abejar NH, Dimaano EM, Cabanban AB</AU>
<TI>Fleroxacin versus chloramphenicol in enteric fever. An open, randomized, parallel study</TI>
<SO>Philippine Journal of Internal Medicine</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>6</NO>
<PG>327-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agalar-1997" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Agalar 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agalar C, Usubutun S, Tutuncu E, Turkyilmaz R</AU>
<TI>Comparison of two regimens for ciprofloxacin treatment of enteric infections</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>11</NO>
<PG>803-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akhtar-1989" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Akhtar 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhtar MA, Karamat KA, Malik AZ, Hashmi A, Khan QM, Rasheed P</AU>
<TI>Efficacy of ofloxacin in typhoid fever, particularly in drug resistant cases</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1989</YR>
<VL>2 Suppl 5</VL>
<PG>1193</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akhtar-1992" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Akhtar 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhtar MA, Hussain A, Karamat KA, Naqi N, Zubdi N</AU>
<TI>Role of ciprofloxacin in typhoid fever</TI>
<SO>Journal of Pakistan Medical Association</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>1</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnold-1993" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Arnold 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold K, Hong C, Nelwan R, Trujillo Z, Kadio A, Barros M, et al</AU>
<TI>Randomized comparative study of fleroxacin and chloramphenicol in typhoid fever</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94</VL>
<NO>3A</NO>
<PG>195S-200S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-1995" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Bai 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai YM, Lin JB, Duan MT, Zhang Y, Liang B</AU>
<TI>Comparison of therapeutic effect of enoxacin and norfloxacin in the treatment of typhoid fever</TI>
<SO>Zhonghua Chuan Ran Bing Za Zhi [Chinese Journal of Infectious Diseases]</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>117-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavdekar-1991" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bavdekar 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bavdekar A, Chaudhari M, Bhave S, Pandit A</AU>
<TI>Ciprofloxacin in typhoid fever</TI>
<SO>Indian Journal Pediatrics</SO>
<YR>1991</YR>
<VL>58</VL>
<NO>3</NO>
<PG>335-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bethell-1996" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bethell 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bethell DB, Day NP, Dung NM, McMullin C, Loan HT, Tam DT, et al</AU>
<TI>Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>9</NO>
<PG>2167-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chakravorty-1991" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Chakravorty 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chakravorty B, Jain N, Gupta B, Rajvanshi P, Sen MK, Krishna A</AU>
<TI>Chloramphenicol resistant enteric fever</TI>
<SO>Journal of Indian Medical Association</SO>
<YR>1993</YR>
<VL>91</VL>
<NO>1</NO>
<PG>10-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chukwani-1998" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Chukwani 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chukwani CM, Onyemelukwe GC, Okonkwo PO, Coker HAB, Ifudu ND</AU>
<TI>Fleroxacin vs ciprofloxacin in the management of typhoid fever</TI>
<SO>Clinical Drugs Investigation</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>279-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daga-1994" MODIFIED="2011-08-24 14:55:58 +0100" MODIFIED_BY="[Empty name]" NAME="Daga 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-08-24 14:55:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daga MK, Sarin K, Sarkar R</AU>
<TI>A study of culture positive multidrug resistant enteric fever - changing pattern and emerging resistance to ciprofloxacin</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>8</NO>
<PG>599-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duong-1995" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Duong 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duong NM, Chau NVV, Anh DCV, Hoa NTT, Tam DTH, Hai DT, et al</AU>
<TI>Short course fleroxacin in the treatment of typhoid fever</TI>
<SO>JAMA Southeast Asia</SO>
<YR>1995</YR>
<VL>11 Suppl</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hou-1993" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Hou 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hou SR</AU>
<TI>Clinical study of Chinese ofloxacin</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>1993</YR>
<VL>73</VL>
<NO>4</NO>
<PG>255-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huai-2000" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Huai 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huai Y, Zhu Q, Wang X</AU>
<TI>Ceftriaxone vs. norfloxacin in the treatment of resistant typhoid fever in 60 children</TI>
<SO>Zhonghua Er Ke Za Zhi [Chinese Journal of Pediatrics]</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>6</NO>
<PG>386-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-1994" MODIFIED="2011-08-24 15:01:49 +0100" MODIFIED_BY="[Empty name]" NAME="Jia 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-08-24 15:01:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia FZ, Zhu JQ, Huang SY, Chen HK, Bai JY, Li ZC, et al</AU>
<TI>Clinical study on therapy of typhoid fever with pefloxacin</TI>
<SO>Zhonghua Chuan Ran Bing Za Zhi [Chinese Journal of Infectious Diseases]</SO>
<YR>1994</YR>
<VL>12 Suppl 3</VL>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jinlong-1998" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Jinlong 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jinlong Z, Wennan H, Guosheng M, Zhigang H, Jianping Z</AU>
<TI>Evaluation of effectiveness of ofloxacin and S-(-) ofloxacin in treating typhoid fever</TI>
<SO>Zhonghua Chuan Ran Bing Za Zhi [Chinese Journal of Infectious Diseases]</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>237</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2007" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar R, Gupta N</AU>
<TI>Multidrug-resistant typhoid fever</TI>
<SO>Indian Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>74</VL>
<NO>1</NO>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liberti-2000" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Liberti 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liberti A, Loiacono L</AU>
<TI>Ciprofloxacin versus chloramphenicol in the treatment of salmonella infection</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>3</NO>
<PG>347-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1995" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Zhang H, Mu G, Qiu D, Hu P</AU>
<TI>Clinical study of intravenous enoxacin versus cefotaxime in aute [sic] infectious diseases</TI>
<SO>Zhongguo Kang Sheng Su Za Zhi [Chinese Journal of Antibiotics]</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>2</NO>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nalin-1987" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Nalin 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nalin DR, Hoagland VL, Acuna G, Bran JL, Carrilo C, Gotuzzo E, et al</AU>
<TI>Clinical trial of norfloxacin versus chloramphenicol therapy for acute typhoid fever</TI>
<SO>Progress in antimicrobial and anti-cancer chemotherapy. Proceedings of the 15th International Congress of Chemotherapy; 1987 July 19-24; Istanbul</SO>
<YR>1987</YR>
<PG>1174-5</PG>
<CY>Copenhagen, Munksgaard</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelwan-1995" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nelwan 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelwan RH, Hendarwanto, Zulkarnain I, Gunawan J, Supandiman I, Yusuf H, et al</AU>
<TI>A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49 Suppl 2</VL>
<PG>463-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peyramond-1986" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Peyramond 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peyramond D, Tiguad S, Lucht F, Vedrinne JM, Salord F, Bertrand JL</AU>
<TI>Clinical evaluation of ofloxacin in the treatment of various infections</TI>
<TO>Bilan d'utilisation de l'ofloxacine dans le traitement d'infections variées</TO>
<SO>Pathologie-Biologie</SO>
<YR>1986</YR>
<VL>34</VL>
<NO>5</NO>
<PG>471-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarma-1991" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Sarma 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarma PS, Durairaj P</AU>
<TI>Randomized treatment of patients with typhoid and paratyphoid fevers using norfloxacin or chloramphenicol</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>85</VL>
<NO>5</NO>
<PG>670-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Secmeer-1997" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Secmeer 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Secmeer G, Kanra G, Figen G, Akan O, Ceyhan M, Ecevit Z</AU>
<TI>Ofloxacin versus co-trimoxazole in the treatment of typhoid fever in children</TI>
<SO>Acta Paediatrica Japonica</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>2</NO>
<PG>218-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1993" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh CP, Singh N, Brar GK, Lal G, Kumar H</AU>
<TI>Efficacy of ciprofloxacin and norfloxacin in multidrug resistant enteric fever in adults</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>1993</YR>
<VL>91</VL>
<NO>6</NO>
<PG>156-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suhendro-2007" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Suhendro 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suhendro, Chen K, Pohan HT</AU>
<TI>Open study on efficacy and tolerability of ciprofloxacin XR compared with ciprofloxacin BID in the treatment of typhoid fever</TI>
<SO>Acta Medica Indonesiana</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>1</NO>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takkar-1994" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Takkar 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takkar VP, Kumar R, Khurana S, Takkar R</AU>
<TI>Comparison of ciprofloxacin versus cephelexin and gentamicin in the treatment of multi-drug resistant typhoid fever</TI>
<SO>Indian Pediatrics</SO>
<YR>1994</YR>
<VL>31</VL>
<NO>2</NO>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanphaichitra-1986" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tanphaichitra 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanphaichitra D, Sahaphong S, Srimuang S</AU>
<TI>Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections</TI>
<SO>Infection</SO>
<YR>1986</YR>
<VL>14 Suppl 4</VL>
<PG>321-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1994" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Tran 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran TH, Nguyen MD, Huynh DH, Nguyen TT, To SD, Le TP, et al</AU>
<TI>A randomized comparative study of fleroxacin and ceftriaxone in enteric fever</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>4</NO>
<PG>464-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uwaydah-1992" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Uwaydah 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uwaydah AK, al Soub H, Matar I</AU>
<TI>Randomized prospective study comparing two dosage regimens of ciprofloxacin for the treatment of typhoid fever</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>5</NO>
<PG>707-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wain-1997" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Wain 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wain J, Hoa NTT, Chinh NT, Vinh H, Everett J, Diep TS, et al</AU>
<TI>Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1404-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weng-1996a" MODIFIED="2011-07-25 18:57:41 +0100" MODIFIED_BY="[Empty name]" NAME="Weng 1996a" YEAR="1996">
<REFERENCE MODIFIED="2011-07-25 18:57:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weng YL, Jia FZ</AU>
<TI>Clinical efficacy evaluation of fluoroquinolones in typhoid fever (clinical analysis of 391 cases)</TI>
<SO>Chinese Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1991" MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 13:00:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang JG, Wa XL, Shen XJ, Wang KL, Zhu XB, Chen ZY</AU>
<TI>Short course of ofloxacin in the treatment of 28 patients of typhoid fever</TI>
<SO>Xin Yao Yu Lin Chuang [New Drugs and Clinical Remedies]</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>2</NO>
<PG>79-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavala-1989" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Zavala 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavala-Trujillo I, Nava-Zavala A, Marcano MG, Renteria M</AU>
<TI>Fleroxacin in the treatment of enteric fever and salmonellosis in adults</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1989</YR>
<VL>2 Suppl 5</VL>
<PG>1188-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1991" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YY, Zhun BY, Jiang SC</AU>
<TI>Clinical evaluation of enoxacin</TI>
<SO>Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]</SO>
<YR>1991</YR>
<VL>30</VL>
<NO>8</NO>
<PG>480-3, 521</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ZhongYang-1997" MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" NAME="ZhongYang 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ZhongYang H, Zheng L, Xinchung L, Hanjun H, Yi L X</AU>
<TI>Compared observation on therapeutic effect of ofloxacin and norfloxacin in treatment of typhoid fever</TI>
<SO>Zhonghua Chuan Ran Bing Za Zhi [Chinese Journal of Infectious Diseases]</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>4</NO>
<PG>229-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-02-28 09:47:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bran-1991" MODIFIED="2011-02-28 09:46:24 +0100" MODIFIED_BY="[Empty name]" NAME="Bran 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-02-28 09:46:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bran JL, Garcia JF, Mendez O</AU>
<TI>Comparative, double blind study of chloramphenicol and ciprofloxacin in the treatment of typhoid fever (abstract 751)</TI>
<SO>Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sept 29-Oct 2; Chicago, Illinois</SO>
<YR>1991</YR>
<PG>224</PG>
<PB>American Society of Microbiology</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores-1991" MODIFIED="2010-12-25 12:50:18 +0100" MODIFIED_BY="[Empty name]" NAME="Flores 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores GR</AU>
<TI>Pharmacological treatment of typhoid fever: A comparative study of ciprofloxacin versus trimethoprim-sulfamethoxazole</TI>
<TO>Tratamiento farmacológico del paciente con fiebre tifoidea: estudio comparativo entre ciprofloxacina y trimetoprim-sulfametoxazol</TO>
<SO>Investigacion Medica International</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>4</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quintero-1988" MODIFIED="2011-02-28 09:47:34 +0100" MODIFIED_BY="[Empty name]" NAME="Quintero 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-02-28 09:47:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Quintero-Perez NP, Andrea-Villanueva J, Leon-Garnica M, Bertin-Montano M, Chagollan-Rodriguez E, Rodiguez-Noriega E</AU>
<TI>Comparative double blind efficacy and safety study of ciprofloxacin with chloramphenicol in the treatment of typhoid fever. Abstract number 385</TI>
<SO>Programs and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1988 Oct 23-26; Los Angeles, California</SO>
<YR>1988</YR>
<PG>177</PG>
<PB>American Society for Microbiology</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soewandojo-1992" MODIFIED="2010-12-25 12:50:24 +0100" MODIFIED_BY="[Empty name]" NAME="Soewandojo 1992" YEAR="1991">
<REFERENCE MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Soewandojo E, Suharto JR</AU>
<TI>Comparative study of ciprofloxacin vs chloramphenicol in patients with typhoid fever. Typhoid fever, profile, diagnosis and treatment in 1990</TI>
<SO>Proceedings of the 1st ISAC International Symposium</SO>
<YR>1992</YR>
<PG>119-25</PG>
<ED>Newlan RHH</ED>
<PB>Acta Medica Indonesia</PB>
<CY>Jakarta</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weng-1996" MODIFIED="2011-02-28 09:21:16 +0100" MODIFIED_BY="[Empty name]" NAME="Weng 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-28 09:21:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weng Y-L, Jia F-Z</AU>
<TI>Clinical efficacy evaluation of fluoroquinolones in typhoid fever (clinical analysis of 391 cases)</TI>
<SO>Zhongguo Lin Chuang Yao Li Xue Za Zhi [Chinese Journal of Clinical Pharmacology]</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-1991" MODIFIED="2011-02-28 09:26:01 +0100" MODIFIED_BY="[Empty name]" NAME="Xiao 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-02-24 17:02:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao YH, Wang QN, Du JZ, Zheng XP, Li ZZ, Qui J, et al</AU>
<TI>Clinical and laboratory study of the fluoroquinolone antibiotics in the treatment of multiresistant typhoid fever</TI>
<SO>Sichuan I Hseuh</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>4</NO>
<PG>196-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1998" MODIFIED="2011-02-28 09:26:11 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-24 17:02:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu Y-S, Zheng J-C, Gan M-J, Ma Y-L</AU>
<TI>Clinical study on the efficacy and safety of the levofloxacin used to treat the patients with typhoid fever or paratyphoid fever</TI>
<SO>Zhongguo Lin Chuang Yao Li Xue Za Zhi [Chinese Journal of Clinical Pharmacology]</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>2</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-12-25 12:49:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN66534807" MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN66534807" YEAR="">
<REFERENCE MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN66534807</AU>
<TI>A randomised clinical trial of Azithromycin versus Ofloxacin in the treatment of adults with uncomplicated typhoid fever at Mahosot Hospital, Vientiane, Lao People's Democratic Republic (PDR)</TI>
<SO>www.controlled-trials.com/ISRCTN66534807</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-08-24 15:13:32 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-24 15:13:32 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ackers-2000" MODIFIED="2011-02-28 07:28:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ackers 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ackers ML, Puhr ND, Tauxe RV, Mintz ED</AU>
<TI>Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>20</NO>
<PG>2668-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adachi-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Adachi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Adachi T, Sagara H, Hirose K, Watanabe H</AU>
<TI>Fluoroquinolone-resistant Salmonella paratyphi A</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>172-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ahmad-2002" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ahmad 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad K</AU>
<TI>Experts call for surveillance of drug-resistant typhoid at a global level</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9306</NO>
<PG>592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ahmed-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ahmed 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed D, D'Costa LT, Alam K, Nair GB, Hossain MA</AU>
<TI>Multidrug-resistant Salmonella enterica serovar typhi isolates with high-level resistance to ciprofloxacin in Dhaka, Bangladesh</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>10</NO>
<PG>3516-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akinyemi-2005" MODIFIED="2011-04-03 21:00:49 +0100" MODIFIED_BY="[Empty name]" NAME="Akinyemi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Akinyemi KO, Smith SI, Oyefolu AOB, Coker AO</AU>
<TI>Multidrug resistance in Salmonella enterica serovar typhi isolated from patients with typhoid fever complications in Lagos, Nigeria</TI>
<SO>Public Health</SO>
<YR>2005</YR>
<VL>119</VL>
<NO>4</NO>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ambrose-2003" MODIFIED="2011-08-05 11:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Ambrose 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH</AU>
<TI>Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction</TI>
<SO>Journal of Antimicrobial and Chemotherapy</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertino-2000" MODIFIED="2011-08-08 07:54:14 +0100" MODIFIED_BY="[Empty name]" NAME="Bertino 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bertino J, Fish D</AU>
<TI>The Safety Profile of the Fluoroquinolones</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>7</NO>
<PG>798-817</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhan-2005" MODIFIED="2011-02-28 05:25:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bhan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bhan MK, Bahl R, Bhatnagar S</AU>
<TI>Typhoid and paratyphoid fever</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9487</NO>
<PG>749-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhutta-1996" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bhutta 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bhutta ZA</AU>
<TI>Impact of age and drug resistant on mortality in typhoid fever</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>3</NO>
<PG>214-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Brooks 2005" TYPE="JOURNAL_ARTICLE">
<AU>Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al</AU>
<TI>Bacteremic typhoid fever in children in an urban slum, Bangladesh</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BSAC-2011" MODIFIED="2011-08-24 09:36:27 +0100" MODIFIED_BY="[Empty name]" NAME="BSAC 2011" TYPE="OTHER">
<AU>British Society for Antimicrobial Chemotherapy</AU>
<TI>BASC methods for antimicrobial susceptibility testing, version 10, January 2011. Bristish Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom</TI>
<SO>http://www.bsac.org.uk/Resources/BSAC/Version%20%2010%202011%20final.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Butt-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Butt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Butt T, Ahmad RN, Salman M, Kazmi SY</AU>
<TI>Changing trends in drug resistance among typhoid salmonellae in Rawalpindi, Pakistan</TI>
<SO>Eastern Mediterranean Health Journal</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>5-6</NO>
<PG>1038-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chandel-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Chandel 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB</AU>
<TI>Drug-resistant Salmonella enterica serotype paratyphi A in India</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>4</NO>
<PG>420-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuang-2009" MODIFIED="2011-08-24 15:02:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chuang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Chuang CH, Su LH, Perera J, Carlos C, Tan BH, Kumarasinghe G et al</AU>
<TI>Surveillance of antimicrobial resistance of Salmonella enterica serotype Typhi in seven Asian countries</TI>
<SO>Epidemiology and Infection</SO>
<YR>2009</YR>
<VL>137</VL>
<NO>2</NO>
<PG>266-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CLSI-2007" MODIFIED="2011-07-25 03:49:38 +0100" MODIFIED_BY="[Empty name]" NAME="CLSI 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clinical and Laboratory Standard Institute</AU>
<TI>Performance Standards for Antimicrobial Susceptibility Testing</TI>
<SO>Seventeenth Informational Supplement</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>MS100-S17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Committee-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Committee 2006" TYPE="JOURNAL_ARTICLE">
<AU>Committee on Infectious Diseases</AU>
<TI>The use of systemic fluoroquinolones</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>3</NO>
<PG>1287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Congeni-2002" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Congeni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Congeni BL, Thomson RB Jr</AU>
<TI>Fluoroqinolones: consideration for future use</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>345-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooke-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Cooke 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cooke FJ, Wain J, Threlfall EJ</AU>
<TI>Fluoroquinolone resistance in Salmonella typhi</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7563</NO>
<PG>353-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooke-2007" MODIFIED="2011-08-24 15:04:19 +0100" MODIFIED_BY="[Empty name]" NAME="Cooke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ</AU>
<TI>Cases of typhoid fever imported into England, Scotland and Wales (2000&#8211;2003)</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>4</NO>
<PG>398-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coovadia-1992" MODIFIED="2010-12-30 07:08:38 +0100" MODIFIED_BY="[Empty name]" NAME="Coovadia 1992" TYPE="JOURNAL_ARTICLE">
<AU>Coovadia YM, Gathiram V, Bhamjee A, Garratt RM, Mlisana K, Pillay N, et al</AU>
<TI>An outbreak of multiresistant Salmonella typhi in South Africa</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>298</NO>
<PG>91-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crump-2003" MODIFIED="2011-02-28 09:33:38 +0100" MODIFIED_BY="[Empty name]" NAME="Crump 2003" TYPE="JOURNAL_ARTICLE">
<AU>Crump JA, Barrett TJ, Nelson JT, Angulo FJ</AU>
<TI>Reevaluating fluoroquinolone breakpoints for salmonella enterica typhi and for non-Typhi salmonellae</TI>
<SO>Clinical Infectious Disease</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>75-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crump-2004" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Crump 2004" TYPE="JOURNAL_ARTICLE">
<AU>Crump JA, Luby SP, Mintz ED</AU>
<TI>The global burden of typhoid fever</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>5</NO>
<PG>346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crump-2008" MODIFIED="2011-04-04 06:12:27 +0100" MODIFIED_BY="[Empty name]" NAME="Crump 2008" TYPE="JOURNAL_ARTICLE">
<AU>Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S</AU>
<TI>Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2008</YR>
<VL>52</VL>
<PG>1278-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimitrov-2009" MODIFIED="2011-07-25 05:33:53 +0100" MODIFIED_BY="[Empty name]" NAME="Dimitrov 2009" TYPE="JOURNAL_ARTICLE">
<AU>Dimitrov T, Dashti AA, Albaksami O, Udo EE, Jadaon MM, Albert MJ et al</AU>
<TI>Ciprofloxacin-resistant Salmonella enterica serovar typhi from Kuwait with novel mutations in gyrA and parC genes</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>1</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fish-2001" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Fish 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fish DN</AU>
<TI>Fluoroquinolone adverse effects and drug interactions</TI>
<SO>Pharmacotherapy</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>10 Part 2</NO>
<PG>253-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frothingham-2005" MODIFIED="2011-08-24 15:04:49 +0100" MODIFIED_BY="[Empty name]" NAME="Frothingham 2005" TYPE="JOURNAL_ARTICLE">
<AU>Frothingham R</AU>
<TI>Glucose homeostasis abnormalities associated with use of gatifloxacin</TI>
<SO>Clinical Infectious Disease</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>1269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fukuda-2001" MODIFIED="2011-07-25 06:56:05 +0100" MODIFIED_BY="[Empty name]" NAME="Fukuda 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda H, Kishii R, Takei M, Hosaka M</AU>
<TI>Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae</TI>
<SO>Antimicrob Agents Chemother. </SO>
<YR>2001</YR>
<VL>45</VL>
<NO>6</NO>
<PG>1649-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaind-2006" MODIFIED="2011-07-25 04:57:08 +0100" MODIFIED_BY="[Empty name]" NAME="Gaind 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P et al</AU>
<TI>Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India</TI>
<SO>Journal of Antimicrobial Agents And Chemotherapy</SO>
<YR>2006</YR>
<VL>58</VL>
<NO>6</NO>
<PG>1139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2009" MODIFIED="2011-04-03 23:09:11 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 2009" TYPE="JOURNAL_ARTICLE">
<AU>Gupta V, Kaur J, Kaistha N</AU>
<TI>Re-emerging chloramphenicol sensitivity and emerging low level ciprofloxacin resistance among Salmonella enterica serotype typhi isolates in North India</TI>
<SO>Tropical Doctor</SO>
<YR>2009</YR>
<VL>39</VL>
<NO>1</NO>
<PG>28-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harish-2004" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Harish 2004" TYPE="JOURNAL_ARTICLE">
<AU>Harish BN, Madhulika U, Parija SC</AU>
<TI>Isolated high-level ciprofloxacin resistance in Salmonella enterica subsp. enterica serotype Paratyphi A</TI>
<SO>Journal of Medical Microbiology</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>Pt 8</NO>
<PG>819</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-08-22 15:11:51 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins J, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hooper-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hooper 2000" TYPE="BOOK_SECTION">
<AU>Hooper DC</AU>
<TI>Quinolones</TI>
<SO>Mandell, Douglas and Bennett's principles and practice of infectious diseases</SO>
<YR>2000</YR>
<PG>405-20</PG>
<EN>5th</EN>
<ED>Mandell GL, Bennett JE, Dolin R</ED>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia. London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ivanoff-1995" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ivanoff 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ivanoff B</AU>
<TI>Typhoid fever: global situation and WHO recommendations</TI>
<SO>Southeast Asian Journal of Topical Medicine and Public Health</SO>
<YR>1995</YR>
<VL>26 Suppl 2</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jesudason-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Jesudason 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jesudason MV</AU>
<TI>Paratyphoid fever in Vellore, South India</TI>
<SO>Tropical Doctor</SO>
<YR>2005</YR>
<VL>35</VL>
<NO>3</NO>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joshi-2007" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Joshi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Joshi S, Amarnath SK</AU>
<TI>Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>3</NO>
<PG>308-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kariuki-2004" MODIFIED="2011-08-24 15:11:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kariuki 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kariuki S, Revathi G, Muyodi J, Mwituria J, Munyalo A, Mirza S, et al</AU>
<TI>Characterization of multidrug-resistant typhoid outbreaks in Kenya</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>4</NO>
<PG>1477-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keddy-2010" MODIFIED="2011-07-25 04:31:38 +0100" MODIFIED_BY="[Empty name]" NAME="Keddy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Keddy KH, Smith AM, Sooka A, Ismail A, Oliver S</AU>
<TI>Fluoroquinolone-Resistant Typhoid</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>5</NO>
<PG>879&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kownhar-2007" MODIFIED="2010-12-30 06:50:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kownhar 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kownhar H, Shankar EM, Rajan R, Rao UA</AU>
<TI>Emergence of nalidixic acid-resistant Salmonella enterica serovar Typhi resistant to ciprofloxacin in India</TI>
<SO>Journal of Medical Microbiology</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>1</NO>
<PG>136-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lakshmi-2006" MODIFIED="2011-08-08 07:03:06 +0100" MODIFIED_BY="[Empty name]" NAME="Lakshmi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lakshmi V, Ashok R, Susmita J, Shailaja VV</AU>
<TI>Changing trends in the antibiograms of Salmonella isolates at a tertiary care hospital in Hyderabad</TI>
<SO>Indian Journal of Medical Microbiology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>1</NO>
<PG>45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2000" TYPE="BOOK_SECTION">
<AU>Lee TP, Hoffman SL</AU>
<TI>Typhoid fever</TI>
<SO>Hunter's Tropical medicine and emerging infectious diseases</SO>
<YR>2000</YR>
<PG>471-83</PG>
<EN>8th</EN>
<ED>Strickland GT</ED>
<PB>Saunders</PB>
<CY>Philadelphia. London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-08-24 15:13:04 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies.</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011)</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration, Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lesser-2001" MODIFIED="2011-02-28 05:28:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lesser 2001" TYPE="BOOK_SECTION">
<AU>Lesser CF, Miller SI</AU>
<TI>Salmonellosis</TI>
<SO>Harrison's Principles of Internal Medicine</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>971-3</PG>
<EN>15th</EN>
<ED>Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, et al</AU>
<TI>The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>62</VL>
<NO>5</NO>
<PG>644-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maskey-2008" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Maskey 2008" TYPE="JOURNAL_ARTICLE">
<AU>Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD</AU>
<TI>Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNabb-2008" MODIFIED="2011-08-24 09:36:52 +0100" MODIFIED_BY="[Empty name]" NAME="McNabb 2008" TYPE="JOURNAL_ARTICLE">
<AU> McNabb SJ, Jajosky RA, Hall-Baker PA, Adams DA, Sharp P, Worshams C et al</AU>
<TI>Centersfor Disease Control and Prevention. Summary of notifiable diseases - United States, 2006</TI>
<SO>Morbidity Mortality Weekly Reports</SO>
<YR>2008</YR>
<VL>55</VL>
<NO>53</NO>
<PG>1-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medalla-2011" MODIFIED="2011-07-25 04:42:28 +0100" MODIFIED_BY="[Empty name]" NAME="Medalla 2011" TYPE="JOURNAL_ARTICLE">
<AU>Medalla F, Sjölund-Karlsson M, Shin S, HarveyE, Joyce K, Theobald L et al</AU>
<TI>Ciprofloxacin-Resistant Salmonella enterica Serotype Typhi, United States,1999&#8211;2008</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>6</NO>
<PG>1095-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mermin-1999" MODIFIED="2010-12-30 07:08:38 +0100" MODIFIED_BY="[Empty name]" NAME="Mermin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mermin JH, Villar R, Carpenter J, Roberts L, Samaridden A, Gasanova L, et al</AU>
<TI>A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>179</VL>
<NO>6</NO>
<PG>1416-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2000" TYPE="BOOK_SECTION">
<AU>Miller SI, Pegues DA</AU>
<TI>Salmonella species, including Salmonella typhi</TI>
<SO>Mandell, Douglas and Bennett's principles and practice of infectious diseases</SO>
<YR>2000</YR>
<PG>2344-56</PG>
<EN>5th</EN>
<ED>Mandell GL, Bennett JE, Dolin R</ED>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia. London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohanty-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Mohanty 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mohanty S, Renuka K, Sood S, Das BK, Kapil A</AU>
<TI>Antibiogram pattern and seasonality of Salmonella serotypes in a North Indian tertiary care hospital</TI>
<SO>Epidemiology and infection</SO>
<YR>2006</YR>
<VL>134</VL>
<NO>5</NO>
<PG>961-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ochiai-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ochiai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ochiai RL, Wang X, von SL, Yang J, Bhutta ZA, Bhattacharya SK, et al</AU>
<TI>Salmonella paratyphi A rates, Asia</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>11</NO>
<PG>1764-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ochiai-2008" MODIFIED="2011-08-24 15:13:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ochiai 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD</AU>
<TI>A study of typhoid fever in five Asian countries: disease burden and implications for controls</TI>
<SO>Bulletin of World Health Organization</SO>
<YR>2008</YR>
<VL>86</VL>
<PG>260-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliphant-2002" MODIFIED="2011-06-22 22:38:29 +0100" MODIFIED_BY="[Empty name]" NAME="Oliphant 2002" TYPE="JOURNAL_ARTICLE">
<AU>Oliphant CM, Green GM</AU>
<TI>Quinolones; A Comprehensive Review</TI>
<SO>American Family Physician</SO>
<YR>2002</YR>
<VL>65</VL>
<NO>3</NO>
<PG>455-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park_x002d_Wyllie-2006" MODIFIED="2011-04-04 09:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="Park-Wyllie 2006" TYPE="JOURNAL_ARTICLE">
<AU>Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C et al</AU>
<TI>Outpatient gatifloxacin therapy and dysglycemia in older adults</TI>
<SO>NEJM</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>1352-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parry-2002" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Parry 2002" TYPE="JOURNAL_ARTICLE">
<AU>Parry CM, Hien TT, Dougan G, Whilte NJ, Farrar JJ</AU>
<TI>Typhoid fever</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>22</NO>
<PG>1770-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parry-2006" MODIFIED="2010-12-30 06:50:24 +0100" MODIFIED_BY="[Empty name]" NAME="Parry 2006" TYPE="JOURNAL_ARTICLE">
<AU>Parry CM, Karunanayake L, Coulter JBS, Beeching NJ</AU>
<TI>Test for quinolone resistance in typhoid fever</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7561</NO>
<PG>260-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parry-2010" MODIFIED="2011-04-03 23:03:38 +0100" MODIFIED_BY="[Empty name]" NAME="Parry 2010" TYPE="JOURNAL_ARTICLE">
<AU>Parry CM, Thuy CT, Dongol S, Karkey A, Vinh H, Chinh NT et al</AU>
<TI>Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>12</NO>
<PG>5201-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Renuka-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Renuka 2005" TYPE="JOURNAL_ARTICLE">
<AU>Renuka K, Sood S, Das BK, Kapil A</AU>
<TI>High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India</TI>
<SO>Journal of Medical Microbiology</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>Pt 10</NO>
<PG>999-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5.1" MODIFIED="2011-08-24 11:29:57 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5.1" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2011</YR>
<EN>5.1 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<MD>CD-ROM and Internet</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richens-2000" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Richens 2000" TYPE="BOOK_SECTION">
<AU>Richens J</AU>
<TI>Typhoid fever</TI>
<SO>Infectious diseases</SO>
<YR>2000</YR>
<PG>6-24.1-4</PG>
<EN>1st</EN>
<ED>Armstrong D, Cohen J</ED>
<PB>Mosby</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodrigues-2003" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Rodrigues 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigues C, Shenai S, Mehta A</AU>
<TI>Enteric fever in Mumbai, India: the good news and the bad news</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>4</NO>
<PG>535</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rupali-2004" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Rupali 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rupali P, Abraham OC, Jesudason MV, John TJ, Zachariah A, Sivaram S, et al</AU>
<TI>Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saha-2001" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Saha 2001" TYPE="JOURNAL_ARTICLE">
<AU>Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, et al</AU>
<TI>Typhoid fever in Bangladesh: implications for vaccination policy</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>5</NO>
<PG>521-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saha-2003" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Saha 2003" TYPE="JOURNAL_ARTICLE">
<AU>Saha MR, Dutta P, Palit A, Dutta D, Bhattacharya MK, Mitra U, et al</AU>
<TI>A note on incidence of typhoid fever in diverse age groups in Kolkata, India</TI>
<SO>Japan Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>3</NO>
<PG>121-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siddiqui-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Siddiqui 2006" TYPE="JOURNAL_ARTICLE">
<AU>Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA</AU>
<TI>Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>3</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sinha-1999" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sinha 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al</AU>
<TI>Typhoid fever in children aged less than 5 years</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9180</NO>
<PG>734-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2010" MODIFIED="2011-04-04 05:36:00 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2010" TYPE="JOURNAL_ARTICLE">
<AU>Smith AM, Govender N, Keddy KH</AU>
<TI>Quinolone resistant Salmonella Typhi in South Africa, 2003-2007</TI>
<SO>Epiemiology and Infection</SO>
<YR>2010</YR>
<VL>138</VL>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sood-1999" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sood 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sood S, Kapil A, Das B, Jain Y, Kabra SK</AU>
<TI>Re-emergence of chloramphenicol-sensitive Salmonella typhi</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9160</NO>
<PG>1241-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sur-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sur 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sur D, von SL, Manna B, Dutta S, Deb AK, Sarkar BL, et al</AU>
<TI>The malaria and typhoid fever burden in the slums of Kolkata, India: data from a prospective community-based study</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>8</NO>
<PG>725-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takkar-1995" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Takkar 1995" TYPE="JOURNAL_ARTICLE">
<AU>Takkar VP, Kumar R, Takkar R, Khurana S</AU>
<TI>Resurgence of chloramphenicol sensitive Salmonella typhi</TI>
<SO>Indian Pediatrics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>5</NO>
<PG>586-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Threlfall-1999" MODIFIED="2011-02-28 07:28:28 +0100" MODIFIED_BY="[Empty name]" NAME="Threlfall 1999" TYPE="JOURNAL_ARTICLE">
<AU>Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S</AU>
<TI>Ciprofloxacin-resistant Salmonella typhi and treatment failure</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9164</NO>
<PG>1590-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Threlfall-2003" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Threlfall 2003" TYPE="JOURNAL_ARTICLE">
<AU>Threlfall EJ, Fisher IS, Berghold C, Gerner-Smidt P, Tschape H, Cormican M, et al</AU>
<TI>Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>5</NO>
<PG>487-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walia-2005" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Walia 2005" TYPE="JOURNAL_ARTICLE">
<AU>Walia M, Gaind R, Mehta R, Paul P, Aggarwal P, Kalaivani M</AU>
<TI>Current perspectives of enteric fever: a hospital-based study from India</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>161-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walia-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Walia 2006" TYPE="JOURNAL_ARTICLE">
<AU>Walia M, Gaind R, Paul P, Mehta R, Aggarwal P, Kalaivani M</AU>
<TI>Age-related clinical and microbiological characteristics of enteric fever in India</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>10</NO>
<PG>942-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasfy-2002" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wasfy 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wasfy MO, Frenck R, Ismail TF, Masour H, Malone JL, Mahoney FJ</AU>
<TI>Trends of multiple-drug resistance among Salmonella serotype Typhi isolates during a 14-year period in Egypt</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>10</NO>
<PG>1265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woods-2006" MODIFIED="2010-12-20 09:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Woods 2006" TYPE="JOURNAL_ARTICLE">
<AU>Woods CW, Murdoch DR, Zimmerman MD, Glover WA, Basnyat B, Wolf L, et al</AU>
<TI>Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>11</NO>
<PG>1063-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2009" MODIFIED="2011-08-24 09:37:10 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2009" TYPE="JOURNAL_ARTICLE">
<AU>WuT, Li Y, Bian Z, Liu G, Moher D</AU>
<TI>Randomized trials published in some Chinese journals: how many are randomized?</TI>
<SO>Trials</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-08-08 07:47:55 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Thaver-2008" MODIFIED="2011-08-08 07:47:55 +0100" MODIFIED_BY="[Empty name]" NAME="Thaver 2008" TYPE="JOURNAL_ARTICLE">
<AU>Thaver DA, Zaidi AK, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA.</AU>
<TI>Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<VL>4</VL>
<PG>CD004530</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-09-01 11:51:42 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-09-01 11:51:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-08-24 14:08:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alam-1995-BGD">
<CHAR_METHODS MODIFIED="2011-08-24 14:08:05 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 64/72 (88.9%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>69 analysed : 35 in 10-day group: 34 in 14-day group</P>
<P>Adults (18 to 65 years) and 11 children (&lt; 18 years)</P>
<P>Both outpatients and inpatients (ciprofloxacin 10-day group had 20 outpatients and 14 inpatients, ciprofloxacin 14-day group had 21 outpatients and 14 inpatients)</P>
<P>Inclusion criteria: blood or bone marrow culture positive for <I>S. typhi</I> or <I>S. paratyphi</I>
</P>
<P>Exclusion criteria: hypersensitivity to quinolones; severe renal disease; pregnant or lactating; patients &lt; 18 years were randomized only if had MDR strain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 10 days)</P>
<P>2. Ciprofloxacin (500 mg oral twice daily for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Convalescent faecal carriage</P>
<P>6. Serious adverse events</P>
<P>7. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Bangladesh</P>
<P>Date: 1992-3</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:12:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arjyal-2011">
<CHAR_METHODS MODIFIED="2011-08-24 14:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: blocks of 50</P>
<P>Allocation concealment: sealed envelops</P>
<P>Blinding: non-blinded</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 348/352 (98.9%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>352 analysed: 175 in chloramphenicol: 177 in gatifloxacin</P>
<P>Adults and children: chloramphenicol 15 yrs (8-22) and in gatifloxacin 16 yrs (9-22)</P>
<P>Outpatients</P>
<P>Inclusion criteria: Patients with fever for more than 3 days who were clinically diagnosed to have enteric fever patients who received amoxicillin or co-trimoxazole were included as long as they did not show evidence of clinical response</P>
<P>Exclusion criteria: pregnancy or lactation, age under 2 years and weight less than 10 kg, shock, jaundice, gastrointestinal bleeding or any other signs of severe typhoid fever, hypersensitivity, known previous treatment with a quinolone antibiotic or 3rd generation cephalosporin or macrolide within one week of hospital admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-24 14:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Gatifloxacin (10 mg/kg/day in a single oral dose for 7 days)</P>
<P>2. Chloramphenicol (75 mg/kg/day in four divided oral doses for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. enteric fever complications</P>
<P>5. Fever clearance time</P>
<P>5. Convalescent faecal carriage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-24 14:09:27 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Nepal</P>
<P>Date: May 2006 - August 2008</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:12:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chinh-1997-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:09:37 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: blocks</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100/107 (93.5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-25 18:52:20 +0100" MODIFIED_BY="[Empty name]">
<P>100 analysed: 47 in 2-day group: 53 in 3-day group</P>
<P>Mean age in 2-day group was 25.3 (8.9) and 3 days group 24.2 (7.1);  adults &gt;15 yrs</P>
<P>Inpatients</P>
<P>Inclusion criteria: clinically suspected uncomplicated enteric fever were included</P>
<P>Exclusion criteria: pregnant, had severe disease required intensive care, had known hypersensitivity to quinolones or had treatment with quinolones in the week before admission, those who had received previous treatment with chloramphenicol, ampicillin, cephalosporins or trimethoprim-sulphamethoxazole were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-24 14:12:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (15 mg/kg/day for two days)</P>
<P>2. Ofloxacin (10 mg/kg/day for three days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 05:54:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-24 14:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Viet Nam</P>
<P>Date: November 1993 - December 1995</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:12:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chinh-2000-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 38/91 (42%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>88 analysed : 44 in ofloxacin group; 44 in azithromycin group</P>
<P>Adult inpatients aged &gt;15 years</P>
<P>Inclusion criteria: clinical with blood culture positive for <I>S. Typhi </I>or <I>S. Paratyphi</I>
</P>
<P>Exclusion criteria: severe or complicated disease; significant underlying disease; hypersensitivity to either trial drug; pregnant; history of treatment with fluoroquinolone or third-generation cephalosporins or macrolides within 1 week of admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-24 14:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (200 mg oral twice daily for 5 days at 8 mg/kg/day)</P>
<P>2. Azithromycin (1 gm oral daily for 5 days at 20 mg/kg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)</P>
<P>5. Complications</P>
<P>6. Length of hospitalization (mean and 95% confidence interval; SD calculated by review author)</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events (number of events stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: not available</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:12:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cristiano-1995-ITA">
<CHAR_METHODS MODIFIED="2011-08-24 14:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>60 analysed: 30 in pefloxacin group; 30 in chloramphenicol group</P>
<P>Adult inpatients aged 17 to 64 years</P>
<P>Inclusion criteria: Severe culture-positive typhoid sepsis</P>
<P>Exclusion criteria: Received any known or presumed antibiotic active against <I>S. Typhi,</I> allergy to pyridoxine-carboxylic acid derivatives or to chloramphenicol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-24 14:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Pefloxacin (1200 mg intravenous in 3 divided doses every 8 hours for 5 days, and orally for the next 10 days)</P>
<P>2. Chloramphenicol (2 g in 4 divided doses every 6 hours for 15 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-14 17:28:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time (no SD)</P>
<P>5. Convalescent faecal carriage</P>
<P>6. Length of hospitalisation (no SD)</P>
<P>7. Serious adverse events</P>
<P>8. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Italy</P>
<P>Date: 1991-3</P>
<P>Severity of illness at entry: all severe</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:11:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolecek-2008-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated, block randomization</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 268/288 (93%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>285 analysed: 145 in gatifloxacin group; 140 in azithromycin group</P>
<P>Adult and children inpatients aged 1 to 41 years (210/287 (73%) participants below the age of 15 years)</P>
<P>Inclusion criteria: clinical or culture-positive enteric fever</P>
<P>Exclusion criteria: no consent; pregnancy; age &lt; 6 months; history of hypersensitivity to either of the trial drugs; any signs of severe typhoid fever or previous reported treatment with a fluoroquinolone antibiotics; a third-generation cephalosporin or macrolide antibiotic within 1 week before to hospital admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Gatifloxacin (10 mg/kg/day oral once daily for 7 days)</P>
<P>2. Azithromycin (20 mg/kg/day oral once daily for 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam (multi-centre, 3 hospitals)</P>
<P>Date: 2004-5</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Received as an unpublished trial (with additional data), but reference updated to current citation upon publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:11:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores-1994-MEX">
<CHAR_METHODS MODIFIED="2011-08-24 14:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>40 analysed: 20 in ofloxacin group; 20 in ampicillin group</P>
<P>Adult male or females; most probably inpatients.</P>
<P>Inclusion criteria: Age over 16 with clinical features of typhoid fever as well as positive blood cultures for <I>S. typhi</I>
</P>
<P>Exclusion criteria: Previous adverse reactions, complicated disease, severe renal insufficiency, severe neutropenia, requirement of concomitant systemic antimicrobial, convulsions, grave psychiatric disorders, pregnancy or lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-15 06:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ampicillin (1 g every 6 hours for 10 days)<BR/>2. Ofloxacin (400 mg every 12 hours for 10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-15 06:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure<BR/>2. Microbiological failure<BR/>3. Serious adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-21 08:33:53 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Mexico</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:11:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gasem-2003-IDN">
<CHAR_METHODS MODIFIED="2011-08-24 14:11:35 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: random-number table</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-19 17:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>55 analysed: 28 in ciprofloxacin group; 27 in chloramphenicol group</P>
<P>Adult inpatients</P>
<P>Inclusion criteria: clinical and &#8805;14 years</P>
<P>Exclusion criteria: severe complications; treatment with chloramphenicol, ciprofloxacin, other fluoroquinolones before admission; history of allergy to chloramphenicol/quinolone; malaria or other infection; white blood cell count &lt; 2000/mL; pregnant or lactating</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-26 09:42:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 7 days)</P>
<P>2. Chloramphenicol (500 mg oral 4 times a day for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-13 21:45:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological response to treatment at day 3 or day 5</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization</P>
<P>7. Serious adverse events</P>
<P>8. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Indonesia</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: none had severe complications on enrolment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:13:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girgis-1999-EGY">
<CHAR_METHODS MODIFIED="2011-08-24 14:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: random-number list, block randomization</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>64 analysed: 28 in ciprofloxacin group; 36 in azithromycin group</P>
<P>Adult inpatients aged &gt; 18 years</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: pregnant or lactating; allergy to ciprofloxacin or erythromycin/other macrolides; those with complications of typhoid fever; inability to swallow medications; significant underlying illness; treatment within past 4 days with an antibiotic with potential efficacy against S. Typhi</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:15:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 7 days)</P>
<P>2. Azithromycin (1 g oral once daily for the first day followed by oral 500 mg once daily for total duration of 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization</P>
<P>7. Cost of treatment</P>
<P>8. Convalescent faecal carriage</P>
<P>9. Serious adverse events</P>
<P>10. Other adverse events (number of events stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:15:50 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Egypt</P>
<P>Date: 1997-8</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:13:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<CHAR_METHODS MODIFIED="2011-08-24 14:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 95/98 (97%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:13:56 +0100" MODIFIED_BY="[Empty name]">
<P>98 analysed: 49 in ciprofloxacin group; 49 in chloramphenicol group</P>
<P>Adult inpatients</P>
<P>Inclusion criteria: clinical with culture positive for <I>S. typhi </I>or <I>S. paratyphi</I>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral every 12 hours for 10 days)</P>
<P>2. Chloramphenicol (750 mg oral every 6 hours for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Relapse</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>Location: not available</P>
<P>Date: not available</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:14:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hajji-1988-MAR">
<CHAR_METHODS MODIFIED="2011-08-24 14:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: random-number table</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>42 analysed: 24 in pefloxacin group; 18 in co-trimoxazole group</P>
<P>Adult inpatients aged &gt; 16 years</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Pefloxacin (400 mg oral twice daily for 14 days)</P>
<P>2. Co-trimoxazole (160/800 mg oral twice daily for 14 days)</P>
<P>5 participants were given intravenous pefloxacin for mean 4.8 days; 4 were given intramuscular co-trimoxazole for mean 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-25 13:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cure</P>
<P>2. Relapse</P>
<P>3. Fever clearance time (no SD, non-exact P value)</P>
<P>4. Chronic carrier state</P>
<P>5. Serious Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Morocco</P>
<P>Date: 1984-5</P>
<P>Severity of illness at entry: comatose or neurological disorders in 3 participants in pefloxacin group and 2 participants in co-trimoxazole group</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:14:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalo-1997-ALB">
<CHAR_METHODS MODIFIED="2011-08-24 14:14:17 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>30 analysed: 15 in 7-day group; 15 in 10-day group</P>
<P>Adult inpatients aged 16 to 42 years</P>
<P>Inclusion criteria: blood-culture positive; ampicillin-resistant <I>S. typhi</I>
</P>
<P>Exclusion criteria: received quinolones within 2 weeks before hospitalization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perfloxacin (400 mg oral twice daily for 7 days)</P>
<P>2. Perfloxacin (400 mg oral twice daily for 10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Convalescent faecal carriage</P>
<P>5. Serious adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Albania</P>
<P>Date: 1992-4</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:14:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Limson-1989-PHL">
<CHAR_METHODS MODIFIED="2011-08-24 14:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: random-number table</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>40 analysed: 20 in ciprofloxacin group; 20 in co-trimoxazole group</P>
<P>Adult inpatients aged 18 to 77 years</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: complications; drug allergy; renal impairment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 10 days)</P>
<P>2. Co-trimoxazole (160/800 mg oral twice daily for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Serious adverse events</P>
<P>4. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Philippines</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: all uncomplicated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:15:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morelli-1992-ITA">
<CHAR_METHODS MODIFIED="2011-08-24 14:14:52 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>156 analysed: 30 each in ofloxacin and chloramphenicol groups; 36 in pefloxacin group; 20 each in ciprofloxacin,</P>
<P>enoxacin, and norfloxacin groups</P>
<P>Adult inpatients aged 16 to 60 years</P>
<P>Inclusion criteria: blood culture positive for <I>S. typhi</I>; high fever for not more than 5 days; toxic symptomatology</P>
<P>Exclusion criteria: hypersensitivity or allergy to fluoroquinolone or antibiotic treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (300 mg oral every 8 hours for 15 days)</P>
<P>2. Pefloxacin (400 mg oral every 8 hours for 15 days)</P>
<P>3. Ciprofloxacin (500 mg oral every 8 hours for 15 days)</P>
<P>4. Enoxacin (300 mg oral every 8 hours for 15 days)</P>
<P>5. Norfloxacin (400 mg oral every 8 hours for 15 days)</P>
<P>6. Chloramphenicol (500 mg oral every 6 hours for 15 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Relapse</P>
<P>3. Fever clearance time (no SD)</P>
<P>4. Convalescent faecal carriage</P>
<P>5. Other adverse events (number of events stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Italy</P>
<P>Date: 1985-90</P>
<P>Severity of illness at entry: not reported</P>
<P>We prepared different comparisons with these data: a combination of all 5 fluoroquinolone groups vs the chloramphenicol</P>
<P>group; and norfloxacin vs ofloxacin, pefloxacin, and enoxacin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:15:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pandit-2007-NPL">
<CHAR_METHODS MODIFIED="2011-08-24 14:15:21 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated, block randomization</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 147/169 (87%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>158 analysed: 88 in gatifloxacin group; 70 in cefixime group</P>
<P>Adults and children outpatients aged 2.75 to 50 years (60/169 (35.5%) were children aged &lt; 14 years)</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: not residing 2.5 km radius from hospital; age not between 2 to 65 years; not willing to give informed consent; not able to take oral medications; pregnant or lactating; history of seizures; not able to stay in city for treatment duration; known contraindication to cephalosporins or fluoroquinolones; complicated typhoid fever or received third-generation cephalosporins, fluoroquinolones, or macrolide in week before presentation to clinic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Gatifloxacin (10 mg/kg/day in single dose oral for 7 days)</P>
<P>2. Cefixime (20 mg/kg/day in 2 divided doses oral for 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Convalescent faecal carriage</P>
<P>6. Complications</P>
<P>7. Serious adverse events</P>
<P>8 Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Nepal</P>
<P>Date: 2005</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:15:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parry-2007-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:15:34 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 114/130 (88%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-14 12:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>125 analysed: 63 in ofloxacin group; 62 in azithromycin group</P>
<P>Adults and children inpatients 3 to 42 years (87% (163/187) were children &lt; 15 years for all three arms)</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: severe or complicated disease; inability to swallow oral medications; history of significant underlying disease or hypersensitivity to either of trial drugs; pregnant or lactating; history of treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:19:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (20 mg/kg/day in 2 divided doses oral for 7 days)</P>
<P>2. Azithromycin (10 mg/kg/day once a day oral for 7 days)</P>
<P>Comparison not included in this review:</P>
<P>3. Ofloxacin-azithromycin (15 mg/kg/day in 2 divided doses oral ofloxacin for 7 days and 10 mg/kg/day once a day</P>
<P>oral azithromycin for first 3 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:19:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)</P>
<P>5. Complications</P>
<P>6. Length of hospitalization (mean and 95% confidence intervals; SD calculated by review author)</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events (numbers not stated)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:19:35 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: 1998-2002</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:16:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phongmany-2005-LAO">
<CHAR_METHODS MODIFIED="2011-08-24 14:16:06 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: random-number table, block randomization</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 48/50 (96%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-25 07:08:48 +0100" MODIFIED_BY="[Empty name]">
<P>50 analysed: 27 in ofloxacin group; 23 in chloramphenicol group</P>
<P>Adult inpatients aged &gt; 15 years</P>
<P>Inclusion criteria: clinical or blood culture positive typhoid fever</P>
<P>Exclusion criteria: age &lt;15 years; pregnant; lactating; not able to take oral medication; not willing to give informed consent; not able to stay in hospital for the duration of treatment; known to have contraindications to chloramphenicol or ofloxacin; severe typhoid fever; or intractable vomiting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (15 mg/kg/day in 2 divided doses oral for 3 days)</P>
<P>2. Chloramphenicol (50 mg/kg/day oral in 4 divided doses for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Fever clearance time</P>
<P>3. Complications</P>
<P>4. Length of hospitalization</P>
<P>5. Serious adverse events</P>
<P>6. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Laos</P>
<P>Date: 2001-3</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:16:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phuong-1999-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:16:18 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 40/82 (49%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 05:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>82 analysed: 38 in ofloxacin group; 44 in cefixime group</P>
<P>Children inpatients aged &lt; 15 years</P>
<P>Inclusion criteria: fever and no obvious source of infection for &gt; 7 days or &lt; 7 days if family history of typhoid fever</P>
<P>Exclusion criteria: severe disease; hypersensitivity to quinolones or third-generation cephalosporins; received either drug during this illness; or responded to ampicillin, chloramphenicol, or co-trimoxazole</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 05:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 5 days)</P>
<P>2. Cefixime (20 mg/kg/day oral in 2 divided doses for 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 05:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 05:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: 1995-6</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-01 11:51:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rizvi-2007-PAK">
<CHAR_METHODS MODIFIED="2011-08-24 14:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: Unclear</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 159/227 (70%) on Typhi Dot and 87/227 (38.3%) on Widal test</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-01 11:51:42 +0100" MODIFIED_BY="[Empty name]">
<P>227 analysed: 48 in ciprofloxacin, 45 in ofloxacin, 46 in cefixime, 44 in chloramphenicol and 44 in co-trimoxazole</P>
<P>&gt;12 yrs of age</P>
<P>Both outpatients and inpatients: hospitalised for 24 hours and then attended clinics for assessments</P>
<P>Inclusion criteria: above 12 yrs of age with clinically and bacteriologically proven diagnosis of typhoid fever, either on positive blood or stool culture or by positive Typhi-Dot test</P>
<P>Exclusion criteria: patients with signs and symptoms similar to those of typhoid fever but proved bacteriologically to be caused by other organism were excluded. Patients with salmonellosis caused by organisms other than <I>S. typhi </I>and <I>S. paratyphi </I>were not included. Pregnant women and patients with previously known hypersensitivity to any of the trial drugs were also not included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-23 10:40:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 7 days)</P>
<P>2. Ofloxacin (200 mg oral twice daily for 7 days)</P>
<P>3. Cefixime (200 mg oral twice daily for 7 days)</P>
<P>4. Chloramphenicol (750 mg oral 6 hourly for 14 days)             </P>
<P>5. Cotrimoxazole (960 mg oral twice daily for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-13 22:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical cure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Clinical Failure</P>
<P>5. Fever Clearance</P>
<P>6. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:21:37 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Pakistan</P>
<P>Date: Jan 2003 to Jan 2004</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:36:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1994-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:36:34 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 50%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>47 analysed: 22 in ofloxacin group; 25 in ceftriaxone group</P>
<P>Adult inpatients aged 15 to 63 years</P>
<P>Inclusion criteria: clinical or culture positive for enteric fever</P>
<P>Exclusion criteria: hypersensitivity to beta-lactam antibiotics or quinolones; previous treatment with broad-spectrum cephalosporins or quinolone within 1 week of hospital admission; those who responded to ampicillin, chloramphenicol, or co-trimoxazole</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (200 mg oral every 12 hours for 5 days)</P>
<P>2. Ceftriaxone (3 g intravenous once a day for 3 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization (mean and range)</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: 1992-3</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:36:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-1995-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 50% (114/228)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-20 00:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>228 analysed: 118 in 3-day group; 110 in 5-day group</P>
<P>Adults and children outpatients (180 culture positive were aged &lt; 17 years)</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: unable to take oral medications due to vomiting; severe disease; shock; impaired consciousness; bleeding; peritonitis; pregnant; neonates; received a fluoroquinolone</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (15 mg/kg/day oral for 3 days)</P>
<P>2. Ofloxacin (10 mg/kg/day oral for 5 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Convalescent faecal carriage</P>
<P>6. Serious adverse events</P>
<P>7. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: 1993-3</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:37:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Unal-1996-TUR">
<CHAR_METHODS MODIFIED="2011-08-24 14:37:03 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 46/46 (100%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:37:11 +0100" MODIFIED_BY="[Empty name]">
<P>46 analysed: 22 in 5-day group: 24 in 7-day group</P>
<P>Mean age was 24 years (18-40 years ) in 5 days and 26 years (18-68) in 7 days group</P>
<P>inpatients</P>
<P>Inclusion criteria: All patients with febrile disease and at least one positive blood and/or bone marrow culture for salmonella</P>
<P>Exclusion criteria: Patients under 16 years of age, pregnant and lactating women, those with jaundice and hepatic failure, and the patients who had received any antibiotic within the last 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Pefloxacin (400 mg oral twice daily for 5 days)</P>
<P>2. Pefloxacin (400 mg oral twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Clinical cure</P>
<P>5. Fever clearance time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Turkey</P>
<P>Date: June 1992 to October 1994</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:37:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinh-1996-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 26/100 (26%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>100 analysed: 53 in 2-day group; 47 in 3-day group</P>
<P>Children inpatients aged 1 to 15 years</P>
<P>Inclusion criteria: clinical or blood culture positive for <I>S. typhi</I>
</P>
<P>Exclusion criteria: severe disease; complications, such as reduced level of consciousness, jaundice, shock, gastrointestinal bleed, clinical signs of intestinal perforation, prostate, and vomiting; unable to take oral medication; allergic to fluoroquinolones; received antibiotics that had efficacy against this organism</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:24:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (15 mg/kg/day oral in 2 divided doses for 2 days)</P>
<P>2. Ofloxacin (15 mg/kg/day oral in 2 divided doses for 3 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:24:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time</P>
<P>5. Complications</P>
<P>6. Length of hospitalization</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:38:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinh-2005-VNM">
<CHAR_METHODS MODIFIED="2011-08-24 14:37:44 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 196/202 (97%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:38:52 +0100" MODIFIED_BY="[Empty name]">
<P>196 analysed: 89 in ofloxacin 2-day group; 107 in ofloxacin 3-day group</P>
<P>Children inpatients aged &lt; 15 years</P>
<P>Inclusion criteria: clinical</P>
<P>Exclusion criteria: no informed consent from parent or guardian; previous treatment active against S. Typhi or S. Paratyphi (but those with no response to chloramphenicol, ampicillin, or co-trimoxazole were included); severe or complicated disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 2 days)</P>
<P>2. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 3 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)</P>
<P>5. Complications</P>
<P>6. Length of hospitalization (mean and 95% confidence intervals; SD calculated by review author)</P>
<P>7. Convalescent faecal carriage</P>
<P>8. Serious adverse events</P>
<P>9. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Vietnam</P>
<P>Date: 1994-6</P>
<P>Severity of illness at entry: all uncomplicated</P>
<P>Author provided further information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:39:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wallace-1993-BHR">
<CHAR_METHODS MODIFIED="2011-08-24 14:39:07 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 41/42 (97.6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-24 14:39:03 +0100" MODIFIED_BY="[Empty name]">
<P>42 analysed: 20 in ciprofloxacin group; 22 in ceftriaxone group</P>
<P>Adult inpatients</P>
<P>Inclusion criteria: blood culture positive for <I>S.</I> Typhi</P>
<P>Exclusion criteria: only positive Widal and/or a positive stool culture; age &lt; 16 years; unable to take oral medications; possible proven pregnancy; and lack of fever at admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 7 days)</P>
<P>2. Ceftriaxone (3 g/day intravenous for 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:25:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure</P>
<P>2. Microbiological failure</P>
<P>3. Relapse</P>
<P>4. Fever clearance time (SD not reported)</P>
<P>5. Convalescent faecal carriage</P>
<P>6. Complication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Bahrain</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-24 14:39:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yousaf-1992--PAK">
<CHAR_METHODS MODIFIED="2011-08-24 14:39:13 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 75/85 (88.4%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-15 05:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>75 analysed <SUP>a</SUP>: 25 in ofloxacin group; 25 in chloramphenicol group; 25 in amoxicillin group</P>
<P>Adult inpatients</P>
<P>Inclusion criteria: culture positive</P>
<P>Exclusion criteria: if received previous antibiotic therapy known to be effective against <I>S</I>. Typhi</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-20 00:26:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin (200 mg oral twice daily for 14 days)<BR/>2. Chloramphenicol (50 mg/kg/day, then 30 mg/kg/day when afebrile for 14 days)<BR/>3. Amoxicillin (4 to 6 g/day oral for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-20 00:26:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure<BR/>2. Microbiological failure<BR/>3. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-20 00:26:46 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Pakistan</P>
<P>Date: 1989-92</P>
<P>Severity of illness at entry: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-08-26 16:45:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:39:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abejar-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:39:31 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:39:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agalar-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:39:24 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized controlled trial because 1 group consisted of participants admitted in 1994 and the other group of participants admitted in 1995</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:39:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akhtar-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:39:28 +0100" MODIFIED_BY="[Empty name]">
<P>No mention of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akhtar-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial: participants were allocated alternatively to either ciprofloxacin group or chloramphenicol group, and resistance strains assigned to a third ciprofloxacin group; author provided this additional information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:39:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnold-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:39:40 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:39:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to norfloxacin which is no longer recommended for use by the WHO and the other arm enoxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavdekar-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Interventions not randomly assigned</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-11 11:58:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bethell-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-11 11:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>Children from the <LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK> trial (which is included in this review) were entered into this pharmacokinetic study of oral vs intravenous ofloxacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chakravorty-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>All treated with chloramphenicol; some switched over to another drug based on culture results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:45:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chukwani-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>2 different fluoroquinolone drugs were given for different durations (one for 7 days and one for 14 days) in this randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daga-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment assigned depending on treatment already taken, clinical course, and complications</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:40:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duong-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:40:03 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hou-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial comparing Chinese ofloxacin with Japanese ofloxacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:40:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huai-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:40:14 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jia-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:02 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to norfloxacin which is no longer recommended for use by the WHO</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jinlong-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:07 +0100" MODIFIED_BY="[Empty name]">
<P>Described as a randomized controlled parallel study of ofloxacin vs ceftriaxone in 93 children with multi-drug resistant typhoid fever proven by blood culture. The main outcome reported for both arms is mean fever clearance time; however the number of children in each arm is not available. We have contacted the author for additional information (December 2007) and will include this study if further information becomes available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liberti-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:14 +0100" MODIFIED_BY="[Empty name]">
<P>No mention of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 130 participants with any infectious disease were randomized into 2 groups (enoxacin and cefotaxime); there were only 2 participants with enteric fever in enoxacin group and 1 participant with enteric fever in cefotaxime group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nalin-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:28 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to norfloxacin which is no longer recommended for use by the WHO</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelwan-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial comparing 3 days with 6 days of ciprofloxacin that included 20 participants with serologically confirmed enteric fever (of a total of 59 participants randomized). We contacted the author (17 December 2003) to obtain additional data for blood culture confirmed cases and will include this in future updates should it become available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peyramond-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarma-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:45 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to norfloxacin which is no longer recommended for use by the WHO</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Secmeer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:49 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization; allocation based on co-trimoxazole susceptibility</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>No mention of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suhendro-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Compares 2 different formulations of ciprofloxacin; described as a prospective, open labelled, clinical trial, comparing safety and efficacy of extended-release ciprofloxacin 1000 mg once daily (Ciprofloxacin XR) and ciprofloxacin intermediate release 500 mg 2 times daily (Ciprofloxacin bid) in adults with typhoid fever</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:42:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takkar-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanphaichitra-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial of gonorrhoea; part of the report, but not part of the trial, were 8 participants with enteric fever that treated with ofloxacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 09:49:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 09:49:14 +0100" MODIFIED_BY="[Empty name]">
<P>One arm allocated to fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uwaydah-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>Compares 2 ciprofloxacin doses, not durations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-11 11:58:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wain-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-11 11:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study on <I>S</I>. Typhi isolates from blood cultures of participants included in 3 trials included in this review: <LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>; <LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>; and Nguyen 1997</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-29 17:39:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weng-1996a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-29 17:39:53 +0100" MODIFIED_BY="[Empty name]">
<P>A description of likely several trials involving fluoroquinolones</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-28 09:49:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-28 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>One group given fleroxacin which is no longer in clinical use</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:42:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zavala-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:42:25 +0100" MODIFIED_BY="[Empty name]">
<P>No mention of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-24 14:42:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-24 14:42:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial including several infections; randomization not applied to the 63 typhoid participants treated with enoxacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:37:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ZhongYang-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial comparing ofloxacin with norfloxacin for 14 days. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-08-24 15:58:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-08-24 14:42:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bran-1991">
<CHAR_METHODS MODIFIED="2011-08-24 14:42:37 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-15 05:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>102 analysed <SUP>a</SUP>: 51 in ciprofloxacin group; 51 in chloramphenicol group; only the total number of participants (102) was provided, but we assumed 51 in each group</P>
<P>Age not mentioned (adult dosages used); most probably inpatients</P>
<P>Inclusion criteria: blood and/or bone marrow culture positive for <I>S</I>. Typhi</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-29 18:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (500 mg oral twice daily for 10 days)<BR/>2. Chloramphenicol (750 mg oral every 6 hours for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-29 18:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Microbiological failure<BR/>2. Fever clearance time (no SD)<BR/>3. Convalescent faecal carriage<BR/>4. Serious adverse events<BR/>5. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-29 18:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Guatemala</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: not reported</P>
<P>Conference abstract</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores-1991">
<CHAR_METHODS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>Unable to retrieve this study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-03-31 11:29:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quintero-1988">
<CHAR_METHODS MODIFIED="2011-03-31 11:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>Reported as a double blind study but exact methods are unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-31 11:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>26 participants: 13 in each group</P>
<P>Age not mentioned (adult dosages used); most probably inpatients</P>
<P>Inclusion criteria: not reported</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-31 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ciprofloxacin (750 mg oral 3 times a day for unknown duration)<BR/>2. Chloramphenicol (750 mg oral 4 times a day for unknown duration)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-31 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure<BR/>2. Fever clearance time<BR/>3. Serious adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-31 11:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Mexico</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: not reported</P>
<P>Conference abstract</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soewandojo-1992">
<CHAR_METHODS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>NA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-25 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>Unable to retrieve this study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-08-24 15:58:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weng-1996">
<CHAR_METHODS MODIFIED="2011-03-29 18:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-29 18:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Children and adults aged 14 to years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-29 18:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>Several different fluoroquinolones given orally and parenterally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-29 18:31:16 +0100" MODIFIED_BY="[Empty name]">
<P>Cure and efficiency rate</P>
<P>Fever clearance</P>
<P>Bacterial clearance rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-24 15:58:24 +0100" MODIFIED_BY="[Empty name]">
<P>Chinese language, unclear if randomized trials</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-03-29 18:26:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-1991">
<CHAR_METHODS MODIFIED="2011-03-29 18:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-29 18:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>Adult and children inpatients aged 11 to 62 years</P>
<P>Inclusion criteria: clinical with blood or bone marrow culture positive for <I>S</I>. Typhi</P>
<P>Exclusion criteria: not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-24 17:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated 3 of the available 5 groups:</P>
<P>1. Norfloxacin (300 to 400 mg oral thrice a day for 14 days)<BR/>2. Pefloxacin (400 mg oral twice daily for 14 days)<BR/>3. Ofloxacin (300 mg oral twice daily for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-24 17:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure<BR/>2. Fever clearance time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-29 18:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>Location: China (Chinese language)</P>
<P>Date: not reported</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-08-24 14:42:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-1998">
<CHAR_METHODS MODIFIED="2011-08-24 14:42:53 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: open</P>
<P>Inclusion of all randomized culture-positive participants in the final analysis: 100%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-29 18:27:25 +0100" MODIFIED_BY="[Empty name]">
<P>80 analysed: 40 in levofloxacin group; 40 in cefixime group</P>
<P>Adult aged 18 to 65 years; most probably inpatients</P>
<P>Inclusion criteria: clinical with blood or bone marrow culture positive for <I>S</I>. Typhi or <I>S</I>. Paratyphi</P>
<P>Exclusion criteria: not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-24 17:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Levofloxacin (200 mg oral twice a day for 10 days)<BR/>2. Cefixime (200 mg oral twice a day for 10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-24 17:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical failure<BR/>2. Microbiological failure<BR/>3. Relapse<BR/>4. Fever clearance time<BR/>5. Complications<BR/>6. Convalescent faecal carriage<BR/>7. Other adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-24 17:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location: China (Chinese language)</P>
<P>Date: not reported</P>
<P>Severity of illness at entry: included 'mild, common, and severe' types (1 'severe type' illness in levofloxacin group and 2 in cefixime group)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-12-25 12:49:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN66534807">
<CHAR_STUDY_NAME MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>"A randomised clinical trial of Azithromycin versus Ofloxacin in the treatment of adults with uncomplicated typhoid fever at Mahosot Hospital, Vientiane, Lao People's Democratic Republic (PDR)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>"randomised clinical trial"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: adult (&#8805;15 years) non-pregnant patients with suspected or blood-culture proven typhoid; fever &gt; 37.5 °C; informed written consent to the study; able to stay in hospital for 7 days; able to take oral medication; bodyweight &gt; 40 kg; likely to be able to complete 6 months' follow up; none of the exclusion criteria</P>
<P>Exclusion criteria: known hypersensitivity to ofloxacin or azithromycin; administration of chloramphenicol, co-trimoxazole, ampicillin, azithromycin, or a fluoroquinolone during previous week; pregnancy or breastfeeding; contraindications to ofloxacin or azithromycin; evidence for severe typhoid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ofloxacin 7.5 mg/kg every 12 hours for 3 days<BR/>2. Azithromycin 20 mg/kg every 24 hours for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fever clearance time<BR/>2. Cure<BR/>3. Relapse<BR/>4. Faecal carriage</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>1 May 2004</P>
<P>Anticipated end date: 31 December 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Paul Newton (paul@tropmedres.ac), Microbiology laboratory, Ministry of Health, Mahosot Hospital, Vientiane, Laos</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-12-25 12:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Laos</P>
<P>Registration number: <LINK REF="STD-ISRCTN66534807" TYPE="STUDY">ISRCTN66534807</LINK>
</P>
<P>Source of funding: The Wellcome Trust (UK)</P>
<P>Percentage of children in trial: none</P>
<P>E-mail update by Dr Newton on 5 December 2007: on hold because of considerable decline in incidence of typhoid in Vientiane</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-08-24 15:59:22 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-08-24 15:59:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>&#8220;Patients randomly assigned to two regimens&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:48:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>&#8220;Patients were randomly allocated to one of two treatments. Randomization was performed in blocks of 50..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:22:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>&#8220; patients were allocated at random...Randomization was in blocks&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-24 15:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>&#8220;Patients were allocated to one of two treatment groups in an open randomised comparison" Computer generated randomization list. Information from trial authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:35:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>&#8220;The enrolled patients were randomly assigned (by means of a computerized list..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-28 15:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>&#8220;An independent administrator from the study generated the random number sequence in excel using RAND function&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:35:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>'A comparative open study with groups assigned randomly...'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>&#8220;..patients were randomly assigned to either..&#8221;  &#8220;....The distribution of the envelopes was derived from a randomly permuted table..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-15 05:33:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>&#8220;..each subject was randomly assigned.. assignments, determined by block randomisation based on a random number list&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:12:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Randomized study but mode of generation of sequence not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-15 05:34:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>&#8220;A comparative open and randomised trial..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:24:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>The patients were divided into two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-15 05:34:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>&#8220;Patients were randomly assigned.. using a table of random numbers&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:31:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>&#8220;..patients in this open study were randomly assigned, by means of a computerized list&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:49:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>"Patients were randomised in blocks from a computer generated randomisation list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-24 15:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>Computer generated randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:47:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>&#8220;..randomised in blocks of 10 from a random number table&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>"..Patients were randomised to receive ofloxacin.or cefixime..." Computer generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>&#8220;The patients were randomly assigned to one of the following&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:47:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>&#8220;Patients were randomised to receive?.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>&#8220;Patients were randomised to receive.. &#8220; Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>&#8220;..were randomised to receive pefloxacin for 5 days..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>&#8220;Patients were randomised to receive either ofloxacin?&#8221; Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>&#8220;A computer-generated, randomised</P>
<P>treatment allocation was..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>&#8220;..patients were randomised to receive&#8221; No indication as to how sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 17:37:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>'The patients were randomly divided into three groups...'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-04-14 12:50:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:07:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>&#8220;The random allocations were placed in sealed opaque envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:22:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>&#8220;Treatment codes were contained in serially numbered sealed envelopes...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:31:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>&#8220;The treatment allocations were kept in serially numbered sealed envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:32:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:22:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>&#8220;..assignments were  folded and kept in opaque, sealed, sequentially numbered envelopes at all three study sites?&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:34:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>&#8220;..treatment group by means of sealed envelopes containing the names of the study drugs.?&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>"Treatment assignments..were sealed in envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:12:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:29:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:38:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>&#8220;Treatment  allocations were kept in sealed opaque envelopes..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:42:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>&#8220;Treatment allocations were kept in serially numbered sealed envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>&#8220;Treatment allocations kept in sealed opaque envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:52:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>&#8220;treatment codes were contained in serially numbered sealed envelops ..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:04:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>&#8220;Treatment codes were contained in individual sealed envelopes?..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:11:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>&#8220;Treatment allocation were kept in sealed envelopes  ...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:50:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>&#8220;..were randomised to receive pefloxacin for 5 days..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-14 12:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>&#8220;After enrolment in the study, a sealed envelope containing the treatment regimen to be given was opened&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:23:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>&#8220;Randomized treatment allocation was contained in serially numbered sealed envelopes..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:24:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 17:37:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-08-24 14:37:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 06:07:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 06:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>Open study for participants and investigators but final outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:45:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>&#8220; in an open, randomised ?&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 06:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>Open comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>&#8220;..an open, randomised clinical study&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-03 12:23:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-24 14:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:46:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>&#8220;..randomised, open-label, parallel controlled trial&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 06:59:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:19:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Double blind. Placebos given during remaining days of therapy in the longer arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:23:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-24 14:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:30:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:33:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:38:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>Open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>&#8220;an open randomised comparison.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>&#8220;..prospective randomised open-label controlled trial&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:52:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 07:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-14 12:47:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>"...open, randomised comparison..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 08:11:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-24 14:37:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 08:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 08:23:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-20 08:25:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-20 17:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-08-24 15:58:17 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes(short term)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes(long term)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:08:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Data was reported for all the patients in short term follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:12:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Data was missed for 3, 22 and 32 patients on 2, 6 and 12 months respectively for patients in 10 days treatment.</P>
<P>Whereas data was missing for 2, 20 and 31 patients on 2, 6, and 12 months respectively for those on 14 days treatment. missing outcome data balanced between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:49:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>Missing data balanced across both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:49:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>Missing data balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:23:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>50% of outcome data at follow up presented but results unlikely to affect observed effect size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-14 12:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>outcomes were presented for all randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-04-14 12:45:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>9/44 from ofloxacin group and 10/44 from azithromycin group were missing from the long term treatment but unlikely to affect estimate of effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:35:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>No pre specified outcomes but all relevant outcome data accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:35:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>No pre specified outcomes but all relevant outcome data accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-24 15:57:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>No loss to follow up and data was analysed for all the participants randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-01-03 12:22:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>In Gatifloxocin group 7, 8, and 80 participants were lost to follow-up and in Azithromycin group 5, 11 and 79participants were lost to follow-up. Unlikely to affect observed effect size as loss is similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-21 08:40:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Relapse and fever clearance times not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-07-25 13:03:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Convalescent faecal carriage not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:54:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>Outcome data addressed, no information on loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>No data provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 06:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 06:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:19:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Fever clearance time not reported for comparison arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Relevant data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:23:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:23:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:27:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:30:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>All outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>All outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:33:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:33:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:38:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>Relevant outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:38:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>Missing outcome data at 1, 3 and 6 months (22/169, 28/169 and 39/169 respectively) unlikely to affect effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:42:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>Incomplete outcome data unlikely to affect observed effect size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:48:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:48:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>Patients not followed up after discharge. No data for long term outcomes like relapse and convalescent faecal carriage.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 07:52:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>All pre specified outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 07:52:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>All data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:01:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>Relevant outcomes addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:01:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>outcomes data presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:04:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>All primary outcome data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:06:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>Specific numbers for post discharge follow up not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:11:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:11:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>291/425 overall but 81, 78 and 132 for D3, D5</P>
<P>and blood culture negative arms respectively but unlikely to affect measured effect size.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:14:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>No data for 34 and 74 subjects at the 1 and 3 month follow up respectively. No indication how these were handled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:23:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>All outcomes addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-08-24 15:58:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>Data for 6 culture positive children randomized to 2-day treatment excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-20 08:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-12-20 08:25:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>All outcome data addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-20 17:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>Relevant short term outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-02-20 17:38:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>Long term outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-02-24 17:02:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:12:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:49:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>Efficacy and adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:22:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>Report includes all pre specified outcomes including efficacy and safety data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-21 08:36:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:55:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:58:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:20:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Efficacy and adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 19:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>Efficacy and adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:27:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:30:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>Safety and efficacy reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:33:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>Efficacy and adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:38:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>Report includes all pre specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:43:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:48:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>Efficacy and adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 07:52:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>Incomplete report of adverse events. Only mortality and associated data for one patient reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:01:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:04:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:11:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:23:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>Efficacy and adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:25:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>No report of adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 17:39:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>Efficacy and safety data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-07-25 17:59:24 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:10:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alam-1995-BGD">
<DESCRIPTION>
<P>Supported by research grant from Beximco pharmaceuticals ltd</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 15:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arjyal-2011">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 15:46:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-1997-VNM">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 15:46:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chinh-2000-VNM">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 16:46:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cristiano-1995-ITA">
<DESCRIPTION>
<P>Pefloxacin was supplied by Rhone-poulenc Pharma Italy S.P.A. Milan, Italy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:24:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2008-VNM">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-08 09:58:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flores-1994-MEX">
<DESCRIPTION>
<P>Language</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:29:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasem-2003-IDN">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 06:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Girgis-1999-EGY">
<DESCRIPTION>
<P>Supported by an unrestricted grant from Pfizer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:29:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A">
<DESCRIPTION>
<P>Study seems free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 17:59:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hajji-1988-MAR">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:30:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalo-1997-ALB">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limson-1989-PHL">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:31:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morelli-1992-ITA">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:31:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2007-NPL">
<DESCRIPTION>
<P>Study seems free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:32:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parry-2007-VNM">
<DESCRIPTION>
<P>Study seems free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 18:20:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phongmany-2005-LAO">
<DESCRIPTION>
<P>Trial stopped early because of apparently significant difference in primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:37:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phuong-1999-VNM">
<DESCRIPTION>
<P>No information on ethical clearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:36:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-2007-PAK">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1994-VNM">
<DESCRIPTION>
<P>No information given on ethical clearance for undertaking this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:45:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1995-VNM">
<DESCRIPTION>
<P>Ofloxacin was provided by Professor A Bryskier of Roussel-UCLAF Pharmaceuticals, Paris</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:38:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Unal-1996-TUR">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vinh-1996-VNM">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vinh-2005-VNM">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-20 08:25:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wallace-1993-BHR">
<DESCRIPTION>
<P>Trial stopped early because of apparent lower efficacy in the control group, cost of control drug and inconvenience of intravenous administration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-25 16:40:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yousaf-1992--PAK">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-08-05 11:52:43 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-08-24 15:55:40 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-08-24 15:53:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Fluoroquinolone versus chloramphenicol</NAME>
<DICH_OUTCOME CHI2="8.55234520543574" CI_END="0.6710196669080263" CI_START="0.19352761224905107" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3603620872245913" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="33" I2="29.843804759114594" I2_Q="56.62495158143806" ID="CMP-001.01" LOG_CI_END="-0.1732647509122847" LOG_CI_START="-0.7132570616948625" LOG_EFFECT_SIZE="-0.4432609063035735" METHOD="MH" MODIFIED="2011-08-24 15:15:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2003628697822789" P_Q="0.09971179445915967" P_Z="0.0012920824628599612" Q="4.610945861547716" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="514" TOTAL_2="506" WEIGHT="300.0" Z="3.217732529748525">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.0269139215279655" CI_END="0.817526172471671" CI_START="0.0692718346728455" DF="2" EFFECT_SIZE="0.23797381759383066" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="50.33417552563122" ID="CMP-001.01.01" LOG_CI_END="-0.08749833484128278" LOG_CI_START="-1.1594433098694223" LOG_EFFECT_SIZE="-0.6234708223553526" MODIFIED="2011-08-24 15:15:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13352650423158463" P_Z="0.022611773628065435" STUDIES="4" TAU2="0.0" TOTAL_1="144" TOTAL_2="149" WEIGHT="99.99999999999999" Z="2.279931126494591">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="71.85363283148561" CI_START="0.12525462729361522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8564487304213015" LOG_CI_START="-0.9022062209819764" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-01-11 16:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="1.6204475740165292" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A" TOTAL_1="48" TOTAL_2="48" VAR="2.6258503401360547" WEIGHT="4.019092633477409">
<FOOTNOTE>Ciprofloxacin 500mg BD for 10 days vs Chloramphenicol 750mg QDS for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-12 23:07:48 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.012853993705974" CI_START="0.0463731309520986" EFFECT_SIZE="0.48214285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7000850553708321" LOG_CI_START="-1.3337335810652582" LOG_EFFECT_SIZE="-0.3168242628472131" MODIFIED="2011-01-12 23:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" VAR="1.4272486772486772" WEIGHT="16.36866817998072">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Chloramphenicol 500mg QDS for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.806765516193301" CI_START="0.002895865179037883" EFFECT_SIZE="0.04833512352309345" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.09325267323446339" LOG_CI_START="-2.538221661177534" LOG_EFFECT_SIZE="-1.315737167205999" MODIFIED="2011-01-13 21:58:07 +0100" MODIFIED_BY="[Empty name]" ORDER="684" O_E="0.0" SE="1.4361868863094416" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="2.0626327724072087" WEIGHT="79.61223918654186">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Chloramphenicol 750mg QDS for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.751955263765735" CI_END="0.6440009065305776" CI_START="0.03399556560879416" DF="2" EFFECT_SIZE="0.1479634247714048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.19111352130330833" LOG_CI_START="-1.4685777287585933" LOG_EFFECT_SIZE="-0.8298456250309508" MODIFIED="2011-08-24 15:15:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4164550629067325" P_Z="0.010884033786618888" STUDIES="4" TAU2="0.0" TOTAL_1="127" TOTAL_2="122" WEIGHT="100.0" Z="2.5464001704262627">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-01-12 23:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="15.128844555278471">
<FOOTNOTE>Ofloxacin 200mg BD for 14 days vs Chloramphenicol 50mg/kg/day for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-13 21:25:36 +0100" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 300mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.69302252386367" CI_START="0.012196679866258772" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.825622286526471" LOG_CI_START="-1.9137583752270222" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-01-11 14:48:09 +0100" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="1.609125760866973" STUDY_ID="STD-Phongmany-2005-LAO" TOTAL_1="27" TOTAL_2="23" VAR="2.5892857142857144" WEIGHT="12.219451371571074">
<FOOTNOTE>Ofloxacin 15mg/kg in 2 divided doses for 3 days vs Cloramphenicol 50mg/kg in 4 divided doses for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.858600410118025" CI_START="0.00308752917945322" EFFECT_SIZE="0.05148741418764302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.06620890841195777" LOG_CI_START="-2.5103889293061608" LOG_EFFECT_SIZE="-1.2882989188590594" MODIFIED="2011-01-13 21:58:29 +0100" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="1.4357234431594867" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="2.061301805237732" WEIGHT="72.65170407315046">
<FOOTNOTE>Ofloxacin 200mg BD for 7 days vs Chloramphenicol 750mg QDS for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:15:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Pefloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-12 23:07:37 +0100" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="36" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Pefloxacin 400mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-12 23:05:19 +0100" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.0" STUDY_ID="STD-Cristiano-1995-ITA" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Pefloxacin 400mg (IV) TDS for 5 days vs Chloramphenicol 500mg (PO) QDS for 15 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.956981465989792" CI_START="0.3196854172943701" DF="0" EFFECT_SIZE="0.7909604519774012" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.29158671259899416" LOG_CI_START="-0.4952771739661313" LOG_EFFECT_SIZE="-0.10184523068356859" MODIFIED="2011-08-24 15:15:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6118998351572955" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="100.0" Z="0.5073634399675728">
<NAME>Gatifloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="1.956981465989792" CI_START="0.3196854172943701" EFFECT_SIZE="0.7909604519774012" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29158671259899416" LOG_CI_START="-0.4952771739661313" LOG_EFFECT_SIZE="-0.10184523068356859" MODIFIED="2011-01-12 23:06:27 +0100" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.4622077420074116" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="0.21363599677158998" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10mg/kg OD for 7 days vs Chloramphenicol 75mg/kg in 4 divided doses for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.41418777702709" CI_END="0.9982923131134995" CI_START="0.06079335758499141" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24635247424261275" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="21" I2="53.22868453049142" I2_Q="61.95256743428222" ID="CMP-001.02" LOG_CI_END="-7.422729570617345E-4" LOG_CI_START="-1.2161438700985943" LOG_EFFECT_SIZE="-0.6084430715278281" METHOD="MH" MODIFIED="2011-08-24 15:16:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09310898711299909" P_Q="0.07220135706762965" P_Z="0.04972082218896426" Q="5.256596477424545" RANDOM="YES" SCALE="1000.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.133862608546325" TOTALS="SUB" TOTAL_1="411" TOTAL_2="408" WEIGHT="300.0" Z="1.9623579722819835">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.806765516193301" CI_START="0.002895865179037883" DF="0" EFFECT_SIZE="0.04833512352309346" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.09325267323446339" LOG_CI_START="-2.538221661177534" LOG_EFFECT_SIZE="-1.3157371672059988" MODIFIED="2011-08-24 15:15:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03490381453459605" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="74" WEIGHT="100.0" Z="2.109472532012793">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-13 21:27:14 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="20" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.806765516193301" CI_START="0.002895865179037883" EFFECT_SIZE="0.04833512352309345" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.09325267323446339" LOG_CI_START="-2.538221661177534" LOG_EFFECT_SIZE="-1.315737167205999" MODIFIED="2011-01-13 21:59:12 +0100" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="1.4361868863094416" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="2.0626327724072087" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.190023692672122" CI_END="1.0659109117959367" CI_START="0.02360565622625227" DF="1" EFFECT_SIZE="0.15862385240456742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="15.9680596144633" ID="CMP-001.02.02" LOG_CI_END="0.027720908131221807" LOG_CI_START="-1.6269839218805198" LOG_EFFECT_SIZE="-0.799631506874649" MODIFIED="2011-08-24 15:15:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2753248369993533" P_Z="0.05818595870468655" STUDIES="3" TAU2="0.31492960444602225" TOTAL_1="100" TOTAL_2="99" WEIGHT="100.0" Z="1.8942942885670842">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="2.991018184415158" CI_START="0.037148256633831506" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4758190534081664" LOG_CI_START="-1.4300615628474915" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-12-18 00:17:59 +0100" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="1.1195237082497775" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="1.2533333333333332" WEIGHT="60.24172429634792"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-13 21:27:21 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 300mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.858600410118025" CI_START="0.00308752917945322" EFFECT_SIZE="0.05148741418764302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.06620890841195777" LOG_CI_START="-2.5103889293061608" LOG_EFFECT_SIZE="-1.2882989188590594" MODIFIED="2011-01-13 21:59:22 +0100" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="1.4357234431594867" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="2.061301805237732" WEIGHT="39.75827570365209"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:15:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Pefloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-13 21:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.0" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="36" TOTAL_2="30" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Pefloxacin 400mg TDS for 15 days vs Chloramphenicol 500mg QDS for 15 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-18 00:17:34 +0100" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.0" STUDY_ID="STD-Cristiano-1995-ITA" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.24226013297809" CI_START="0.23905338538636325" DF="0" EFFECT_SIZE="4.943820224719101" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="2.00963044128803" LOG_CI_START="-0.621505101605481" LOG_EFFECT_SIZE="0.6940626698412746" MODIFIED="2011-08-24 15:16:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3011216937837825" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="100.0" Z="1.0340309829927063">
<NAME>Gatifloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="102.24226013297809" CI_START="0.23905338538636325" EFFECT_SIZE="4.943820224719101" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.00963044128803" LOG_CI_START="-0.621505101605481" LOG_EFFECT_SIZE="0.6940626698412746" MODIFIED="2010-12-18 00:19:42 +0100" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="1.5455420422266395" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="2.3887002042900916" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.31600120473412" CI_END="0.6365395622009413" CI_START="0.1152155881194992" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.27081225973044504" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.19617459890488517" LOG_CI_START="-0.9384887589657759" LOG_EFFECT_SIZE="-0.5673316789353304" METHOD="MH" MODIFIED="2011-08-24 15:16:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8039140268722744" P_Q="0.5423853203958913" P_Z="0.0027363576196254816" Q="2.147389201138159" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="461" TOTAL_2="458" WEIGHT="400.0" Z="2.9959004363076622">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08805167979360823" CI_END="1.1548606325256137" CI_START="0.019813547668945622" DF="1" EFFECT_SIZE="0.15126759796312939" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.06252957714844243" LOG_CI_START="-1.7030377559050534" LOG_EFFECT_SIZE="-0.8202540893783055" MODIFIED="2011-08-24 15:16:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7666688230832196" P_Z="0.06858629664312063" STUDIES="4" TAU2="0.0" TOTAL_1="143" TOTAL_2="149" WEIGHT="100.0" Z="1.8211352727882237">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="3.874842793761362" CI_START="0.01147716514449839" EFFECT_SIZE="0.2108843537414966" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.5882540874392553" LOG_CI_START="-1.9401653692670622" LOG_EFFECT_SIZE="-0.6759556409139034" MODIFIED="2011-03-02 15:30:05 +0100" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="1.4852061047474552" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="20" TOTAL_2="30" VAR="2.205837173579109" WEIGHT="38.828527081120825"/>
<DICH_DATA CI_END="2.050118743047932" CI_START="0.006275461221834619" EFFECT_SIZE="0.11342592592592593" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3117790161567294" LOG_CI_START="-2.2023543497295264" LOG_EFFECT_SIZE="-0.9452876667863984" MODIFIED="2010-12-18 00:37:14 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="1.4768143842824606" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A" TOTAL_1="47" TOTAL_2="48" VAR="2.180980725623583" WEIGHT="61.17147291887918"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-13 21:44:00 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Gasem 2003 IDN reports that no relapses were observed but patients were not routinely monitored after day 14.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-12 23:13:10 +0100" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6515870907376713" CI_START="0.007696584184088997" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-08-24 15:16:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19166919687502434" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="74" WEIGHT="100.0" Z="1.3056570887327816">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-01-13 21:29:04 +0100" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-12 23:15:40 +0100" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.057970963961310976" CI_END="1.2115908511124664" CI_START="0.018947684457653886" DF="1" EFFECT_SIZE="0.15151515151515152" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.08335598525641665" LOG_CI_START="-1.7224438563401538" LOG_EFFECT_SIZE="-0.8195439355418687" MODIFIED="2011-08-24 15:16:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.809732143370448" P_Z="0.07523655928358482" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="100.0" Z="1.7790195351774016">
<NAME>Pefloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="2.22925013439873" CI_START="0.00642636010730932" EFFECT_SIZE="0.11969111969111969" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.34815880149697825" LOG_CI_START="-2.1920349419909364" LOG_EFFECT_SIZE="-0.9219380702469792" MODIFIED="2011-01-13 21:28:52 +0100" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="1.492122379086625" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="36" TOTAL_2="30" VAR="2.2264291941711294" WEIGHT="60.37296037296037"/>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254143" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-02-19 16:35:08 +0100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Cristiano-1995-ITA" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="39.62703962703963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8957125321012693" CI_START="0.16837630942926982" DF="0" EFFECT_SIZE="0.5649717514124294" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.2777724811098878" LOG_CI_START="-0.773719013833501" LOG_EFFECT_SIZE="-0.2479732663618066" MODIFIED="2011-08-24 15:16:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.35525899780616665" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="100.0" Z="0.924436714010826">
<NAME>Gatifloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="1.8957125321012693" CI_START="0.16837630942926982" EFFECT_SIZE="0.5649717514124294" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777724811098878" LOG_CI_START="-0.773719013833501" LOG_EFFECT_SIZE="-0.2479732663618066" MODIFIED="2010-12-18 00:46:32 +0100" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.6176513090965912" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="0.3814931396287328" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.406370141385509" CI_END="0.5497507489608556" CI_START="0.040420694122554925" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14906812827493413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.2598341702994227" LOG_CI_START="-1.3933962328541882" LOG_EFFECT_SIZE="-0.8266152015768056" METHOD="MH" MODIFIED="2011-08-24 15:19:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9819520486268967" P_Q="0.9631093951855807" P_Z="0.004256669892625435" Q="0.28345563111986016" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="255" TOTAL_2="254" WEIGHT="400.0" Z="2.8584866725558444">
<NAME>Convalescent faecal carriage</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8892324517090806" CI_START="0.009311449561956696" DF="0" EFFECT_SIZE="0.164021164021164" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.46078248418874984" LOG_CI_START="-2.030982704866693" LOG_EFFECT_SIZE="-0.7851001103389715" MODIFIED="2011-08-24 15:19:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21679978009313905" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="30" WEIGHT="100.0" Z="1.2350826211727517">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="2.8892324517090806" CI_START="0.009311449561956696" EFFECT_SIZE="0.164021164021164" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.46078248418874984" LOG_CI_START="-2.030982704866693" LOG_EFFECT_SIZE="-0.7851001103389715" MODIFIED="2011-01-13 21:29:51 +0100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.46367520648778" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="20" TOTAL_2="30" VAR="2.142345110087046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9774190029426773" CI_START="0.006243329812231785" DF="0" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2960987033983009" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2011-08-24 15:19:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13470149407860718" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4958164473948934">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="1.9774190029426781" CI_START="0.006243329812231785" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29609870339830113" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2011-01-13 21:29:54 +0100" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13140590236108138" CI_END="1.0055092445200515" CI_START="0.016607515841487612" DF="1" EFFECT_SIZE="0.12922465208747516" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.0023860677975943508" LOG_CI_START="-1.779695324623738" LOG_EFFECT_SIZE="-0.8886546284130717" MODIFIED="2011-08-24 15:19:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7169788682750267" P_Z="0.050616658725856356" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="100.0" Z="1.9547155071496902">
<NAME>Pefloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="1.66254492214909" CI_START="0.005212685603969583" EFFECT_SIZE="0.09309309309309309" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.22077338881898523" LOG_CI_START="-2.28293846816308" LOG_EFFECT_SIZE="-1.031082539672047" MODIFIED="2011-01-13 21:29:57 +0100" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="1.470692738364838" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="36" TOTAL_2="30" VAR="2.162937130679066" WEIGHT="66.2027833001988"/>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254143" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-12-18 01:25:40 +0100" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Cristiano-1995-ITA" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="33.79721669980119"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.821560530350207" CI_START="0.013209170488384148" DF="0" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.8932934106181998" LOG_CI_START="-1.8791244544239887" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2011-08-24 15:19:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.48584386244244826" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="134" WEIGHT="99.99999999999999" Z="0.6969343853479575">
<NAME>Gatifloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="7.821560530350207" CI_START="0.013209170488384148" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8932934106181998" LOG_CI_START="-1.8791244544239887" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2011-02-24 06:53:24 +0100" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.6285319776155462" STUDY_ID="STD-Arjyal-2011" TOTAL_1="139" TOTAL_2="134" VAR="2.652116402116402" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="43.3803413801475" CI_END="-60.2589586475586" CI_START="-78.45215387510281" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-69.3555562613307" ESTIMABLE="YES" I2="93.08442510004562" I2_Q="51.88880297069991" ID="CMP-001.05" MODIFIED="2011-08-24 15:20:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="2.043417879349363E-9" P_Q="0.14938517976166654" P_Z="1.7188833930255658E-50" Q="2.078518228076912" RANDOM="NO" SCALE="146.01923105809738" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="151" TOTAL_2="136" UNITS="" WEIGHT="200.0" Z="14.94343249767882">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="23.296290251125043" CI_END="-49.39050618302162" CI_START="-75.52231122085368" DF="1" EFFECT_SIZE="-62.456408701937654" ESTIMABLE="YES" I2="95.70747106418925" ID="CMP-001.05.01" MODIFIED="2011-02-24 07:33:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.388711372229956E-6" P_Z="7.333607873659825E-21" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="9.368837053719835">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<CONT_DATA CI_END="9.084698161777407" CI_START="-37.88469816177742" EFFECT_SIZE="-14.400000000000006" ESTIMABLE="YES" MEAN_1="122.4" MEAN_2="136.8" MODIFIED="2011-02-24 07:26:07 +0100" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="33.6" SD_2="52.8" SE="11.982209033952518" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" WEIGHT="30.95343577307809">
<FOOTNOTE>Days</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-68.27580658217917" CI_START="-99.72419341782083" EFFECT_SIZE="-84.0" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="156.0" MODIFIED="2011-02-24 07:33:02 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="24.0" SD_2="48.0" SE="8.022695081058258" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" WEIGHT="69.0465642269219">
<FOOTNOTE>Days</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.005532900945536" CI_END="-63.172996663926746" CI_START="-88.51738343450981" DF="1" EFFECT_SIZE="-75.84519004921827" ESTIMABLE="YES" I2="94.44615160516862" ID="CMP-001.05.02" MODIFIED="2011-08-24 15:20:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.2026692705123807E-5" P_Z="8.871015382333329E-32" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="65" WEIGHT="99.99999999999999" Z="11.730711201866944">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<CONT_DATA CI_END="-17.09593010144831" CI_START="-59.90406989855169" EFFECT_SIZE="-38.5" ESTIMABLE="YES" MEAN_1="55.0" MEAN_2="93.5" MODIFIED="2011-03-01 11:25:21 +0100" MODIFIED_BY="[Empty name]" ORDER="591" SD_1="20.1" SD_2="46.8" SE="10.920644495196983" STUDY_ID="STD-Phongmany-2005-LAO" TOTAL_1="27" TOTAL_2="21" WEIGHT="35.05184339266387"/>
<CONT_DATA CI_END="-80.27580658217917" CI_START="-111.72419341782083" EFFECT_SIZE="-96.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="156.0" MODIFIED="2011-02-24 07:35:08 +0100" MODIFIED_BY="[Empty name]" ORDER="590" SD_1="24.0" SD_2="48.0" SE="8.022695081058258" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" WEIGHT="64.94815660733612"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="90.60275464493654" CI_END="-3.194099059222813" CI_START="-5.106426393533171" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.150262726377992" ESTIMABLE="YES" I2="98.8962807986149" I2_Q="98.8962807986149" ID="CMP-001.06" MODIFIED="2011-08-24 15:20:19 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="1.780396051392228E-17" Q="90.60275464493654" RANDOM="NO" SCALE="104.95" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="50" UNITS="" WEIGHT="200.0" Z="8.507294043373982">
<NAME>Duration of hospitalization</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8290513818500209" CI_START="-1.6290513818500216" DF="0" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2011-08-24 15:20:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5235527028918578" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.6378786154863056">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<CONT_DATA CI_END="0.8290513818500209" CI_START="-1.6290513818500216" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="12.1" MODIFIED="2011-01-13 21:49:42 +0100" MODIFIED_BY="[Empty name]" ORDER="598" SD_1="2.0" SD_2="2.6" SE="0.6270785542717222" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999">
<FOOTNOTE>Days</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.37818033066196" CI_START="-11.42181966933804" DF="0" EFFECT_SIZE="-9.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" MODIFIED="2011-08-24 15:20:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.1058421949532685E-37" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="12.750290877359161">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<CONT_DATA CI_END="-8.37818033066196" CI_START="-11.42181966933804" EFFECT_SIZE="-9.9" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="18.8" MODIFIED="2011-03-01 11:37:26 +0100" MODIFIED_BY="[Empty name]" ORDER="599" SD_1="2.33" SD_2="3.04" SE="0.7764528743088948" STUDY_ID="STD-Phongmany-2005-LAO" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8255568970938452" CI_END="5.524805254854814" CI_START="0.17600894123866173" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9861111111111113" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.7423169740797643" LOG_CI_START="-0.7544652695041505" LOG_EFFECT_SIZE="-0.006074147712193103" METHOD="MH" MODIFIED="2011-08-24 15:20:30 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.3635605181058398" P_Q="1.0" P_Z="0.9873081024286829" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="99" WEIGHT="100.0" Z="0.015907605536753428">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolones</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8255568970938452" CI_END="5.524805254854814" CI_START="0.17600894123866173" DF="1" EFFECT_SIZE="0.9861111111111113" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.7423169740797643" LOG_CI_START="-0.7544652695041505" LOG_EFFECT_SIZE="-0.006074147712193103" MODIFIED="2011-02-19 17:35:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3635605181058398" P_Z="0.9873081024286829" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="100.0" Z="0.015907605536753428">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="21.342886702279365" CI_START="0.1874160724272041" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.329253158953714" LOG_CI_START="-0.7271931676257516" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-12-31 07:12:10 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="1.2079667518062687" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A" TOTAL_1="49" TOTAL_2="49" VAR="1.4591836734693877" WEIGHT="39.583333333333336"/>
<DICH_DATA CI_END="7.572301178989834" CI_START="0.013678852869532623" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8792278791655181" LOG_CI_START="-1.8639503217183169" LOG_EFFECT_SIZE="-0.4923612212763993" MODIFIED="2011-02-19 17:35:33 +0100" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="60.41666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:20:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-31 07:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.0" STUDY_ID="STD-Phongmany-2005-LAO" TOTAL_1="27" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.836886541895048" CI_END="0.9397217916388433" CI_START="0.6112911218841447" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7579205685755513" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="141" I2="62.243391207228974" I2_Q="63.8773098843633" ID="CMP-001.08" LOG_CI_END="-0.027000701974311692" LOG_CI_START="-0.21375191166110288" LOG_EFFECT_SIZE="-0.12037630681770728" METHOD="MH" MODIFIED="2011-08-24 15:53:22 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0045667851870312415" P_Q="0.040110923707618706" P_Z="0.011513599955911846" Q="8.305029305393198" RANDOM="NO" SCALE="602.35" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="764" TOTAL_2="646" WEIGHT="100.00000000000001" Z="2.5267116218453824">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.514183920103264" CI_END="1.644692734043843" CI_START="0.6124795821826181" DF="3" EFFECT_SIZE="1.0036636481241914" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="20" I2="71.46711506288226" ID="CMP-001.08.01" LOG_CI_END="0.21608477379138158" LOG_CI_START="-0.21290838450338448" LOG_EFFECT_SIZE="0.001588194643998506" MODIFIED="2011-08-24 15:20:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014665008050296913" P_Z="0.9884213942736808" STUDIES="4" TAU2="0.0" TOTAL_1="145" TOTAL_2="108" WEIGHT="15.901846253625546" Z="0.014512139611036135">
<NAME>Ciprofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="4.87417293900238" CI_START="1.0386377470299948" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.6879009341884694" LOG_CI_START="0.01646410203425554" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-01-02 13:46:26 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.39440531887330776" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="20" TOTAL_2="10" VAR="0.15555555555555559" WEIGHT="3.5021090636703915"/>
<DICH_DATA CI_END="0.7908095168837045" CI_START="0.0028674082035340396" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.10192811287226529" LOG_CI_START="-2.5425104765955733" LOG_EFFECT_SIZE="-1.3222192947339193" MODIFIED="2010-12-31 07:02:49 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="1.4336101615286128" STUDY_ID="STD-Gottuzzo-1992-N_x002f_A" TOTAL_1="49" TOTAL_2="49" VAR="2.0552380952380953" WEIGHT="6.894777219101084"/>
<DICH_DATA CI_END="7.572301178989834" CI_START="0.013678852869532623" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8792278791655181" LOG_CI_START="-1.8639503217183169" LOG_EFFECT_SIZE="-0.4923612212763993" MODIFIED="2011-01-02 13:44:01 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Gasem-2003-IDN" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="1.0022483175635661"/>
<DICH_DATA CI_END="3.8707789248574502" CI_START="0.7033468076713425" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.5877983677911217" LOG_CI_START="-0.15283047936330926" LOG_EFFECT_SIZE="0.21748394421390627" MODIFIED="2010-12-31 07:48:47 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.43504905099043345" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="22" VAR="0.18926767676767675" WEIGHT="4.502711653290503"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7286820769781417" CI_END="1.8706010246674052" CI_START="0.5983290071118226" DF="2" EFFECT_SIZE="1.0579389650597082" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" I2="26.704542941298428" ID="CMP-001.08.02" LOG_CI_END="0.27198116790488164" LOG_CI_START="-0.2230599419628545" LOG_EFFECT_SIZE="0.024460612971013554" MODIFIED="2011-08-24 15:20:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25554923745084257" P_Z="0.8464196849237315" STUDIES="4" TAU2="0.0" TOTAL_1="127" TOTAL_2="80" WEIGHT="11.07966687447587" Z="0.19368864325538082">
<NAME>Ofloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="1.4839194109057916" CI_START="0.2995071303590222" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.1714103158019857" LOG_CI_START="-0.5235928339133483" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-12-31 07:53:51 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="30" TOTAL_2="10" VAR="0.1666666666666667" WEIGHT="4.924840870786489"/>
<DICH_DATA CI_END="3.0126911750632708" CI_START="0.1867101429631887" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47895461529768624" LOG_CI_START="-0.7288320885142859" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-12-18 06:15:27 +0100" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.7094598884597586" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="0.5033333333333332" WEIGHT="2.626581797752794"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-19 17:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.0" STUDY_ID="STD-Phongmany-2005-LAO" TOTAL_1="27" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.875077639773892" CI_START="0.6894477092403806" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.687981536600069" LOG_CI_START="-0.16149866705090624" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2011-02-19 17:48:53 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.4989888766194082" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="22" VAR="0.24898989898989898" WEIGHT="3.528244205936589"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.02881568021361517" CI_END="2.522677703170457" CI_START="0.6871435292364252" DF="1" EFFECT_SIZE="1.3166023166023166" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.4018617686802357" LOG_CI_START="-0.16295253885774394" LOG_EFFECT_SIZE="0.1194546149112459" MODIFIED="2011-08-24 15:20:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8652053498918347" P_Z="0.40708194905216855" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="40" WEIGHT="7.394398756717105" Z="0.8290397034512091">
<NAME>Pefloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="2.8563281253895703" CI_START="0.5470309892309355" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.45580809626261487" LOG_CI_START="-0.26198807024650195" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2010-12-31 07:58:23 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.4216370213557839" STUDY_ID="STD-Morelli-1992-ITA" TOTAL_1="36" TOTAL_2="10" VAR="0.17777777777777778" WEIGHT="4.1111715095261125"/>
<DICH_DATA CI_END="3.9216336868411763" CI_START="0.49979170838333803" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5934670245144897" LOG_CI_START="-0.3012109531580137" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2010-12-31 07:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Cristiano-1995-ITA" TOTAL_1="30" TOTAL_2="30" VAR="0.2761904761904762" WEIGHT="3.2832272471909922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7836545050442689" CI_START="0.43635741955255236" DF="0" EFFECT_SIZE="0.5847678664580073" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="99" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-0.10587536540733299" LOG_CI_START="-0.36015763515884597" LOG_EFFECT_SIZE="-0.23301650028308948" MODIFIED="2011-08-24 15:20:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="3.280211696583367E-4" STUDIES="1" TAU2="0.0" TOTAL_1="426" TOTAL_2="418" WEIGHT="65.62408811518148" Z="3.5921021847470374">
<NAME>Gatifloxacin versus chloramphenicol</NAME>
<DICH_DATA CI_END="0.7836545050442689" CI_START="0.43635741955255236" EFFECT_SIZE="0.5847678664580073" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="99" LOG_CI_END="-0.10587536540733299" LOG_CI_START="-0.36015763515884597" LOG_EFFECT_SIZE="-0.23301650028308948" MODIFIED="2010-12-31 07:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.14936666396957435" STUDY_ID="STD-Arjyal-2011" TOTAL_1="426" TOTAL_2="418" VAR="0.02231040030539974" WEIGHT="65.62408811518148"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-08-24 15:23:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Fluoroquinolone versus co-trimoxazole</NAME>
<DICH_OUTCOME CHI2="0.9717906290322031" CI_END="0.2453417929583871" CI_START="0.009684985222527791" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.04874558071528589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.6102284652253508" LOG_CI_START="-2.0139010375963453" LOG_EFFECT_SIZE="-1.3120647514108479" METHOD="MH" MODIFIED="2011-08-24 15:21:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6151462509121952" P_Q="0.7797722945974476" P_Z="2.4820797774921066E-4" Q="0.07818499397577972" RANDOM="NO" SCALE="452.166373244016" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="126" WEIGHT="200.0" Z="3.664101883541087">
<NAME>Clinical Failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cotrimoxazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7955112292196425" CI_END="0.42802191326256483" CI_START="0.008146569070860128" DF="1" EFFECT_SIZE="0.05905006418485238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.36853399602095377" LOG_CI_START="-2.089025255961027" LOG_EFFECT_SIZE="-1.2287796259909902" MODIFIED="2011-08-24 15:21:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3724388858659847" P_Z="0.005116225419810253" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="64" WEIGHT="100.00000000000001" Z="2.799623419142304">
<NAME>Ciprofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-06-23 10:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Limson-1989-PHL" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="15.083440308087292">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 10 days vs Co-trimoxazole 160/800 mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5557242641583109" CI_START="0.0020818334375382005" EFFECT_SIZE="0.034013605442176874" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.25514064053690366" LOG_CI_START="-2.681554020287411" LOG_EFFECT_SIZE="-1.4683473304121573" MODIFIED="2011-06-23 10:41:01 +0100" MODIFIED_BY="[Empty name]" ORDER="696" O_E="0.0" SE="1.4252872302053876" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="2.031443688586546" WEIGHT="84.91655969191272">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5914255828581242" CI_START="0.002219635843357097" DF="0" EFFECT_SIZE="0.036231884057971016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.22809989344904222" LOG_CI_START="-2.653718270681393" LOG_EFFECT_SIZE="-1.4409090820652177" MODIFIED="2011-08-24 15:21:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.019881034298866725" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="2.3285855123400325">
<NAME>Ofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.5914255828581242" CI_START="0.002219635843357097" EFFECT_SIZE="0.036231884057971016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.22809989344904222" LOG_CI_START="-2.653718270681393" LOG_EFFECT_SIZE="-1.4409090820652177" MODIFIED="2011-06-23 10:43:25 +0100" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="1.4248202417908966" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="2.030112721417069" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:21:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Pefloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 10:44:33 +0100" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="0.0" STUDY_ID="STD-Hajji-1988-MAR" TOTAL_1="24" TOTAL_2="18" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Pefloxacin 400 mg BD for 14 days vs Co-trimoxazole 160/800 mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9717906290322031" CI_END="0.2453417929583871" CI_START="0.009684985222527791" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.04874558071528589" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.6102284652253508" LOG_CI_START="-2.0139010375963453" LOG_EFFECT_SIZE="-1.3120647514108479" METHOD="MH" MODIFIED="2011-08-24 15:22:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6151462509121952" P_Q="0.7797722945974476" P_Z="2.4820797774921066E-4" Q="0.07818499397577972" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="126" WEIGHT="200.0" Z="3.664101883541087">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cotrimoxazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7955112292196425" CI_END="0.42802191326256483" CI_START="0.008146569070860128" DF="1" EFFECT_SIZE="0.05905006418485238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.36853399602095377" LOG_CI_START="-2.089025255961027" LOG_EFFECT_SIZE="-1.2287796259909902" MODIFIED="2011-08-24 15:22:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3724388858659847" P_Z="0.005116225419810253" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="64" WEIGHT="100.00000000000001" Z="2.799623419142304">
<NAME>Ciprofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-06-23 10:43:09 +0100" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Limson-1989-PHL" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="15.083440308087292">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 10 days vs Co-trimoxazole 160/800 mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5557242641583109" CI_START="0.0020818334375382005" EFFECT_SIZE="0.034013605442176874" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.25514064053690366" LOG_CI_START="-2.681554020287411" LOG_EFFECT_SIZE="-1.4683473304121573" MODIFIED="2011-06-23 10:50:17 +0100" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="1.4252872302053876" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="2.031443688586546" WEIGHT="84.91655969191272">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5914255828581242" CI_START="0.002219635843357097" DF="0" EFFECT_SIZE="0.036231884057971016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.22809989344904222" LOG_CI_START="-2.653718270681393" LOG_EFFECT_SIZE="-1.4409090820652177" MODIFIED="2011-08-24 15:21:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.019881034298866725" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="2.3285855123400325">
<NAME>Ofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.5914255828581242" CI_START="0.002219635843357097" EFFECT_SIZE="0.036231884057971016" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.22809989344904222" LOG_CI_START="-2.653718270681393" LOG_EFFECT_SIZE="-1.4409090820652177" MODIFIED="2011-06-23 10:43:32 +0100" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.4248202417908966" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="2.030112721417069" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 ays</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:22:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Pefloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 10:44:46 +0100" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.0" STUDY_ID="STD-Hajji-1988-MAR" TOTAL_1="24" TOTAL_2="18" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Pefloxacin 400 mg BD for 14 days vs Co-trimoxazole 160/800 mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-24 15:23:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroqunolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cotrimoxazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:23:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 10:50:39 +0100" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:23:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Ofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 10:50:55 +0100" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="44" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 200mg BD for 7 days vs Co-trimoxazole 960mg BD for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-20 20:58:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Convalescent faecal carriage</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pefloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cotrimoxazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-20 20:58:29 +0100" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="0.0" STUDY_ID="STD-Hajji-1988-MAR" TOTAL_1="24" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8741721854304635" CI_END="-76.4150893848936" CI_START="-100.962394058815" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-88.6887417218543" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2011-08-24 15:23:31 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3498029527177492" P_Q="0.3498029527177492" P_Z="1.5612582187227732E-45" Q="0.8741721854304635" RANDOM="NO" SCALE="174.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="96" TOTAL_2="88" UNITS="" WEIGHT="200.0" Z="14.162592750452122">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cotrimoxazole</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-68.27580658217917" CI_START="-99.72419341782083" DF="0" EFFECT_SIZE="-84.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" MODIFIED="2011-08-24 15:23:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.1827138299875854E-25" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="44" WEIGHT="100.0" Z="10.470296970194676">
<NAME>ciprofloxacin versus co-trimoxazole</NAME>
<CONT_DATA CI_END="-68.27580658217917" CI_START="-99.72419341782083" EFFECT_SIZE="-84.0" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="156.0" MODIFIED="2011-02-28 10:53:37 +0100" MODIFIED_BY="[Empty name]" ORDER="659" SD_1="24.0" SD_2="48.0" SE="8.022695081058258" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-76.36475678312009" CI_START="-115.63524321687991" DF="0" EFFECT_SIZE="-96.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" MODIFIED="2011-08-24 15:23:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.463861937281286E-22" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="44" WEIGHT="100.0" Z="9.582592914056287">
<NAME>Ofloxacin versus co-trimoxazole</NAME>
<CONT_DATA CI_END="-76.36475678312009" CI_START="-115.63524321687991" EFFECT_SIZE="-96.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="156.0" MODIFIED="2011-02-28 10:54:14 +0100" MODIFIED_BY="[Empty name]" ORDER="658" SD_1="48.0" SD_2="48.0" SE="10.018165319240662" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.4962091388907681" CI_END="1.080690537612088" CI_START="0.45903087486302413" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7043225986267008" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.033701348857648944" LOG_CI_START="-0.3381581024111333" LOG_EFFECT_SIZE="-0.1522283767767422" METHOD="MH" MODIFIED="2011-08-24 15:23:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6831455636404213" P_Q="0.650960589772074" P_Z="0.10855900687243623" Q="0.8586124132662218" RANDOM="NO" SCALE="29.22" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="82" WEIGHT="100.0" Z="1.6047037927335097">
<NAME>Non serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cotrimoxazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cotrimoxazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5920518244527565" CI_END="1.1182380751167629" CI_START="0.3385243084418966" DF="1" EFFECT_SIZE="0.6152647975077883" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.048534275555983615" LOG_CI_START="-0.47041014044076945" LOG_EFFECT_SIZE="-0.21093793244239295" MODIFIED="2011-08-24 15:23:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4416269374472105" P_Z="0.11108108402555919" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="42" WEIGHT="54.493627587604834" Z="1.5933527284086626">
<NAME>Ciprofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="2.2928589592378805" CI_START="0.3028727264913275" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.36037734077066724" LOG_CI_START="-0.5187398328659169" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-12-31 12:41:34 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Limson-1989-PHL" TOTAL_1="20" TOTAL_2="20" VAR="0.2666666666666667" WEIGHT="17.82501836977728"/>
<DICH_DATA CI_END="1.0736659857286481" CI_START="0.24155090744099883" EFFECT_SIZE="0.5092592592592593" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.030869194662850055" LOG_CI_START="-0.6169913266482617" LOG_EFFECT_SIZE="-0.2930610659927058" MODIFIED="2010-12-31 12:56:25 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.38055647717944874" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="22" VAR="0.1448232323232323" WEIGHT="36.66860921782755"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.827840198298879" CI_START="0.4597107441666954" DF="0" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.26193822420380225" LOG_CI_START="-0.33751534598260186" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2011-08-24 15:23:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8048263676899525" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="22" WEIGHT="31.925406035421997" Z="0.24710577117020668">
<NAME>Ofloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="1.827840198298879" CI_START="0.4597107441666954" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.26193822420380225" LOG_CI_START="-0.33751534598260186" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-12-31 12:56:56 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.3521219944705229" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="22" VAR="0.12398989898989897" WEIGHT="31.925406035421997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.205943822037795" CI_START="0.14343350308337044" DF="0" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.34359444822672297" LOG_CI_START="-0.8433493946599226" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2011-08-24 15:23:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4092410186467549" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="18" WEIGHT="13.580966376973166" Z="0.8252300241287481">
<NAME>Pefloxacin versus co-trimoxazole</NAME>
<DICH_DATA CI_END="2.205943822037795" CI_START="0.14343350308337044" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.34359444822672297" LOG_CI_START="-0.8433493946599226" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2010-12-31 12:44:58 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.6972166887783963" STUDY_ID="STD-Hajji-1988-MAR" TOTAL_1="24" TOTAL_2="18" VAR="0.48611111111111105" WEIGHT="13.580966376973166"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-08-24 15:53:37 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Fluroqunolone versus ampicillin/amoxicillin</NAME>
<DICH_OUTCOME CHI2="0.03257436153418172" CI_END="0.5701502018735578" CI_START="0.021653380059810233" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.24401071757017812" LOG_CI_START="-1.6644743013084717" LOG_EFFECT_SIZE="-0.9542425094393249" METHOD="MH" MODIFIED="2011-06-23 10:49:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8567729062315782" P_Q="0.8571877265831762" P_Z="0.008454995458126217" Q="0.03238390079752559" RANDOM="NO" SCALE="347.26268116728113" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="2.6333388232257287">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ampicillin/Amoxycillin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ampicillin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5422965811171738" CI_START="0.005358543169388946" DF="0" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-06-23 10:47:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09691091981099019" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="40.74074074074074" Z="1.6600175608856702">
<NAME>Ofloxacin versus ampicillin</NAME>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-06-23 10:47:21 +0100" MODIFIED_BY="[Empty name]" ORDER="934" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Flores-1994-MEX" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="40.74074074074074">
<FOOTNOTE>Ofloxacin 400 mg BD 10 days vs Ampicillin 1 g QDS for 10 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9269426096039015" CI_START="0.01685649126290228" DF="0" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2011-06-23 10:49:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04193383242476808" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="59.25925925925926" Z="2.0341762084790993">
<NAME>Ofloxacin versus amoxicillin</NAME>
<DICH_DATA CI_END="0.9269426096039015" CI_START="0.01685649126290228" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2011-06-23 10:49:09 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="1.0222524150130436" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="1.045" WEIGHT="59.25925925925926">
<FOOTNOTE>Ofloxacin 200 mg oral BD for 14 days vs Amoxicillin 4 to 6 g/day for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005511433342424357" CI_END="0.6777051446500234" CI_START="0.025104180849864384" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.16895921749611753" LOG_CI_START="-1.6002539450997435" LOG_EFFECT_SIZE="-0.8846065812979305" METHOD="MH" MODIFIED="2011-08-24 09:38:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9408201914145938" P_Q="0.9408226403903733" P_Z="0.015405751388620218" Q="0.0055109763653121025" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="2.4226974450383003">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ampicillin/Amoxycillin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ampicillin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5983769423254333" CI_START="0.007854196568971131" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-08-24 09:38:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18858341780432855" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="30.43478260869565" Z="1.3147812884090506">
<NAME>Ofloxacin versus ampicillin/amoxicillin</NAME>
<DICH_DATA CI_END="2.5983769423254333" CI_START="0.007854196568971131" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-06-23 10:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Flores-1994-MEX" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="30.43478260869565">
<FOOTNOTE>Ofloxacin 400 mg BD 10 days vs Ampicillin 1 g QDS for 10 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9269426096039015" CI_START="0.01685649126290228" DF="0" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2011-06-23 10:49:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04193383242476808" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="69.56521739130434" Z="2.0341762084790993">
<NAME>Ofloxacin versus amoxicillin</NAME>
<DICH_DATA CI_END="0.9269426096039015" CI_START="0.01685649126290228" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.032947153777727334" LOG_CI_START="-1.7732328202061596" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2011-06-23 10:49:21 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="1.0222524150130436" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="1.045" WEIGHT="69.56521739130434">
<FOOTNOTE>Ofloxacin 200 mg oral BD for 14 days vs Amoxicillin 4 to 6 g/day for 14 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7522141142287503" CI_END="0.9338259453163245" CI_START="0.11898481903228045" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.029734063847945556" LOG_CI_START="-0.9245084455913795" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2011-08-24 15:53:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.38577616665620984" P_Q="1.0" P_Z="0.036597475509950544" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="2.0902263064058992">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ampicillin/Amoxycillin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroqunolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ampicillin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7522141142287503" CI_END="0.9338259453163245" CI_START="0.11898481903228045" DF="1" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-0.029734063847945556" LOG_CI_START="-0.9245084455913795" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-24 09:39:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38577616665620984" P_Z="0.036597475509950544" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="2.0902263064058992">
<NAME>Ofloxacin versus amoxicillin</NAME>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-21 08:52:52 +0100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Flores-1994-MEX" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="8.333333333333334"/>
<DICH_DATA CI_END="0.861285305124041" CI_START="0.086359496495234" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.06485296246452768" LOG_CI_START="-1.0636898984125978" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2010-12-18 11:17:44 +0100" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.5867217604984702" STUDY_ID="STD-Yousaf-1992--PAK" TOTAL_1="25" TOTAL_2="25" VAR="0.34424242424242424" WEIGHT="91.66666666666667"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-08-24 15:54:01 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Fluoroquinolone versus cefixime</NAME>
<DICH_OUTCOME CHI2="0.7558249856473926" CI_END="0.27292055367556656" CI_START="0.017220356207707222" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06855500821018064" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.5639637563354136" LOG_CI_START="-1.763957869291095" LOG_EFFECT_SIZE="-1.1639608128132544" METHOD="MH" MODIFIED="2011-08-24 15:24:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38463828367267205" P_Q="0.39233627700229023" P_Z="1.4340484859322406E-4" Q="0.7316890479690361" RANDOM="NO" SCALE="307.89" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="219" TOTAL_2="206" WEIGHT="200.0" Z="3.8022207740850824">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-24 07:24:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:24:31 +0100" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Cefixime 200mg BD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1053921063616905" CI_START="0.018951423067019205" DF="0" EFFECT_SIZE="0.14473684210526316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.04351635894685979" LOG_CI_START="-1.7223581731919921" LOG_EFFECT_SIZE="-0.8394209071225663" MODIFIED="2011-06-24 07:24:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06241087552157339" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="90" WEIGHT="100.0" Z="1.863365393052518">
<NAME>Ofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="1.1053921063616905" CI_START="0.018951423067019205" EFFECT_SIZE="0.14473684210526316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.04351635894685979" LOG_CI_START="-1.7223581731919921" LOG_EFFECT_SIZE="-0.8394209071225663" MODIFIED="2011-06-24 07:24:38 +0100" MODIFIED_BY="[Empty name]" ORDER="701" O_E="0.0" SE="1.0372834413982723" STUDY_ID="STD-Phuong-1999-VNM" TOTAL_1="38" TOTAL_2="44" VAR="1.075956937799043" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 10mg/kg in 2 divided doses for 5 days vs Cefixime 20mg/kg in 2 divided doses for 7 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:24:15 +0100" MODIFIED_BY="[Empty name]" ORDER="702" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 7 days vs Cefixime 200 mg BD for 7 days)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3051198986311701" CI_START="0.005744510166834596" DF="0" EFFECT_SIZE="0.041866028708133975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="19" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.5155294685820587" LOG_CI_START="-2.240746997595423" LOG_EFFECT_SIZE="-1.3781382330887406" MODIFIED="2011-08-24 15:24:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0017402433312508525" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="70" WEIGHT="100.0" Z="3.1313167842855543">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="0.30511989863116995" CI_START="0.005744510166834601" EFFECT_SIZE="0.041866028708133975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="19" LOG_CI_END="-0.515529468582059" LOG_CI_START="-2.2407469975954224" LOG_EFFECT_SIZE="-1.3781382330887406" MODIFIED="2011-06-24 07:24:44 +0100" MODIFIED_BY="[Empty name]" ORDER="703" O_E="0.0" SE="1.013401316506949" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="88" TOTAL_2="70" VAR="1.0269822282980177" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10mg/kg/day in single oral dose for 7 days vs Cefixime 20mg/kg in 2 divided doses oral for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004045207776782564" CI_END="2.194120161305465" CI_START="0.02746199841461721" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.245468784963079" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.34126040808960634" LOG_CI_START="-1.5612678622609022" LOG_EFFECT_SIZE="-0.610003727085648" METHOD="MH" MODIFIED="2011-08-24 15:24:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9492871807160738" P_Q="0.9494144920988893" P_Z="0.20881216666599745" Q="0.004024895548130809" RANDOM="NO" SCALE="647.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="219" TOTAL_2="206" WEIGHT="200.0" Z="1.256838444038263">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 10:51:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:25:05 +0100" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Cefixime 200mg BD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.662708375234555" CI_START="0.011421352909969106" DF="0" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.6686382537588086" LOG_CI_START="-1.9422824489331572" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2011-08-05 10:51:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3390226035636432" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="90" WEIGHT="100.0" Z="0.9560982641435425">
<NAME>Ofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="4.662708375234555" CI_START="0.011421352909969106" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6686382537588086" LOG_CI_START="-1.9422824489331572" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2011-06-24 07:25:25 +0100" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="1.533667745027179" STUDY_ID="STD-Phuong-1999-VNM" TOTAL_1="38" TOTAL_2="44" VAR="2.352136752136752" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 10mg/kg in 2 divided doses for 5 days vs Cefixime 20mg/kg in 2 divided doses for 7 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:25:47 +0100" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 7 days vs Cefixime 200 mg BD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.428926661637823" CI_START="0.010999063343687169" DF="0" EFFECT_SIZE="0.26591760299625467" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.8081384715496895" LOG_CI_START="-1.9586442968406894" LOG_EFFECT_SIZE="-0.5752529126454999" MODIFIED="2011-08-24 15:24:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.41506776097416465" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="70" WEIGHT="100.0" Z="0.8150079606306591">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="6.428926661637823" CI_START="0.010999063343687169" EFFECT_SIZE="0.26591760299625467" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8081384715496895" LOG_CI_START="-1.9586442968406894" LOG_EFFECT_SIZE="-0.5752529126454999" MODIFIED="2011-06-24 07:26:08 +0100" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="1.6252218939480951" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="88" TOTAL_2="70" VAR="2.6413462045682334" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10mg/kg/day in single oral dose for 7 days vs Cefixime 20mg/kg in 2 divided doses oral for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08898634759377055" CI_END="0.8772603127587711" CI_START="0.05428529376632285" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21822541966426862" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.056871517671801625" LOG_CI_START="-1.265317807633526" LOG_EFFECT_SIZE="-0.6610946626526638" METHOD="MH" MODIFIED="2011-08-24 15:24:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.765469796651866" P_Q="0.7655234528780898" P_Z="0.03199745627166234" Q="0.08894440653279553" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="200" TOTAL_2="163" WEIGHT="200.0" Z="2.144442396710768">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 10:51:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500mg BD for 7 days vs Cefixime 200mg BD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.723921203524791" CI_START="0.014385324265142151" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-05 11:01:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49327758741034344" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="66" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Ofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-05 11:01:08 +0100" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Phuong-1999-VNM" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 10mg/kg in 2 divided doses for 5 days vs Cefixime 20mg/kg in 2 divided doses for 7 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-24 07:26:32 +0100" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.0" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="46" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 7 days vs Cefixime 200 mg BD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9322387435289311" CI_START="0.04095738206669414" DF="0" EFFECT_SIZE="0.19540229885057472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="-0.03047285189562816" LOG_CI_START="-1.387667810585061" LOG_EFFECT_SIZE="-0.7090703312403446" MODIFIED="2011-08-24 15:24:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.040562212411838945" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="51" WEIGHT="100.0" Z="2.0479774152402803">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="0.9322387435289309" CI_START="0.04095738206669416" EFFECT_SIZE="0.19540229885057472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.030472851895628265" LOG_CI_START="-1.3876678105850608" LOG_EFFECT_SIZE="-0.7090703312403446" MODIFIED="2011-06-24 07:26:16 +0100" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="0.7972230369575684" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="87" TOTAL_2="51" VAR="0.6355645706558485" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10mg/kg/day in single oral dose for 7 days vs Cefixime 20mg/kg in 2 divided doses oral for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.400940090572013" CI_START="0.010976033261629646" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.26506024096385544" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.8062437624471969" LOG_CI_START="-1.9595545855549321" LOG_EFFECT_SIZE="-0.5766554115538677" METHOD="MH" MODIFIED="2011-08-24 15:32:40 +0100" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;Phuong 1999 :Data for relapse and faecal carriage likely as unpublished data from authors. refer previous review update.&lt;/p&gt;&lt;p&gt;40 pts assessed at follow up. Nos in each arm not stated but said to be 20 in each arm in previous review&lt;/p&gt;" NOTES_MODIFIED="2011-08-24 15:32:40 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="1.0" P_Q="1.0" P_Z="0.41376513553825434" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="65" WEIGHT="100.0" Z="0.8172857858217458">
<NAME>Convalescent faecal carriage</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.400940090572013" CI_START="0.010976033261629646" DF="0" EFFECT_SIZE="0.26506024096385544" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.8062437624471969" LOG_CI_START="-1.9595545855549321" LOG_EFFECT_SIZE="-0.5766554115538677" MODIFIED="2011-08-24 15:32:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41376513553825434" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="65" WEIGHT="100.0" Z="0.8172857858217458">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="6.400940090572011" CI_START="0.010976033261629655" EFFECT_SIZE="0.26506024096385544" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8062437624471968" LOG_CI_START="-1.959554585554932" LOG_EFFECT_SIZE="-0.5766554115538677" MODIFIED="2011-02-24 17:44:31 +0100" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="1.6246436405390774" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="82" TOTAL_2="65" VAR="2.639466958744067" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.2045388420133838" CI_END="-5.910076601983016" CI_START="-26.155096514106596" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.032586558044805" ESTIMABLE="YES" I2="16.98067632850242" I2_Q="16.980676328502387" ID="CMP-004.05" MODIFIED="2011-08-24 15:33:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.272416459394201" P_Q="0.272416459394201" P_Z="0.0019073081133439422" Q="1.2045388420133833" RANDOM="NO" SCALE="244.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="93" TOTAL_2="92" UNITS="" WEIGHT="200.0" Z="3.104298476285638">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cefixime</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.854459229473277E-32" CI_END="0.42281902881420663" CI_START="-24.42281902881421" DF="0" EFFECT_SIZE="-12.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-004.05.01" MODIFIED="2011-08-24 15:32:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.058323928131016715" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="46" WEIGHT="100.0" Z="1.893255287703057">
<NAME>Ciprofloxacin versus cefixime</NAME>
<CONT_DATA CI_END="0.4228190288142084" CI_START="-24.42281902881421" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="84.0" MODIFIED="2011-02-24 17:48:41 +0100" MODIFIED_BY="[Empty name]" ORDER="636" SD_1="24.0" SD_2="36.0" SE="6.3382894414406685" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.538281344785155" CI_START="-41.461718655214845" DF="0" EFFECT_SIZE="-24.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" MODIFIED="2011-08-24 15:33:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007063334159178389" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="2.693843404407007">
<NAME>Ofloxacin versus cefixime</NAME>
<CONT_DATA CI_END="-6.538281344785155" CI_START="-41.461718655214845" EFFECT_SIZE="-24.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="84.0" MODIFIED="2011-02-24 17:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="638" SD_1="48.0" SD_2="36.0" SE="8.909203838922885" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.473139489361569" CI_START="-4.526860510638431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2011-08-24 15:33:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.176515621670825E-4" Q="0.0" RANDOM="NO" SCALE="11.24667015409581" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="3.85096864622007">
<NAME>Duration of hospitalization</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.473139489361569" CI_START="-4.526860510638431" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" MODIFIED="2011-08-24 15:33:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.176515621670825E-4" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="100.0" Z="3.85096864622007">
<NAME>Ofloxacin versus cefixime</NAME>
<CONT_DATA CI_END="-1.473139489361569" CI_START="-4.526860510638431" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="14.0" MODIFIED="2010-12-18 09:29:30 +0100" MODIFIED_BY="[Empty name]" ORDER="643" SD_1="3.0" SD_2="4.0" SE="0.7790247793745761" STUDY_ID="STD-Phuong-1999-VNM" TOTAL_1="37" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.12915216967889243" CI_END="14.423749551864194" CI_START="0.33810286655407895" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2083276636277045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="1.159078172866614" LOG_CI_START="-0.47095114711846325" LOG_EFFECT_SIZE="0.34406351287407533" METHOD="MH" MODIFIED="2011-06-21 17:21:10 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7193128030384328" P_Q="0.7195664797756692" P_Z="0.4080041566977034" Q="0.1289085366305239" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="121" WEIGHT="200.0" Z="0.8274109985134434">
<NAME>Serious adverse Events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.55522443307134" CI_START="0.1451422196837977" DF="0" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="1.9167445624038815" LOG_CI_START="-0.8382062394668675" LOG_EFFECT_SIZE="0.5392691614685069" MODIFIED="2011-06-21 17:21:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4428983161375418" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="44" WEIGHT="100.0" Z="0.7673081738764034">
<NAME>Ofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="82.55522443307134" CI_START="0.14514221968379762" EFFECT_SIZE="3.4615384615384617" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9167445624038815" LOG_CI_START="-0.8382062394668678" LOG_EFFECT_SIZE="0.5392691614685069" MODIFIED="2010-12-31 13:14:30 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="1.6182717382452858" STUDY_ID="STD-Phuong-1999-VNM" TOTAL_1="38" TOTAL_2="44" VAR="2.618803418803419" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.10982243741844" CI_START="0.15472183047676963" DF="0" EFFECT_SIZE="1.673913043478261" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="1.2579141921789172" LOG_CI_START="-0.8104484051971015" LOG_EFFECT_SIZE="0.22373289349090783" MODIFIED="2011-06-21 17:21:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6715548538965298" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="77" WEIGHT="100.0" Z="0.42401502904318517">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="18.10982243741844" CI_START="0.15472183047676963" EFFECT_SIZE="1.673913043478261" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2579141921789172" LOG_CI_START="-0.8104484051971015" LOG_EFFECT_SIZE="0.22373289349090783" MODIFIED="2010-12-31 15:16:14 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="1.2149664282586559" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="92" TOTAL_2="77" VAR="1.4761434217955958" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.158495226478747" CI_END="4.13038488099749" CI_START="1.6593167204900814" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.617941308566441" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="21" I2="75.48567542812411" I2_Q="67.22594906044864" ID="CMP-004.08" LOG_CI_END="0.6159905223356559" LOG_CI_START="0.21992928948002927" LOG_EFFECT_SIZE="0.41795990590784254" METHOD="MH" MODIFIED="2011-08-24 15:54:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.016920260912495655" P_Q="0.04730254875207707" P_Z="3.523896579833117E-5" Q="6.102388757766963" RANDOM="NO" SCALE="23.69" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="185" TOTAL_2="169" WEIGHT="300.0" Z="4.136665215399829">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.186417622977704E-31" CI_END="2.9495674835295276" CI_START="0.8337473980874299" DF="0" EFFECT_SIZE="1.568181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="100.0" ID="CMP-004.08.01" LOG_CI_END="0.46975833689751195" LOG_CI_START="-0.07896550839537637" LOG_EFFECT_SIZE="0.1953964142510678" MODIFIED="2011-02-24 18:12:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.16275764465355747" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="46" WEIGHT="99.99999999999999" Z="1.395856724381813">
<NAME>Ciprofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="2.9495674835295285" CI_START="0.83374739808743" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.46975833689751206" LOG_CI_START="-0.07896550839537632" LOG_EFFECT_SIZE="0.19539641425106788" MODIFIED="2011-02-24 18:12:54 +0100" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.32232310295188354" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="48" TOTAL_2="46" VAR="0.10389218269653051" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.489566558425764" CI_START="0.8317956575452625" DF="0" EFFECT_SIZE="1.7037037037037037" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="0.5427714862788856" LOG_CI_START="-0.0799833512337122" LOG_EFFECT_SIZE="0.23139406752258676" MODIFIED="2011-02-24 18:17:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14525194062497906" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="1.4565090827458247">
<NAME>Ofloxacin versus cefixime</NAME>
<DICH_DATA CI_END="3.489566558425764" CI_START="0.8317956575452626" EFFECT_SIZE="1.7037037037037037" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5427714862788856" LOG_CI_START="-0.07998335123371214" LOG_EFFECT_SIZE="0.23139406752258676" MODIFIED="2011-02-24 18:17:31 +0100" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.3658092742410626" STUDY_ID="STD-Rizvi-2007-PAK" TOTAL_1="45" TOTAL_2="46" VAR="0.1338164251207729" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="150.8994285461534" CI_START="2.9013372765499437" DF="0" EFFECT_SIZE="20.92391304347826" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" I2="0.0" ID="CMP-004.08.03" LOG_CI_END="2.17868759511209" LOG_CI_START="0.46259821788583855" LOG_EFFECT_SIZE="1.3206429064989642" MODIFIED="2011-02-28 22:52:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.002555925669220219" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="77" WEIGHT="100.0" Z="3.0166407035978158">
<NAME>Gatifloxacin versus cefixime</NAME>
<DICH_DATA CI_END="150.8994285461534" CI_START="2.9013372765499437" EFFECT_SIZE="20.92391304347826" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="2.17868759511209" LOG_CI_START="0.46259821788583855" LOG_EFFECT_SIZE="1.3206429064989642" MODIFIED="2011-02-23 11:02:57 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="1.0080393949621194" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="92" TOTAL_2="77" VAR="1.0161434217955958" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-08-24 15:54:21 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Fluoroquinolone versus ceftriaxone</NAME>
<DICH_OUTCOME CHI2="2.4197774051605206E-4" CI_END="0.6277883919925414" CI_START="0.01166939318831154" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0855915275317529" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.20218671880512645" LOG_CI_START="-1.9329517268012175" LOG_EFFECT_SIZE="-1.0675692228031721" METHOD="MH" MODIFIED="2011-06-23 11:25:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9875889006045516" P_Q="0.98758892055334" P_Z="0.015610917857884675" Q="2.4197696257557277E-4" RANDOM="NO" SCALE="602.35" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="47" WEIGHT="200.0" Z="2.4178871401152797">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ceftriaxone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4063197619422108" CI_START="0.005047151002846366" DF="0" EFFECT_SIZE="0.08424908424908426" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.1480840796154903" LOG_CI_START="-2.296953701661817" LOG_EFFECT_SIZE="-1.0744348110231632" MODIFIED="2011-06-23 11:24:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08496939787625994" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="99.99999999999999" Z="1.7225529596858702">
<NAME>Ciprofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="1.40631976194221" CI_START="0.00504715100284637" EFFECT_SIZE="0.08424908424908426" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1480840796154901" LOG_CI_START="-2.2969537016618164" LOG_EFFECT_SIZE="-1.0744348110231632" MODIFIED="2011-06-23 11:24:24 +0100" MODIFIED_BY="[Empty name]" ORDER="704" O_E="0.0" SE="1.436227295854504" STUDY_ID="STD-Wallace-1993-BHR" TOTAL_1="20" TOTAL_2="22" VAR="2.062748845357541" WEIGHT="99.99999999999999">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Ceftriaxone 3 g/day IV for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.518539574700668E-32" CI_END="1.4606013993334561" CI_START="0.005176933745523254" DF="0" EFFECT_SIZE="0.08695652173913042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="100.0" ID="CMP-005.01.02" LOG_CI_END="0.1645317123827332" LOG_CI_START="-2.285927393089957" LOG_EFFECT_SIZE="-1.0606978403536118" MODIFIED="2011-06-23 11:25:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.08974064388751353" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="1.6967674024263897">
<NAME>Ofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="1.4606013993334568" CI_START="0.0051769337455232585" EFFECT_SIZE="0.08695652173913043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1645317123827334" LOG_CI_START="-2.2859273930899566" LOG_EFFECT_SIZE="-1.0606978403536116" MODIFIED="2011-06-23 11:25:28 +0100" MODIFIED_BY="[Empty name]" ORDER="705" O_E="0.0" SE="1.4394118085228598" STUDY_ID="STD-Smith-1994-VNM" TOTAL_1="22" TOTAL_2="25" VAR="2.07190635451505" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Ceftriaxone 3 g IV OD for 3 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.802545501889" CI_START="0.01613021795743741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" METHOD="MH" MODIFIED="2011-06-23 11:26:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5437968993265574" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="47" WEIGHT="100.0" Z="0.6070813957017506">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ceftriaxone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-06-23 11:25:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 11:25:50 +0100" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="0.0" STUDY_ID="STD-Wallace-1993-BHR" TOTAL_1="20" TOTAL_2="22" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Ceftriaxone 3 g/day IV for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.802545501889" CI_START="0.01613021795743741" DF="0" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" MODIFIED="2011-06-23 11:26:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5437968993265574" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="0.6070813957017506">
<NAME>Ofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="8.802545501889" CI_START="0.01613021795743741" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" MODIFIED="2011-06-23 11:26:14 +0100" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Smith-1994-VNM" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Ceftriaxone 3 g IV OD for 3 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3507833287207367E-5" CI_END="3.3071279846375408" CI_START="0.03986360599719858" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3630895853118075" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.5194510022757582" LOG_CI_START="-1.399423418283521" LOG_EFFECT_SIZE="-0.4399862080038813" METHOD="MH" MODIFIED="2011-06-23 11:26:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.996131481652303" P_Q="0.9961318337651648" P_Z="0.36875090513450537" Q="2.3503554078553928E-5" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="34" WEIGHT="200.0" Z="0.8988155891208472">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ceftriaxone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.480958434278998" CI_START="0.015715551943756602" DF="0" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.9284449347092995" LOG_CI_START="-1.8036703615812775" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2011-06-23 11:26:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5300898079630069" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.6278689326734501">
<NAME>Ciprofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="8.480958434278998" CI_START="0.015715551943756602" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9284449347092995" LOG_CI_START="-1.8036703615812775" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2011-06-23 11:26:00 +0100" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Wallace-1993-BHR" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Ceftriaxone 3 g/day IV for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.039573882065785" CI_START="0.016219918677380755" DF="0" EFFECT_SIZE="0.36111111111111116" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.44235914846045044" MODIFIED="2011-06-23 11:26:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5199803810336917" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.6433756537466847">
<NAME>Ofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="8.039573882065785" CI_START="0.016219918677380755" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2011-06-23 11:26:26 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Smith-1994-VNM" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Ceftriaxone 3 g IV OD for 3 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.480958434278998" CI_START="0.015715551943756602" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.9284449347092995" LOG_CI_START="-1.8036703615812775" LOG_EFFECT_SIZE="-0.43761271343598884" METHOD="MH" MODIFIED="2011-02-25 10:46:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5300898079630069" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.6278689326734501">
<NAME>Convalescent faecal carriage</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ceftriaxone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.480958434278998" CI_START="0.015715551943756602" DF="0" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.9284449347092995" LOG_CI_START="-1.8036703615812775" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2011-01-02 08:50:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5300898079630069" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.6278689326734501">
<NAME>Ciprofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="8.480958434278998" CI_START="0.015715551943756602" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9284449347092995" LOG_CI_START="-1.8036703615812775" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2010-12-18 10:04:52 +0100" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Wallace-1993-BHR" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.098044693187137E-31" CI_END="-79.33247379738842" CI_START="-150.66752620261155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-114.99999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2011-01-03 12:05:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="2.626525892904972E-10" Q="0.0" RANDOM="NO" SCALE="166.51093468103153" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="25" UNITS="" WEIGHT="99.99999999999999" Z="6.319357752531848">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ceftriaxone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.098044693187137E-31" CI_END="-79.33247379738842" CI_START="-150.66752620261155" DF="0" EFFECT_SIZE="-114.99999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-005.05.01" MODIFIED="2010-12-29 15:09:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="2.626525892904972E-10" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="99.99999999999999" Z="6.319357752531848">
<NAME>Ofloxacin versus ceftriaxone</NAME>
<CONT_DATA CI_END="-79.33247379738845" CI_START="-150.66752620261155" EFFECT_SIZE="-115.0" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="196.0" MODIFIED="2010-12-20 11:01:04 +0100" MODIFIED_BY="[Empty name]" ORDER="649" SD_1="25.0" SD_2="87.0" SE="18.19805184378512" STUDY_ID="STD-Smith-1994-VNM" TOTAL_1="22" TOTAL_2="25" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.846029954711332" CI_START="0.05522219027499622" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.7668610363263285" LOG_CI_START="-1.2578863719546283" LOG_EFFECT_SIZE="-0.2455126678141498" METHOD="MH" MODIFIED="2011-08-24 15:54:21 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6345627668179517" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="0.47531458462033344">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Ceftriaxone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.846029954711332" CI_START="0.05522219027499622" DF="0" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.7668610363263285" LOG_CI_START="-1.2578863719546283" LOG_EFFECT_SIZE="-0.2455126678141498" MODIFIED="2010-12-29 15:10:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6345627668179517" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="0.47531458462033344">
<NAME>Ofloxacin versus ceftriaxone</NAME>
<DICH_DATA CI_END="5.846029954711332" CI_START="0.05522219027499622" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7668610363263285" LOG_CI_START="-1.2578863719546283" LOG_EFFECT_SIZE="-0.2455126678141498" MODIFIED="2010-12-18 10:06:06 +0100" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="1.1893466502855483" STUDY_ID="STD-Smith-1994-VNM" TOTAL_1="22" TOTAL_2="25" VAR="1.4145454545454546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-08-24 15:54:30 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Fluoroquinolone versus azithromycin</NAME>
<DICH_OUTCOME CHI2="1.752291793196178" CI_END="3.018448602673618" CI_START="1.091032674985171" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.814724787200596" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" I2="0.0" I2_Q="37.860604356660176" ID="CMP-006.01" LOG_CI_END="0.4797837852034808" LOG_CI_START="0.037837757328268204" LOG_EFFECT_SIZE="0.25881077126587443" METHOD="MH" MODIFIED="2011-08-24 15:34:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4163849947765572" P_Q="0.20459238629326038" P_Z="0.021700280582131016" Q="1.6092850431627608" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="280" TOTAL_2="284" WEIGHT="200.0" Z="2.295573479553378">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:33:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 11:20:37 +0100" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="0.0" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="28" TOTAL_2="36" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Azithromycin 1 g OD followed by 500 mg OD for 6 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.19875773673091537" CI_END="3.943708390011592" CI_START="1.2291815246349633" DF="1" EFFECT_SIZE="2.2017114914425426" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.5959047943799837" LOG_CI_START="0.08961602391643687" LOG_EFFECT_SIZE="0.3427604091482103" MODIFIED="2011-08-24 15:33:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6557254488514097" P_Z="0.007958773609959481" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="2.6538137776258477">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="14.060891857278824" CI_START="0.6400731967326114" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1480128680814434" LOG_CI_START="-0.19377035864211847" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-06-23 11:16:30 +0100" MODIFIED_BY="[Empty name]" ORDER="692" O_E="0.0" SE="0.7881701093115123" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" VAR="0.6212121212121212" WEIGHT="15.28117359413203">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Azithromycin 1 gm OD for 5 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.85257620419684" CI_START="1.099059852815075" EFFECT_SIZE="2.057720057720058" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" LOG_CI_END="0.5857512378472699" LOG_CI_START="0.04102134396081025" LOG_EFFECT_SIZE="0.31338629090404" MODIFIED="2011-06-23 11:17:50 +0100" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.31997703612536904" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="63" TOTAL_2="62" VAR="0.10238530364757574" WEIGHT="84.71882640586797">
<FOOTNOTE>Ofloxacin 10 mg/kg BD for 7 days vs Azithromycin 10 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.859161807768854E-32" CI_END="2.9646736849687123" CI_START="0.3234921793750287" DF="0" EFFECT_SIZE="0.9793103448275863" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="100.0" ID="CMP-006.01.03" LOG_CI_END="0.4719768985041966" LOG_CI_START="-0.49013621420803327" LOG_EFFECT_SIZE="-0.00907965785191838" MODIFIED="2011-08-24 15:34:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.9704904591659135" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="142" WEIGHT="100.0" Z="0.03699316046434366">
<NAME>Gatifloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="2.964673684968711" CI_START="0.3234921793750287" EFFECT_SIZE="0.9793103448275862" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4719768985041964" LOG_CI_START="-0.49013621420803327" LOG_EFFECT_SIZE="-0.00907965785191843" MODIFIED="2011-06-23 11:18:55 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.5651500049438809" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="142" VAR="0.3193945280880686" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10 mg/kg OD for 7 days vs Azithromycin 20 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5655455950577719" CI_END="2.9910259977932223" CI_START="0.32127238473653796" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9802724392330998" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.47582018790563074" LOG_CI_START="-0.49312660302602473" LOG_EFFECT_SIZE="-0.008653207560197012" METHOD="MH" MODIFIED="2011-08-24 15:34:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7536910312751127" P_Q="0.5410832435208435" P_Z="0.972074134389857" Q="0.3735363209063324" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="280" TOTAL_2="282" WEIGHT="200.0" Z="0.0350070309896555">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azthithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:34:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 11:21:11 +0100" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.0" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="28" TOTAL_2="36" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Azithromycin 1 g OD followed by 500 mg OD for 6 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20779568214837857" CI_END="5.7587245466124335" CI_START="0.30300491934126256" DF="1" EFFECT_SIZE="1.3209549071618036" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.7603263056965606" LOG_CI_START="-0.5185503205887113" LOG_EFFECT_SIZE="0.12088799255392466" MODIFIED="2011-08-24 15:34:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6485006514661635" P_Z="0.7109817647504253" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="0.37053787159635926">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="21.262664318268648" CI_START="0.18812317873838816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3276176828694957" LOG_CI_START="-0.7255576915415332" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-06-23 11:21:44 +0100" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="1.2060453783110545" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" VAR="1.4545454545454546" WEIGHT="33.15649867374005">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Azithromycin 1 gm OD for 5 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.768958319042341" CI_START="0.1430804970629359" EFFECT_SIZE="0.9841269841269841" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8305218398668487" LOG_CI_START="-0.8444195597775044" LOG_EFFECT_SIZE="-0.006948859955327855" MODIFIED="2011-06-23 11:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="0.9838688692447382" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="63" TOTAL_2="62" VAR="0.9679979518689197" WEIGHT="66.84350132625995">
<FOOTNOTE>Ofloxacin 10 mg/kg BD for 7 days vs Azithromycin 10 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.79430842053346" CI_START="0.10919554472762392" DF="0" EFFECT_SIZE="0.6436781609195402" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="0.5791326296342894" LOG_CI_START="-0.9617950808591256" LOG_EFFECT_SIZE="-0.1913312256124181" MODIFIED="2011-08-24 15:34:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.626454799697597" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="140" WEIGHT="99.99999999999999" Z="0.48672278234021626">
<NAME>Gatifloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="3.79430842053346" CI_START="0.10919554472762392" EFFECT_SIZE="0.6436781609195402" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5791326296342894" LOG_CI_START="-0.9617950808591256" LOG_EFFECT_SIZE="-0.1913312256124181" MODIFIED="2011-06-23 11:22:40 +0100" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.9051485648590171" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="140" VAR="0.8192939244663382" WEIGHT="99.99999999999999">
<FOOTNOTE>Gatifloxacin 10 mg/kg OD for 7 days vs Azithromycin 20 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.461319038365829" CI_END="2.731507828185692" CI_START="0.1711462472007047" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6837304395690808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="71.10927975965707" I2_Q="70.85562865171197" ID="CMP-006.03" LOG_CI_END="0.43640244949016843" LOG_CI_START="-0.7666326193884728" LOG_EFFECT_SIZE="-0.16511508494915222" METHOD="MH" MODIFIED="2011-08-24 15:35:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06282029557344526" P_Q="0.06397592476944924" P_Z="0.5905733939187465" Q="3.4311942709264884" RANDOM="NO" SCALE="339.01" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="249" WEIGHT="200.0" Z="0.5380052970629666">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:34:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 11:21:24 +0100" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="0.0" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="36" TOTAL_2="28" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ciprofloxacin 500 mg BD for 7 days vs Azithromycin 1 g OD followed by 500 mg OD for 6 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="119.32947705937026" CI_START="0.3129627308579002" DF="0" EFFECT_SIZE="6.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="2.0767477374083168" LOG_CI_START="-0.5045073772984789" LOG_EFFECT_SIZE="0.7861201800549189" MODIFIED="2011-08-24 15:34:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.23255136377763852" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="84" WEIGHT="100.0" Z="1.1938124454643837">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="119.32947705937026" CI_START="0.3129627308579002" EFFECT_SIZE="6.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0767477374083168" LOG_CI_START="-0.5045073772984789" LOG_EFFECT_SIZE="0.7861201800549189" MODIFIED="2011-06-23 11:21:52 +0100" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="1.516242031797661" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="17" TOTAL_2="21" VAR="2.298989898989899" WEIGHT="100.0">
<FOOTNOTE>Ofloxacin 200 mg BD for 5 days vs Azithromycin 1 gm OD for 5 days</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-23 11:22:20 +0100" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.0" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="62" TOTAL_2="63" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ofloxacin 10 mg/kg BD for 7 days vs Azithromycin 10 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2030091779306304" CI_START="0.006513837321484658" DF="0" EFFECT_SIZE="0.11979166666666669" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="0.3430163064636706" LOG_CI_START="-2.186163091835584" LOG_EFFECT_SIZE="-0.9215733926859566" MODIFIED="2011-08-24 15:35:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.15319706658400153" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="137" WEIGHT="100.0" Z="1.4283294099180757">
<NAME>Gatifloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="2.2030091779306304" CI_START="0.006513837321484658" EFFECT_SIZE="0.11979166666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3430163064636706" LOG_CI_START="-2.186163091835584" LOG_EFFECT_SIZE="-0.9215733926859567" MODIFIED="2011-06-23 11:22:49 +0100" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="1.4856524982009178" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="127" TOTAL_2="137" VAR="2.207163345410628" WEIGHT="100.0">
<FOOTNOTE>Gatifloxacin 10 mg/kg OD for 7 days vs Azithromycin 20 mg/kg OD for 7 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7617283387952939" CI_END="45.082666039646725" CI_START="2.59934329585718" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="10.82521712158809" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="1.6540095908716472" LOG_CI_START="0.41486364065942977" LOG_EFFECT_SIZE="1.0344366157655387" METHOD="MH" MODIFIED="2011-08-24 15:35:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6832708578186164" P_Q="0.39683309219396357" P_Z="0.0010665812949887925" Q="0.7179016542503762" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="262" TOTAL_2="263" WEIGHT="200.0" Z="3.272348202151214">
<NAME>Convalescent faecal carriage</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:35:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-18 06:50:42 +0100" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.0" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="28" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03311555353854723" CI_END="69.3627963551211" CI_START="2.6365918998477387" DF="1" EFFECT_SIZE="13.52336448598131" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="1.8411265933654744" LOG_CI_START="0.42104291350218137" LOG_EFFECT_SIZE="1.1310847534338277" MODIFIED="2011-08-24 15:35:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8556009871272747" P_Z="0.0017951117653956959" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="96" WEIGHT="100.0" Z="3.122189785894987">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="275.6152880284314" CI_START="0.9911185995002789" EFFECT_SIZE="16.52777777777778" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.44030330366462" LOG_CI_START="-0.0038743737420950503" LOG_EFFECT_SIZE="1.2182144649612623" MODIFIED="2010-12-18 06:50:52 +0100" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="1.4357220665833355" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="35" TOTAL_2="34" VAR="2.0612978524743233" WEIGHT="33.64485981308411"/>
<DICH_DATA CI_END="89.50550939161546" CI_START="1.6088395114311185" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9518497685531864" LOG_CI_START="0.20651272354206332" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2010-12-18 06:51:00 +0100" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="1.0252196197972434" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="62" TOTAL_2="62" VAR="1.0510752688172043" WEIGHT="66.35514018691589"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.81584193800033" CI_START="0.11794464276710341" DF="0" EFFECT_SIZE="2.869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.04.03" LOG_CI_END="1.8439539797237052" LOG_CI_START="-0.9283217806751536" LOG_EFFECT_SIZE="0.45781609952427577" MODIFIED="2011-08-24 15:35:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5174116560671055" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="131" WEIGHT="100.0" Z="0.6473404121104366">
<NAME>Gatifloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="69.81584193800026" CI_START="0.11794464276710341" EFFECT_SIZE="2.869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8439539797237048" LOG_CI_START="-0.9283217806751536" LOG_EFFECT_SIZE="0.45781609952427577" MODIFIED="2010-12-18 06:52:43 +0100" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="1.6284485046446249" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="137" TOTAL_2="131" VAR="2.6518445322793145" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="18.535641660453607" CI_END="2.2885356995770003" CI_START="-21.820737864603704" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.766101082513352" ESTIMABLE="YES" I2="89.20997699115502" I2_Q="57.84741779052442" ID="CMP-006.05" MODIFIED="2011-08-24 15:35:41 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="9.44143607800596E-5" P_Q="0.12350245799827775" P_Z="0.11231554557038134" Q="2.3723339059764825" RANDOM="YES" SCALE="105.82" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1053.151853156857" TOTALS="SUB" TOTAL_1="135" TOTAL_2="142" UNITS="" WEIGHT="200.0" Z="1.5878708531095698">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38527103089115755" CI_START="-24.385271030891158" DF="0" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.01" MODIFIED="2011-08-24 15:35:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05756513283502894" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="36" WEIGHT="100.0" Z="1.8989950042932848">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<CONT_DATA CI_END="0.38527103089115755" CI_START="-24.385271030891158" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="79.2" MEAN_2="91.2" MODIFIED="2011-02-25 14:52:03 +0100" MODIFIED_BY="[Empty name]" ORDER="613" SD_1="24.0" SD_2="26.4" SE="6.319131947619749" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="28" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.102465891745783" CI_END="82.92734165623119" CI_START="-22.11537351162132" DF="1" EFFECT_SIZE="30.405984072304932" ESTIMABLE="YES" I2="85.92038293119911" ID="CMP-006.05.02" MODIFIED="2011-08-24 15:35:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.007697816862695772" P_Z="0.2565118356946745" STUDIES="2" TAU2="1234.2291167300903" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="1.1346742818097808">
<NAME>Ofloxacin versus azithromycin</NAME>
<CONT_DATA CI_END="30.37820494317396" CI_START="-22.37820494317396" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="134.0" MEAN_2="130.0" MODIFIED="2010-12-29 16:23:33 +0100" MODIFIED_BY="[Empty name]" ORDER="614" SD_1="76.14" SD_2="46.61" SE="13.458515131523779" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" WEIGHT="50.735104342714706"/>
<CONT_DATA CI_END="86.89278380483273" CI_START="28.30721619516732" EFFECT_SIZE="57.60000000000002" ESTIMABLE="YES" MEAN_1="196.8" MEAN_2="139.2" MODIFIED="2010-12-29 16:23:31 +0100" MODIFIED_BY="[Empty name]" ORDER="615" SD_1="97.18" SD_2="67.49" SE="14.945572488010209" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="63" TOTAL_2="62" WEIGHT="49.264895657285294"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.057032388912482274" CI_END="1.8266611340800303" CI_START="0.1942266043686719" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0104438692243511" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2011-08-24 15:35:52 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.811249390065597" P_Q="1.0" P_Z="0.015251304844566835" Q="0.0" RANDOM="NO" SCALE="3.71" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="107" TOTAL_2="106" UNITS="" WEIGHT="99.99999999999997" Z="2.4263559193754647">
<NAME>Duration of Hospitalization</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.057032388912482274" CI_END="1.8266611340800303" CI_START="0.1942266043686719" DF="1" EFFECT_SIZE="1.0104438692243511" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2011-08-24 15:35:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.811249390065597" P_Z="0.015251304844566835" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="106" WEIGHT="99.99999999999997" Z="2.4263559193754647">
<NAME>Ofloxacin versus azithromycin</NAME>
<CONT_DATA CI_END="2.119756423161225" CI_START="-0.319756423161224" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="9.6" MODIFIED="2010-12-18 08:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="622" SD_1="3.38" SD_2="2.37" SE="0.6223361412671392" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" WEIGHT="44.77806538782436"/>
<CONT_DATA CI_END="2.1983733023469743" CI_START="0.0016266976530248112" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="12.6" MODIFIED="2010-12-18 08:23:07 +0100" MODIFIED_BY="[Empty name]" ORDER="623" SD_1="3.85" SD_2="2.21" SE="0.5604048395841981" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="63" TOTAL_2="62" WEIGHT="55.221934612175616"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.4889800508606" CI_START="0.06456203034133534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="1.190022820414652" LOG_CI_START="-1.1900228204146521" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2011-01-03 11:07:54 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroqunolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.4889800508606" CI_START="0.06456203034133534" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="1.190022820414652" LOG_CI_START="-1.1900228204146521" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-31 13:51:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.0">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="15.4889800508606" CI_START="0.06456203034133534" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.190022820414652" LOG_CI_START="-1.1900228204146521" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-31 13:51:55 +0100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="1.3980505908390635" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" VAR="1.9545454545454546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5904078129103962" CI_END="1.354205137861312" CI_START="0.5951190433261797" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.897726721286284" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" I2="16.444032089820173" I2_Q="38.4549319264975" ID="CMP-006.08" LOG_CI_END="0.13168445718004673" LOG_CI_START="-0.22539615244205766" LOG_EFFECT_SIZE="-0.04685584763100546" METHOD="MH" MODIFIED="2011-08-24 15:54:30 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3092246066551545" P_Q="0.1969461853853921" P_Z="0.6069933424560909" Q="3.2496511298215243" RANDOM="NO" SCALE="56.49" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="280" TOTAL_2="284" WEIGHT="300.0" Z="0.5143699845200567">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluoroquinolone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9918363207266956" CI_START="0.7294202976008932" DF="0" EFFECT_SIZE="1.2053571428571428" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.2992536473779282" LOG_CI_START="-0.13702215572827928" LOG_EFFECT_SIZE="0.08111574582482448" MODIFIED="2010-12-31 15:18:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46610988836595235" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="36" WEIGHT="100.0" Z="0.7288230943078823">
<NAME>Ciprofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="1.9918363207266956" CI_START="0.7294202976008932" EFFECT_SIZE="1.2053571428571428" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2992536473779282" LOG_CI_START="-0.13702215572827928" LOG_EFFECT_SIZE="0.08111574582482448" MODIFIED="2010-12-31 15:18:07 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.25627056634464124" STUDY_ID="STD-Girgis-1999-EGY" TOTAL_1="28" TOTAL_2="36" VAR="0.06567460317460316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17816950001586654" CI_END="1.155901799017301" CI_START="0.2729716252655941" DF="1" EFFECT_SIZE="0.5617191404297852" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-006.08.02" LOG_CI_END="0.06292093965850357" LOG_CI_START="-0.5638824944648416" LOG_EFFECT_SIZE="-0.25048077740316904" MODIFIED="2010-12-31 14:01:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6729510909281315" P_Z="0.11723943654450475" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="106" WEIGHT="100.0" Z="1.5664665373648783">
<NAME>Ofloxacin versus azithromycin</NAME>
<DICH_DATA CI_END="1.1284402435022434" CI_START="0.2520686816003996" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.052478565979697814" LOG_CI_START="-0.5984811101071733" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2010-12-31 14:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.3823769360357933" STUDY_ID="STD-Chinh-2000-VNM" TOTAL_1="44" TOTAL_2="44" VAR="0.14621212121212118" WEIGHT="93.7031484257871"/>
<DICH_DATA CI_END="15.38729241325557" CI_START="0.06294193252950347" EFFECT_SIZE="0.9841269841269841" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.18716220700285" LOG_CI_START="-1.201059926913506" LOG_EFFECT_SIZE="-0.006948859955327855" MODIFIED="2010-12-31 13:59:37 +0100" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="1.4028535033526914" STUDY_ID="STD-Parry-2007-VNM" TOTAL_1="63" TOTAL_2="62" VAR="1.9679979518689197" WEIGHT="6.296851574212894"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.359938617880143" CI_START="0.179597660581949" DF="0" EFFECT_SIZE="1.9586206896551723" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.08.03" LOG_CI_END="1.329600000324953" LOG_CI_START="-0.7456993247008274" LOG_EFFECT_SIZE="0.29195033781206275" MODIFIED="2010-12-31 15:21:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5813250765202982" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="142" WEIGHT="100.0" Z="0.5514502322491114">
<NAME>Gatifloxain versus azithromycin</NAME>
<DICH_DATA CI_END="21.359938617880132" CI_START="0.1795976605819491" EFFECT_SIZE="1.9586206896551723" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296000003249528" LOG_CI_START="-0.7456993247008273" LOG_EFFECT_SIZE="0.29195033781206275" MODIFIED="2010-12-31 15:21:35 +0100" MODIFIED_BY="[Empty name]" ORDER="427" O_E="0.0" SE="1.2190410964174814" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="142" VAR="1.4860611947547353" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-08-24 15:54:51 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Fluoroquinolone 2 days vs 3 days</NAME>
<DICH_OUTCOME CHI2="4.527331457345388" CI_END="2.5266517259854298" CI_START="0.5354310082020899" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1631198051017484" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="55.82386624785134" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.40254538283537206" LOG_CI_START="-0.2712964812979313" LOG_EFFECT_SIZE="0.06562445076872035" METHOD="MH" MODIFIED="2011-01-03 11:08:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10396879448789809" P_Q="1.0" P_Z="0.7026424192172104" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="207" WEIGHT="100.0" Z="0.3817559188826804">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5047796408222336" CI_START="0.0234736495149016" EFFECT_SIZE="0.1879432624113475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.17747290671937346" LOG_CI_START="-1.6294193841565177" LOG_EFFECT_SIZE="-0.7259732387185721" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.0613774759215895" STUDY_ID="STD-Chinh-1997-VNM" TOTAL_1="47" TOTAL_2="53" VAR="1.126522146393684" WEIGHT="49.505588993981085"/>
<DICH_DATA CI_END="12.551513397046413" CI_START="0.5638848054159529" EFFECT_SIZE="2.660377358490566" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0986960939732382" LOG_CI_START="-0.24880960786405654" LOG_EFFECT_SIZE="0.42494324305459086" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.7915315195200276" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" VAR="0.6265221463936839" WEIGHT="18.608483806248213"/>
<DICH_DATA CI_END="6.191431674485791" CI_START="0.5252656194308262" EFFECT_SIZE="1.803370786516854" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7917910846317949" LOG_CI_START="-0.2796210244398388" LOG_EFFECT_SIZE="0.2560850300959781" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.6293527764441526" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="0.39608491721796346" WEIGHT="31.885927199770713"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0143062054531153" CI_END="8.470712654276799" CI_START="0.44337611448646563" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.937965857177206" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="50.355114962521235" I2_Q="100.0" ID="CMP-007.02" LOG_CI_END="0.927919949740402" LOG_CI_START="-0.353227706860088" LOG_EFFECT_SIZE="0.28734612144015703" METHOD="MH" MODIFIED="2011-02-22 12:18:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15582286511587284" P_Q="0.0" P_Z="0.3792966289108206" Q="2.176440919424213E-32" RANDOM="NO" SCALE="164.13303109847587" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="154" WEIGHT="99.99999999999999" Z="0.8791930363661488">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.1029421955171115" CI_START="0.012359877468003412" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8514382803527396" LOG_CI_START="-1.907985834686827" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2011-02-22 12:18:32 +0100" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="1.6208993845439064" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" VAR="2.6273148148148144" WEIGHT="63.62106275547006"/>
<DICH_DATA CI_END="42.253108783964684" CI_START="0.5473295006753945" EFFECT_SIZE="4.808988764044944" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6258586677958193" LOG_CI_START="-0.2617511430593007" LOG_EFFECT_SIZE="0.6820537623682593" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="1.1087913467155563" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="1.229418250551297" WEIGHT="36.37893724452993"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18895148077894094" CI_END="2.9662484753895115" CI_START="0.1418564225470791" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6486766506546106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.47220752800412535" LOG_CI_START="-0.8481509967478397" LOG_EFFECT_SIZE="-0.18797173437185716" METHOD="MH" MODIFIED="2011-02-25 15:46:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6637907347456663" P_Q="1.0" P_Z="0.5768052879238661" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="165" WEIGHT="100.0" Z="0.5580572588033674">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.434974839029426" CI_START="0.015364598291429213" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9260837914554372" LOG_CI_START="-1.8134787899208629" LOG_EFFECT_SIZE="-0.44369749923271273" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-Chinh-1997-VNM" TOTAL_1="24" TOTAL_2="26" VAR="2.5896296296296293" WEIGHT="34.61429782424414"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-25 15:46:32 +0100" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.0" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="34" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.691200484839996" CI_START="0.13693706977708886" EFFECT_SIZE="0.8014981273408239" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6712839935097619" LOG_CI_START="-0.8634789695405307" LOG_EFFECT_SIZE="-0.09609748801538441" MODIFIED="2011-02-22 15:32:29 +0100" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.901527361694935" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="0.8127515838846301" WEIGHT="65.38570217575587"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.445623552308804" CI_START="0.013266250907011331" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.8719010746855007" LOG_CI_START="-1.877251793069602" LOG_EFFECT_SIZE="-0.5026753591920506" METHOD="MH" MODIFIED="2011-01-03 11:09:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.47352929798604837" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="139" WEIGHT="100.0" Z="0.7167485020479547">
<NAME>Convalecsent faecal carriage</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.445623552308804" CI_START="0.013266250907011331" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8719010746855007" LOG_CI_START="-1.877251793069602" LOG_EFFECT_SIZE="-0.5026753591920506" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="1.6148660030455182" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="34" TOTAL_2="32" VAR="2.6077922077922078" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.0" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7941448880133032" CI_END="3.7779054356204327" CI_START="-14.588285269519602" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.405189916949585" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2010-12-31 14:57:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.672285539195547" P_Q="1.0" P_Z="0.24864819382764924" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="1.1536390683186535">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.143625249429006" CI_START="-15.143625249429006" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="446" SD_1="33.0" SD_2="44.0" SE="7.726481388882647" STUDY_ID="STD-Chinh-1997-VNM" TOTAL_1="47" TOTAL_2="53" WEIGHT="36.772104019192355"/>
<CONT_DATA CI_END="17.31293757553681" CI_START="-31.31293757553681" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="100.0" MEAN_2="107.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="445" SD_1="64.0" SD_2="60.0" SE="12.40478792840795" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" WEIGHT="14.266036066155188"/>
<CONT_DATA CI_END="4.123816227251147" CI_START="-22.123816227251147" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="92.0" MEAN_2="101.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="447" SD_1="48.13" SD_2="44.86" SE="6.695947645349677" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" WEIGHT="48.96185991465246"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.44177527637461234" CI_END="0.06440456768929476" CI_START="-0.7281069047174131" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.33185116851405916" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2011-01-03 12:07:42 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.801806901237744" P_Q="1.0" P_Z="0.10071327224274138" Q="0.0" RANDOM="NO" SCALE="4.173376197852419" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="1.6414054841121646">
<NAME>Duration of hospitalization</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3880023088514377" CI_START="-0.7880023088514381" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="7.8" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="448" SD_1="1.4" SD_2="1.6" SE="0.30000669067877017" STUDY_ID="STD-Chinh-1997-VNM" TOTAL_1="47" TOTAL_2="53" WEIGHT="45.4143456942441"/>
<CONT_DATA CI_END="0.5767125251694842" CI_START="-1.7767125251694835" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="12.7" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="450" SD_1="2.3" SD_2="3.5" SE="0.6003745652732612" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" WEIGHT="11.339929951273586"/>
<CONT_DATA CI_END="0.20256510009989548" CI_START="-1.002565100099896" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="8.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="2.17" SD_2="2.11" SE="0.307436822744118" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" WEIGHT="43.24572435448231"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="26.082642996674668" CI_START="0.22166439321025616" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.404494382022472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="1.4163515970565599" LOG_CI_START="-0.6543040636480038" LOG_EFFECT_SIZE="0.38102376670427807" METHOD="MH" MODIFIED="2011-03-02 14:51:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.47071848869514643" Q="0.0" RANDOM="NO" SCALE="249.8052987918976" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="207" WEIGHT="100.0" Z="0.7213105241651548">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>FQ 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>Fq 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-02 14:30:42 +0100" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.0" STUDY_ID="STD-Chinh-1997-VNM" TOTAL_1="47" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-02 14:51:45 +0100" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.0" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="26.082642996674668" CI_START="0.22166439321025616" EFFECT_SIZE="2.404494382022472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4163515970565599" LOG_CI_START="-0.6543040636480038" LOG_EFFECT_SIZE="0.38102376670427807" MODIFIED="2010-12-31 14:37:05 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="1.2163133850086896" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="1.479418250551297" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.611583401049066" CI_START="0.008750992227515653" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="0.5576976483246993" LOG_CI_START="-2.0579427018914997" LOG_EFFECT_SIZE="-0.7501225267834001" METHOD="MH" MODIFIED="2011-08-24 15:54:51 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.26094063040003845" Q="0.0" RANDOM="NO" SCALE="162.8088829728936" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="154" WEIGHT="100.0" Z="1.124170711287677">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>Fluoroquinolone 2D</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluoroquinolone 3D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FQ 2D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FQ 3D</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.611583401049066" CI_START="0.008750992227515653" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5576976483246993" LOG_CI_START="-2.0579427018914997" LOG_EFFECT_SIZE="-0.7501225267834001" MODIFIED="2010-12-31 14:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.5364400893455454" STUDY_ID="STD-Vinh-1996-VNM" TOTAL_1="53" TOTAL_2="47" VAR="2.360648148148148" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-31 14:27:57 +0100" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.0" STUDY_ID="STD-Vinh-2005-VNM" TOTAL_1="89" TOTAL_2="107" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-08-24 15:55:08 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Fluoroquinolone 3 days vs 5 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.654298023107709" CI_START="0.013100845756860689" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31666666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.88390536764435" LOG_CI_START="-1.8827006665059793" LOG_EFFECT_SIZE="-0.4993976494308147" METHOD="MH" MODIFIED="2011-01-03 11:09:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.47920438908104845" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="75" WEIGHT="100.0" Z="0.7075827889958052">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>FQ 3D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 5D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5D</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.654298023107709" CI_START="0.013100845756860689" EFFECT_SIZE="0.31666666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.88390536764435" LOG_CI_START="-1.8827006665059793" LOG_EFFECT_SIZE="-0.4993976494308147" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="1.6251180793806412" STUDY_ID="STD-Tran-1995-VNM" TOTAL_1="79" TOTAL_2="75" VAR="2.6410087719298243" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-5.926953284748731" CI_START="-18.07304671525127" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2010-12-31 15:09:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0760138773649115E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="3.872779004880015">
<NAME>Fever Clearance time</NAME>
<GROUP_LABEL_1>FQ 3D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 5D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5D</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.926953284748731" CI_START="-18.07304671525127" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="72.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="460" SD_1="21.6" SD_2="21.6" SE="3.0985501586532638" STUDY_ID="STD-Tran-1995-VNM" TOTAL_1="103" TOTAL_2="92" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.027282736096788" CI_START="0.7392670351170595" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7254672897196262" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.6050121203986649" LOG_CI_START="-0.13119865912907247" LOG_EFFECT_SIZE="0.23690673063479625" METHOD="MH" MODIFIED="2011-08-24 15:55:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.20716428341552984" Q="0.0" RANDOM="NO" SCALE="26.518462373166376" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="214" TOTAL_2="211" WEIGHT="100.0" Z="1.2614014156032567">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>FQ 3D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 5D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5D</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.027282736096788" CI_START="0.7392670351170595" EFFECT_SIZE="1.7254672897196262" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6050121203986649" LOG_CI_START="-0.13119865912907247" LOG_EFFECT_SIZE="0.23690673063479625" MODIFIED="2011-03-02 15:05:10 +0100" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.4324538561967262" STUDY_ID="STD-Tran-1995-VNM" TOTAL_1="214" TOTAL_2="211" VAR="0.18701633773941875" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-08-24 15:55:20 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Fluoroquinolone 5 days vs 7 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.10446177057408" CI_START="0.139719407692762" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.260869565217391" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="1.8814101188669905" LOG_CI_START="-0.854743264118776" LOG_EFFECT_SIZE="0.5133334273741071" METHOD="MH" MODIFIED="2011-01-03 11:10:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.46208193987479707" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.7354229744356342">
<NAME>Microbiological Failure</NAME>
<GROUP_LABEL_1>FQ 5D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 7D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7D</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.10446177057408" CI_START="0.139719407692762" EFFECT_SIZE="3.260869565217391" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8814101188669905" LOG_CI_START="-0.854743264118776" LOG_EFFECT_SIZE="0.5133334273741071" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.6072300413435225" STUDY_ID="STD-Unal-1996-TUR" TOTAL_1="22" TOTAL_2="24" VAR="2.583188405797101" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.10446177057408" CI_START="0.139719407692762" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.260869565217391" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="1.8814101188669905" LOG_CI_START="-0.854743264118776" LOG_EFFECT_SIZE="0.5133334273741071" METHOD="MH" MODIFIED="2011-01-03 11:10:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.46208193987479707" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.7354229744356342">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>FQ 5D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 7D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7D</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.10446177057408" CI_START="0.139719407692762" EFFECT_SIZE="3.260869565217391" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8814101188669905" LOG_CI_START="-0.854743264118776" LOG_EFFECT_SIZE="0.5133334273741071" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="1.6072300413435225" STUDY_ID="STD-Unal-1996-TUR" TOTAL_1="22" TOTAL_2="24" VAR="2.583188405797101" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-6.621491098795699" CI_START="-7.778508901204278" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.199999999999989" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2011-02-22 12:11:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="24.393299151165653">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>FQ 5D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 7D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7D</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.621491098795699" CI_START="-7.778508901204278" EFFECT_SIZE="-7.199999999999989" ESTIMABLE="YES" MEAN_1="74.4" MEAN_2="81.6" MODIFIED="2011-02-22 12:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="465" SD_1="1.0" SD_2="1.0" SE="0.2951630263451236" STUDY_ID="STD-Unal-1996-TUR" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.254288004956864" CI_START="0.20570443875393235" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.5124559854258586" LOG_CI_START="-0.6867563368636588" LOG_EFFECT_SIZE="-0.08715017571890014" METHOD="MH" MODIFIED="2011-08-24 15:55:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7757419539802312" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.28487233241444904">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>FQ 5D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 7D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7D</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.254288004956864" CI_START="0.20570443875393235" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5124559854258586" LOG_CI_START="-0.6867563368636588" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-02-22 12:11:35 +0100" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.7044232543095956" STUDY_ID="STD-Unal-1996-TUR" TOTAL_1="22" TOTAL_2="24" VAR="0.49621212121212116" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-08-24 15:37:14 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Fluoroquinolone 7 days vs 10 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-03 11:11:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological failure</NAME>
<GROUP_LABEL_1>FQ 7D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 10D or 14D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 7D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10 or 14D</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalo-1997-ALB" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-03 11:11:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>FQ 7D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 10 or 14D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 7</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10 or 14D</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalo-1997-ALB" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-08-24 15:50:46 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Gatifloxacin (OD for 7 days) vs chloramphenicol (QDS for 14 days)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="73" EVENTS_2="117" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-24 15:50:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="234.21" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1111" TOTAL_2="1099" WEIGHT="0.0" Z="0.0">
<NAME>All outcomes</NAME>
<GROUP_LABEL_1>Gatifloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloramphenicol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours gatifloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloramphenicol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:48:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (need for rescue medication or persistence of fever until day 10)</NAME>
<DICH_DATA CI_END="1.956981465989792" CI_START="0.3196854172943701" EFFECT_SIZE="0.7909604519774012" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29158671259899416" LOG_CI_START="-0.4952771739661313" LOG_EFFECT_SIZE="-0.10184523068356859" MODIFIED="2011-01-15 10:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.4622077420074116" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="0.21363599677158998" WEIGHT="0.0">
<FOOTNOTE>This data includes culture positive patients only</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-02-26 09:06:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological failure (blood culture +ve on day 8)</NAME>
<DICH_DATA CI_END="102.24226013297809" CI_START="0.23905338538636325" EFFECT_SIZE="4.943820224719101" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.00963044128803" LOG_CI_START="-0.621505101605481" LOG_EFFECT_SIZE="0.6940626698412746" MODIFIED="2011-01-03 10:26:28 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="1.5455420422266395" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="2.3887002042900916" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-02-26 09:06:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="175" WEIGHT="0.0" Z="0.0">
<NAME>Relapse (reappearance of culture confirmed or syndromic enteric fever on days 11 to 31)</NAME>
<DICH_DATA CI_END="1.8957125321012693" CI_START="0.16837630942926982" EFFECT_SIZE="0.5649717514124294" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2777724811098878" LOG_CI_START="-0.773719013833501" LOG_EFFECT_SIZE="-0.2479732663618066" MODIFIED="2011-01-03 10:26:37 +0100" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.6176513090965912" STUDY_ID="STD-Arjyal-2011" TOTAL_1="177" TOTAL_2="175" VAR="0.3814931396287328" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:50:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="156" WEIGHT="0.0" Z="0.0">
<NAME>Convalescent faecal carriage</NAME>
<DICH_DATA CI_END="8.22446154412034" CI_START="0.013860724287004578" EFFECT_SIZE="0.33763440860215055" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9151074742728142" LOG_CI_START="-1.8582140752342544" LOG_EFFECT_SIZE="-0.4715533004807202" MODIFIED="2011-01-15 10:45:16 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="1.629062806343527" STUDY_ID="STD-Arjyal-2011" TOTAL_1="154" TOTAL_2="156" VAR="2.6538456270118482" WEIGHT="0.0">
<FOOTNOTE>3 patients in the chloramphenicol arm had positive stool cuture during convalescence but only one remained positive at 3 months</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:46:20 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="59" EVENTS_2="99" I2="0.0" ID="CMP-011.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:46:36 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="426" TOTAL_2="418" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events (selected gastrointestinal adverse events)</NAME>
<DICH_DATA CI_END="0.7836545050442689" CI_START="0.43635741955255236" EFFECT_SIZE="0.5847678664580073" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="99" LOG_CI_END="-0.10587536540733299" LOG_CI_START="-0.36015763515884597" LOG_EFFECT_SIZE="-0.23301650028308948" MODIFIED="2011-01-03 20:13:54 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.14936666396957435" STUDY_ID="STD-Arjyal-2011" TOTAL_1="426" TOTAL_2="418" VAR="0.02231040030539974" WEIGHT="0.0">
<FOOTNOTE>Note: The adverse event data from Arjyal 2010 includes all randomized patients including test negative</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-08-24 15:55:40 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Fluoroquinolone 10 days vs 14 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9074989067326817" CI_START="0.009675918759737532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.5918988651813" LOG_CI_START="-2.0143077866873607" LOG_EFFECT_SIZE="-0.7112044607530305" METHOD="MH" MODIFIED="2011-01-03 12:09:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2847524816687219" Q="0.0" RANDOM="NO" SCALE="221.35694826365477" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="34" WEIGHT="100.0" Z="1.0697042214367098">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>FQ 10D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 14D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 10D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 14D</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9074989067326817" CI_START="0.009675918759737532" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5918988651813" LOG_CI_START="-2.0143077866873607" LOG_EFFECT_SIZE="-0.7112044607530305" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="1.5308986882386417" STUDY_ID="STD-Alam-1995-BGD" TOTAL_1="35" TOTAL_2="34" VAR="2.3436507936507938" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.048695691845452" CI_START="-42.64869569184545" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" MODIFIED="2010-12-31 15:09:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2027161413932549" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="34" UNITS="" WEIGHT="99.99999999999999" Z="1.2738513127631654">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>FQ 10D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 14D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 10D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 14D</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.048695691845452" CI_START="-42.64869569184545" EFFECT_SIZE="-16.799999999999997" ESTIMABLE="YES" MEAN_1="100.8" MEAN_2="117.6" MODIFIED="2010-12-15 05:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="472" SD_1="45.6" SD_2="62.4" SE="13.188352385929875" STUDY_ID="STD-Alam-1995-BGD" TOTAL_1="35" TOTAL_2="34" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2702080084818286" CI_START="0.14675126804722244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.43174603174603177" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.10387484657696704" LOG_CI_START="-0.8334181374157331" LOG_EFFECT_SIZE="-0.36477164541938295" METHOD="MH" MODIFIED="2011-08-24 15:55:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.12712429530973937" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="34" WEIGHT="100.0" Z="1.5255406789836248">
<NAME>Non-serious adverse events</NAME>
<GROUP_LABEL_1>FQ 10D</GROUP_LABEL_1>
<GROUP_LABEL_2>FQ 14D</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 10D</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 14D</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2702080084818286" CI_START="0.14675126804722244" EFFECT_SIZE="0.43174603174603177" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.10387484657696704" LOG_CI_START="-0.8334181374157331" LOG_EFFECT_SIZE="-0.36477164541938295" MODIFIED="2010-12-31 15:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.5505705384724106" STUDY_ID="STD-Alam-1995-BGD" TOTAL_1="35" TOTAL_2="34" VAR="0.30312791783380016" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-08-24 15:37:37 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Gatifloxacin (OD for 7 days) vs cefixime (BD for 7 days)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-08 07:58:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="447" TOTAL_2="345" WEIGHT="0.0" Z="0.0">
<NAME>All outcomes</NAME>
<GROUP_LABEL_1>Gatifloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Cefixime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours gatifloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cefixime</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="19" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:48:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (need for rescue medication or persistence of fever until day 7)</NAME>
<DICH_DATA CI_END="0.30511989863116995" CI_START="0.005744510166834601" EFFECT_SIZE="0.041866028708133975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="19" LOG_CI_END="-0.515529468582059" LOG_CI_START="-2.2407469975954224" LOG_EFFECT_SIZE="-1.3781382330887406" MODIFIED="2011-01-15 10:48:09 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="1.013401316506949" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="88" TOTAL_2="70" VAR="1.0269822282980177" WEIGHT="0.0">
<FOOTNOTE>This data includes culture positive patients only</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:15:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Relapse (fever plus +ve blood culture within 1 month of successful treatment)</NAME>
<DICH_DATA CI_END="0.9322387435289309" CI_START="0.04095738206669416" EFFECT_SIZE="0.19540229885057472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.030472851895628265" LOG_CI_START="-1.3876678105850608" LOG_EFFECT_SIZE="-0.7090703312403446" MODIFIED="2011-01-03 10:31:47 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.7972230369575684" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="87" TOTAL_2="51" VAR="0.6355645706558485" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-013.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-03 15:47:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological failure (blood culture +ve on day 10)</NAME>
<DICH_DATA CI_END="6.428926661637823" CI_START="0.010999063343687169" EFFECT_SIZE="0.26591760299625467" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8081384715496895" LOG_CI_START="-1.9586442968406894" LOG_EFFECT_SIZE="-0.5752529126454999" MODIFIED="2011-01-03 10:32:54 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="1.6252218939480951" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="88" TOTAL_2="70" VAR="2.6413462045682334" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-013.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-08 07:58:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<DICH_DATA CI_END="18.10982243741844" CI_START="0.15472183047676963" EFFECT_SIZE="1.673913043478261" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2579141921789172" LOG_CI_START="-0.8104484051971015" LOG_EFFECT_SIZE="0.22373289349090783" MODIFIED="2011-01-15 10:13:33 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="1.2149664282586559" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="92" TOTAL_2="77" VAR="1.4761434217955958" WEIGHT="0.0">
<FOOTNOTE>2 patients developed severe vomiting requiring IV reydration in the gatifloxacin group, 1 patient died in the cefixime group</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-013.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-08 07:58:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events (may be incompletely reported)</NAME>
<DICH_DATA CI_END="139.29730436995885" CI_START="2.660227358139145" EFFECT_SIZE="19.25" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="2.143942712198698" LOG_CI_START="0.4249187554903411" LOG_EFFECT_SIZE="1.2844307338445196" MODIFIED="2011-01-15 10:13:20 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="1.0097631814763108" STUDY_ID="STD-Pandit-2007-NPL" TOTAL_1="92" TOTAL_2="77" VAR="1.019621682665161" WEIGHT="0.0">
<FOOTNOTE>23 patients in the gatifloxacin developed vomiting, 1 patient in the cefixime group developed a rash</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2011-08-24 15:51:08 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Gatifloxacin (OD for 7 days) vs azithromycin (OD for 7 days)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-24 15:51:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="339.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="709" TOTAL_2="679" WEIGHT="0.0" Z="0.0">
<NAME>All outcomes</NAME>
<GROUP_LABEL_1>Gatifloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours gatifloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:47:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="140" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (need for rescue medication of persistence of fever until day 10)</NAME>
<DICH_DATA CI_END="2.922407822420981" CI_START="0.318991598725068" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4657408216832335" LOG_CI_START="-0.4962207547967073" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2011-01-15 10:47:59 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.565060991810918" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="140" VAR="0.31929392446633825" WEIGHT="0.0">
<FOOTNOTE>This data incudes culture positive patients only</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-014.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:25:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Relapse (symptoms and signs of typhoid fever within 1 month of successful treatment)</NAME>
<DICH_DATA CI_END="153.51933900800523" CI_START="0.4539245728151426" EFFECT_SIZE="8.347826086956522" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.186163091835584" LOG_CI_START="-0.34301630646367065" LOG_EFFECT_SIZE="0.9215733926859567" MODIFIED="2011-01-14 00:13:08 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="1.4856524982009178" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="137" TOTAL_2="127" VAR="2.207163345410628" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-014.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:34:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="140" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological failure (blood culture +ve on day 7 to 9)</NAME>
<DICH_DATA CI_END="3.79430842053346" CI_START="0.10919554472762392" EFFECT_SIZE="0.6436781609195402" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5791326296342894" LOG_CI_START="-0.9617950808591256" LOG_EFFECT_SIZE="-0.1913312256124181" MODIFIED="2011-01-14 00:15:32 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.9051485648590171" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="140" VAR="0.8192939244663382" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-014.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 15:51:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="131" WEIGHT="0.0" Z="0.0">
<NAME>Convalescent faecal carriage</NAME>
<DICH_DATA CI_END="69.81584193800026" CI_START="0.11794464276710341" EFFECT_SIZE="2.869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8439539797237048" LOG_CI_START="-0.9283217806751536" LOG_EFFECT_SIZE="0.45781609952427577" MODIFIED="2011-01-15 10:28:22 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.6284485046446249" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="137" TOTAL_2="131" VAR="2.6518445322793145" WEIGHT="0.0">
<FOOTNOTE>Only 1 patient was shown to be a persistent carrier during follow-up</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-03 10:23:44 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-014.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-15 10:47:18 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="145" TOTAL_2="141" WEIGHT="0.0" Z="0.0">
<NAME>Other adverse events (may be incompletely reported)</NAME>
<DICH_DATA CI_END="21.20866494957016" CI_START="0.17834004870485737" EFFECT_SIZE="1.9448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3265133312566257" LOG_CI_START="-0.7487511190878534" LOG_EFFECT_SIZE="0.28888110608438616" MODIFIED="2011-01-15 10:31:12 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.2190206108570527" STUDY_ID="STD-Dolecek-2008-VNM" TOTAL_1="145" TOTAL_2="141" VAR="1.4860112496943019" WEIGHT="0.0">
<FOOTNOTE>One patient developed vomiting on day 3 and 1 diarrhoea on day 4 in gatifloxacin group, one patient developed a rash in azithromycin group</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-08-24 15:59:23 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-08-24 15:59:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-08-24 15:59:23 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-02-24 00:04:17 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2011-09-02 10:20:23 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-08-24 16:00:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-08-05 11:28:43 +0100" MODIFIED_BY="[Empty name]">Detailed Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-24 16:00:17 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="69">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fluoroquinolone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>QUINOLINES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>QUINOLONE DERIVED ANTIINFECTIVE AGENT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enteric fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>amifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>QUINOLONES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fluoroquinolones</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid fever</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>paratyphoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>balofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ANTI-INFECTIVE AGENTS, QUINOLONE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>amifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enteric fever</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella typhi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>cetefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BALOFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella typhi</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLUOROQUINOLONES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>balofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella paratyphi</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>clinafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fluoroquinolones</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CETEFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enoxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>amifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>cetefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>balofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CIPROFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gatifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>cetefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gemifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CIPROFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CLINAFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>grepafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>clinafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>irloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>clinafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ENOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>levofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ENOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enoxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lomefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enoxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLEROXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>moxifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FLEROXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>nordifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>fleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GATIFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gatifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gatifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gemifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GEMIFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>grepafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gemifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>oxociprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>irloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GREPAFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>pefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>levofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>grepafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>premafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lomefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IRLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prulifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>moxifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>irloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>rufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>nordifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LEVOFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sitafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>levofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sparfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NORFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LOMEFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>temafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lomefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tosufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MOXIFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>trovafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>oxociprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>moxifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/29 - OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PEFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NORDIFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>pefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>nordifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enteric fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>premafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NORFLEROXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>paratyphoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prulifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfleroxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella typhi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>rufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NORFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sitafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>norfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31/35 - OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sparfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 and 36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>temafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tosufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OXOCIPROFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>trovafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>oxociprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 - 39/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PEFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TYPHOID FEVER</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>pefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PREMAFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enteric fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>premafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PARATYPHOID FEVER</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRULIFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>paratyphoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prulifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SALMONELLA TYPHI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RUFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella typhi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>rufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SALMONELLA PARATYPHI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SITAFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sitafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhus</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SPARFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41 - 50/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>sparfloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 and 51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TEMAFLOXACIN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>limit 52 to human</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>temafloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tosufloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 - 54/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TYPHOID FEVER</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>57</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>enteric fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PARATYPHOID FEVER</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>paratyphoid fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SALMONELLA TYPHI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella typhi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SALMONELLA PARATYPHI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Salmonella paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>typhus</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56 - 65/OR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 and 66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>limit 67 to human</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-09-02 10:20:23 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-09-02 10:20:23 +0100" MODIFIED_BY="[Empty name]">Description of drug resistance by study</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="9" ROWS="26">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparison</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Culture positive (site)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<I>S</I>. Typhi/Paratyphi</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Number (%)<SUP>a</SUP> with MDR</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MDR defined as<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Number (%*)<SUP>a</SUP> NaR<SUP>c</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Notes on resistance</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="7" VALIGN="TOP">
<P>Fluoroquinolone vs chloramphenicol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60/0</P>
<P>Fluoroquinolone: 30</P>
<P>Chloramphenicol: 30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>No resistance to chloramphenicol, ampicillin, or co-trimoxazole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>MIC range of pefloxacin was &lt; 0.016 to 0.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>55 (blood and/or bone marrow)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50/5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>No resistance to chloramphenicol</P>
<P>12.8% resistant to ampicillin or co-trimoxazole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>MIC range of ciprofloxacin was &lt; 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>
</P>
</TD>
<TD>
<P>853 enrolled and randomized</P>
</TD>
<TD>
<P>352 (blood)</P>
</TD>
<TD>
<P>124/53 Fluoroquinolone</P>
<P>125/50</P>
<P>Chloramphenicol</P>
<P/>
</TD>
<TD>
<P>2(0.58%) both in the gatifloxacin arm</P>
</TD>
<TD>
<P>Resistance to all first line antibiotics: chloramphenicol, amoxicillin and trimethoprim-sulphamethoxazole</P>
</TD>
<TD>
<P>251(72.2%)</P>
<P/>
</TD>
<TD>
<P>Two <I>S</I>. Paratyphi isolates were chloramphenicol resistant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>98 (not stated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>156/0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>MIC range for chloramphenicol was 0.5 to 4 mg/L</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>MIC ranges were: ofloxacin 0.03 to 0.25; pefloxacin 0.06 to 0.5; ciprofloxacin 0.016 to 0.063; enoxacin 0.25; norfloxacin 0.063 to 0.25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50/0</P>
<P>Fluoroquinolone: 27</P>
<P>Chloramphenicol: 23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/50 (6%)</P>
<P>Fluoroquinolone: 1/27</P>
<P>Chloramphenicol: 2/23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chloramphenicol resistance: 4/50</P>
<P>Fluoroquinolone: 1/27</P>
<P>Chloramphenicol: 3/23<SUP>d</SUP>
</P>
<P>Ampicillin: 2/50</P>
<P>Fluoroquinolone: 1/27</P>
<P>Chloramphenicol: 1/23</P>
<P>Co-trimoxazole: 1/50</P>
<P>Fluoroquinolone: 0/27</P>
<P>Chloramphenicol: 1/23</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85 (not stated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluoroquinolone vs ampicillin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (not stated)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40/0</P>
<P>Fluoroquinolone: 20</P>
<P>Ampicillin: 20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs co-trimoxazole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>77 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42 (blood and/or stool)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28/4 (from blood culture)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>1 isolate resistant to co-trimoxazole was in pefloxacin group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>53 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28/12</P>
<P>Fluoroquinolone: 15/5</P>
<P>Co-trimoxazole: 13/7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>No resistance to co-trimoxazole</P>
<P>16 were resistant to chloramphenicol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Fluoroquinolone vs azithromycin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>358 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>288 (blood or bone marrow)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>282/5</P>
<P>Fluoroquinolone: 144/1</P>
<P>Azithromycin: 138/4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>153 (58%) of 263 <I>S</I>. Typhi</P>
<P>Fluoroquinolone: 87/137</P>
<P>Azithromycin: 66/126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>253 (96%) of 263 <I>S</I>. Typhi</P>
<P>Fluoroquinolone: 132/137</P>
<P>Azithromycin: 121/126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All 5 <I>S</I>. Paratyphi were susceptible</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>91 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>86/2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68 (78%) of 87</P>
<P>Fluoroquinolone: 35</P>
<P>Azithromycin: 33</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 (52.3%; of 87 strains evaluated)</P>
<P>Fluoroquinolone: 21</P>
<P>Azithromycin: 25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>123 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>64 (62 by blood, 2 by stool)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60/4</P>
<P>Fluoroquinolone: 34/2</P>
<P>Azithromycin: 26/2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21/64 (33%)</P>
<P>Fluoroquinolone: 15</P>
<P>Azithromycin: 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>160 enrolled and randomized (excluding fluoroquinolone with azithromycin combination arm)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130 (blood and/or bone marrow)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>125/0</P>
<P>Fluoroquinolone: 63/0</P>
<P>Azithromycin: 62/0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>110/125 (88%)</P>
<P>Fluoroquinolone: 57/63</P>
<P>Azithromycin: 53/62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>117/125 (94%)</P>
<P>Fluoroquinolone: 62/63</P>
<P>Azithromycin: 55/62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs cefixime</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>138 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>82 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>82/0</P>
<P>Fluoroquinolone: 38</P>
<P>Cefixime: 44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70 (85%)</P>
<P>
<I>S</I>. Typhi: 32</P>
<P>
<I>S</I>. Paratyphi: 38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole) and tetracycline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>390 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>169 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>119/50</P>
<P>Fluoroquinolone: 65/27</P>
<P>Cefixime: 54/23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>136/163 (83%)</P>
<P>Fluoroquinolone: 71/89</P>
<P>Cefixime: 65/74</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs ceftriaxone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47 (44 by blood and/or bone marrow, 3 by stool)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41/6</P>
<P>Fluoroquinolone: 21/1</P>
<P>Ceftriaxone: 20/5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26 (55%)</P>
<P>Fluoroquinolone: 14</P>
<P>Ceftriaxone: 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole) and tetracycline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43 enrolled and 42 randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42/0</P>
<P>Fluoroquinolone: 20</P>
<P>Ceftriaxone: 22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 (52%)</P>
<P>Fluoroquinolone: 11</P>
<P>Ceftriaxone: 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>Different durations of fluoroquinolone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>76 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72 (blood or bone marrow)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61/8</P>
<P>Fluoroquinolone 10-day: 30/5</P>
<P>Fluoroquinolone 14-day: 31/3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36/69 (52%)</P>
<P>Fluoroquinolone 10-day: 18</P>
<P>Fluoroquinolone 14-day: 18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistance to all drugs used conventionally against <I>S</I>. Typhi and <I>S</I>. Paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/69 (7%)</P>
<P>Fluoroquinolone 10-day: 2</P>
<P>Fluoroquinolone 14-day: 3</P>
<P>(derived from data presented for MIC for ciprofloxacin)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kalo-1997-ALB" TYPE="STUDY">Kalo 1997 ALB</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (ampicillin-resistant) enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30/0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/30 (40%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>95/5</P>
<P>Fluoroquinolone 2-day: 43/4</P>
<P>Fluoroquinolone 3-day: 52/1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75/95 (79%)</P>
<P>Fluoroquinolone 2-day: 35</P>
<P>Fluoroquinolone 3-day: 40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole) and tetracycline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/95 (5%)</P>
<P>Fluoroquinolone 2-day: 1</P>
<P>Fluoroquinolone 3-day: 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>438 enrolled, 425 randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>228 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>207/19<BR/>(2 other Salmonella)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>189</P>
<P>Fluoroquinolone 3-day: 98</P>
<P>Fluoroquinolone 5-day: 91</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to standard antibiotics</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Few NaR strains present, number not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 (blood and/or bone marrow)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19/27</P>
<P>Fluoroquinolone 5-day: 8/14</P>
<P>Fluoroquinolone 7-day: 11/13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/46 (13%)</P>
<P>Fluoroquinolone 5-day: 3</P>
<P>Fluoroquinolone 7-day: 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
<P>MIC for pefloxacin was 0.06 to 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>108 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100/0</P>
<P>Fluoroquinolone 2-day: 53</P>
<P>Fluoroquinolone 3-day: 47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>84</P>
<P>Fluoroquinolone 2-day: 46</P>
<P>Fluoroquinolone 3-day: 38</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole) and tetracycline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13 (13%)</P>
<P>Fluoroquinolone 2-day: 6</P>
<P>Fluoroquinolone 3-day: 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>235 enrolled and randomized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>202 (blood)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>196/0</P>
<P>Fluoroquinolone 2-day: 89</P>
<P>Fluoroquinolone 3-day: 107</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>176/196 (90%)</P>
<P>Fluoroquinolone 2-day: 82/89</P>
<P>Fluoroquinolone 3-day: 94/107</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Resistant to all 3 (chloramphenicol, ampicillin, co-trimoxazole)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4/161 (2.5%)</P>
<P>Fluoroquinolone 2-day: 1/72</P>
<P>Fluoroquinolone 3-day: 3/89</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>MDR: multiple-drug-resistant strain; MIC: minimum inhibitory concentration; NaR: nalidixic acid resistant strain.<BR/>
<SUP>a</SUP>Calculation: number with MDR or NaR divided by number culture positive.<BR/>
<SUP>b</SUP>As stated or implied in text of report.<BR/>
<SUP>c</SUP>Or MIC of fluoroquinolone if available (all ranges in mg/L).<BR/>
<SUP>d</SUP>These participants were switched to fluoroquinolone when organisms were found resistant to assigned drug.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-08-05 11:32:38 +0100" MODIFIED_BY="[Empty name]">Definitions of outcomes</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="8" ROWS="27">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparison</P>
</TH>
<TH>
<P>
<B>Specific FQ</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Clinical failure</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Microbiological failure</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Relapse</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Fever clearance time</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Convalescent Faecal Carriage</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>Fluoroquinolones vs chloramphenicol</P>
</TD>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not afebrile within 7 days of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood culture positive at days 3 and 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reappearance of fever after defervescence during hospitalization (under 14 days)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Defined as first day that temperature fell &lt; 37.5 °C and remained below that level for &#8805; 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"One participant who developed a gastrointestinal bleed in first 36 hours of treatment was considered a failure"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistence of fever</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 weeks during follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin and Ofloxacin and</P>
<P>Cotrimoxazole</P>
</TD>
<TD>
<P>
<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>
</P>
</TD>
<TD>
<P>No significant response to therapy</P>
</TD>
<TD>
<P>Persistence of <I>S.</I> Typhi and <I>S.</I> Paratyphi on day 7 or 14 or recurrence of the initial pathogen at the end of treatment</P>
</TD>
<TD>
<P>Reapperance of signs and symptoms after initial disappearance for at least 48 hours or reappearance of pathogen in blood and/or stool within three weeks after end of treatment.</P>
</TD>
<TD>
<P>Reported but not defined</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Ofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuation of symptoms and tympanic temperature &gt; 38 °C for &gt; 10 days after start of treatment or continuation of symptoms and high tympanic temperature &gt; 39 °C at 7 days after start of treatment or development of signs of severe disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time from onset of treatment to first recording of a tympanic temperature &lt; 38 °C (~ 37.5 °C axillary) which remained &lt; 38 °C for 48 hours ('Fever Clearance Time 38')</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Pefloxacin</P>
</TD>
<TD>
<P>
<LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>
</P>
</TD>
<TD>
<P>Not defined</P>
</TD>
<TD>
<P>Blood culture positive at end of treatment (at 15 days)</P>
</TD>
<TD>
<P>Within 30 days after end of treatment (the 2 relapses were blood culture negative and were stool culture positive before relapse)</P>
</TD>
<TD>
<P>Not defined</P>
</TD>
<TD>
<P>30 days</P>
</TD>
</TR>
<TR>
<TD>
<P>Gatifloxacin</P>
</TD>
<TD>
<P>
<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>
</P>
</TD>
<TD>
<P>Not specifically defined but denoted as part of composite end point of treatment failure</P>
</TD>
<TD>
<P>Positive blood culture for S.Typhi or S.Paratyphi A on day 8</P>
</TD>
<TD>
<P>Reappearance of culture confirmed or syndromic enteric fever on or after day 11 to day 31 in patients who were initially categorized as successfully treated</P>
</TD>
<TD>
<P>Time from the first dose of treatment given until temperature was fro the first time &#8804;37.5<SUP>o</SUP>C and the patient remained afebrile for at least 48 hours</P>
</TD>
<TD>
<P>Faecal carriage at the follow up visits at 1, 3 and 6 months.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs ampicillin</P>
</TD>
<TD ROWSPAN="2">
<P>Ofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistence of signs and symptoms of infection 5-7 days after the end of treatment.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistence of <I>S.</I> Typhi from blood culture 5-7 days after the end of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD>
<P>Persistence or reappearance of all presenting signs and symptoms or increase in severity of at least 1 sign or symptom or both</P>
</TD>
<TD>
<P>Persistence of baseline pathogen at day 14</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs co-trimoxazole</P>
</TD>
<TD>
<P>Pefloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fever and presence of clinical symptoms and positive cultures</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Positive cultures at days 4, 15, and 30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reappearance of fever, clinical symptoms, and/or bacteraemia at days 4, 15, and 30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time for rectal temperature to be sustained &#8804; 37.5 °C for &#8805; 2 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 days</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistent fever or no improvement in symptoms after 5 days of therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Positive cultures during and after therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Fluoroquinolone vs azithromycin</P>
</TD>
<TD>
<P>Gatifloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistence of fever and symptoms 2 days after the end of treatment, i.e. on day 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Positive blood culture on day 7 to 9 after the start of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Symptoms and signs suggestive of<BR/>typhoid fever within 1 month after completion of treatment (only culture positive data extracted)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time from start of antibiotic treatment to when the axillary temperature first fell &#8804; 37. 5 °C and remained there for at least 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Follow ups at 1, 3, and 6 months; participants who attended at least 2 consecutive follow-up visits were evaluated</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistence of fever and symptoms for &gt; 5 days after the end of treatment or development of severe complications (severe gastrointestinal bleed, intestinal perforation, visible jaundice, myocarditis, renal failure, shock, coma) during treatment requiring change in treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isolation of <I>S</I>. Typhi/<I>S</I>. Paratyphi from blood or other sterile site after completion of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of signs and symptoms suggestive of enteric fever after discharge at 4 to 6 weeks of follow up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time from start of treatment until body temperature fell &lt; 37.5 °C and remained at &#8804; 37.5 °C for 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Days 2 to 3 after end of treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lack of resolution of symptoms by day 7 or development of major complications of typhoid fever after 5 days of therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood culture positive for <I>S</I>. Typhi/<I>S</I>. Paratyphi on day 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of fever with signs/symptoms of typhoid fever in 4 weeks of therapy completion and culture positive</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>First day on which maximum temperature &#8804; 38 °C and at this level for &#8805; 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Presence of fever and at least 1 other typhoid related symptom for &gt; 7 days after start of treatment or development of severe complications (severe gastrointestinal bleeding, perforation, visible jaundice, myocarditis, pneumonia, renal failure, shock, or altered consciousness level, during treatment requiring change in therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Isolation of <I>S</I>. Typhi or <I>S</I>. Paratyphi from blood or sterile site after completion of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of symptoms or signs suggestive of enteric fever within 4-week period after patient had been discharged well from hospital accompanied by positive blood culture for <I>S</I>. Typhi or <I>S</I>. Paratyphi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time from start of treatment until body temperature reached &#8804; 37.5 °C and remained at this for 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>After end of initial 7-day treatment and before hospital discharge (with isolate having the same susceptibility pattern as original isolate)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs cefixime</P>
</TD>
<TD>
<P>Ofloxacin</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Deterioration in clinical condition or failure of resolution of symptoms requiring further treatment</P>
</TD>
<TD VALIGN="TOP">
<P>Blood culture positive for <I>S</I>. Typhi after completion of treatment</P>
</TD>
<TD VALIGN="TOP">
<P>Symptoms suggestive of typhoid fever with a positive blood or bone marrow culture up to 4 weeks after discharge</P>
</TD>
<TD VALIGN="TOP">
<P>Time from onset of treatment until fever was 37.5 °C or below for at least 24 hours</P>
</TD>
<TD VALIGN="TOP">
<P>1 month mostly, few seen after a longer period</P>
</TD>
</TR>
<TR>
<TD>
<P>Gatifloxacin</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any severe complication, persistence of fever (&gt; 38 °C), persistence of symptoms for &gt; 7 days after start of treatment, requiring additional or rescue treatment</P>
</TD>
<TD VALIGN="TOP">
<P>Blood culture positive on day 10</P>
</TD>
<TD VALIGN="TOP">
<P>Fever with blood culture positive within a month of completing treatment (patients given rescue treatment or prolonged treatment were excluded)</P>
</TD>
<TD VALIGN="TOP">
<P>Time to 1st drop in oral temperature &#8804; 37.5 °C remaining &#8804; 37.5 °C for 48 hours</P>
</TD>
<TD VALIGN="TOP">
<P>1 month</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Fluoroquinolone vs ceftriaxone</P>
</TD>
<TD>
<P>Ofloxacin</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acute treatment failure as continuing symptoms and fever for at least 7 days after starting the treatment regimen</P>
</TD>
<TD VALIGN="TOP">
<P>Blood culture positive at day 8</P>
</TD>
<TD VALIGN="TOP">
<P>Recurrence of fever and symptoms in the period up to 6 weeks after discharge with a positive blood or bone marrow culture <SUP>b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to defervescence to &lt; 37.5 °C for at least 48 hours</P>
</TD>
<TD VALIGN="TOP">
<P>4 to 6 weeks</P>
</TD>
</TR>
<TR>
<TD>
<P>Ciprofloxacin</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Fever &gt; 38 °C after 7 days of therapy or who deteriorated clinically after 5 full days</P>
</TD>
<TD VALIGN="TOP">
<P>Blood culture positive at day 3</P>
</TD>
<TD VALIGN="TOP">
<P>Readmission for typhoid within 2 months of discharge with stool or blood culture positive for <I>S</I>. Typhi of the same antibiogram (1 relapse had both stool and blood culture positive)</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Days 1, 7, and 28; results unclear</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>Different durations of fluoroquinolones</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lack of improvement or deterioration in clinical condition during treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Growth of <I>S</I>. Typhi or <I>S</I>. Paratyphi in blood in first follow up (day 3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of febrile illness with growth of <I>S</I>. Typhi or <I>S</I>. Paratyphi in blood culture after initial cure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time to return of oral temperature to &#8804; 37.5 °C after initiation of therapy and remained so for at least 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Second follow up (at 2 months)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kalo-1997-ALB" TYPE="STUDY">Kalo 1997 ALB</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fever at day 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood culture positive at day 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Relapse during hospitalization and 2 month follow up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Outcome not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Days 7 to 12</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continuing fever and symptoms for 7 days after the start of treatment or deterioration in clinical condition before 7 days that warranted further treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood or bone marrow culture positive after end of treatment before discharge</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrent fever and symptoms with bone marrow or blood culture positive mostly up to 6 weeks after discharge <SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time at which fever fell below 37.5 °C for at least 24 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usually 6 weeks (occasionally up to 12 weeks)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Persistent fever and symptoms for &gt; 7 days after start of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood or bone marrow culture positive after end of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Symptoms since study with positive blood culture</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continued or worsening symptoms after 7 days of therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Failure to eradicate organism</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Similar signs and symptoms after apparently being cured for a month (the participant had a positive stool culture)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time for temperature to be below 37.5 °C for at least 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month; results unclear</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Continued fever and symptoms for &gt; 7 days after treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Positive blood culture or bone marrow culture for <I>S</I>. Typhi taken &gt; 48 hours after the last dose of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of fever and symptoms with positive blood or bone marrow culture up to 6 weeks (26 participants followed up to 12 weeks) after discharge</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Time from start of treatment until axillary temperature fell below 37.5 °C and remained below this level for &gt; 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 to 6 weeks (for 66 participants); and at 3 months (for 26 participants)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fever and symptoms persisting for &#8805; 7 days after start of therapy, or development of severe or complicated disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blood culture positive for same organism between 7 to 28 days after completion of therapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Recurrence of typhoid fever symptoms usually with positive blood culture after hospital discharge until 28 days post discharge (only data for blood culture-confirmed relapse extracted)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Period from start of treatment until temperature remained at or below 37.5 °C for at least 48 hours</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Immediately after treatment</P>
</TD>
</TR>
</TABLE>
<P>
<I>S</I>. Typhi/<I>S</I>. Paratyphi: <I>Salmonella enterica </I>serovar Typhi/Paratyphi.<BR/>
<SUP>a</SUP>All definitions as stated or implied by trial authors.<BR/>
<SUP>b</SUP>With an organism with the same sensitivity pattern, ribotype, and plasmid profile as the original isolate.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-08-05 11:36:03 +0100" MODIFIED_BY="[Empty name]">Serious adverse events</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-26 17:21:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="21">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparison</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="8" VALIGN="TOP">
<P>Fluoroquinolone vs chloramphenicol</P>
</TD>
<TD>
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>
</P>
</TD>
<TD>
<P>Gastrointestinal bleeding(1)</P>
</TD>
<TD>
<P>Severe leukopenia(1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>
</P>
</TD>
<TD>
<P>Skin rash (1)</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxacin: Rash (2)</P>
<P>Pefloxacin: Rash (2)</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxacin: None</P>
</TD>
<TD>
<P>Chloramphenicol: Intestinal bleeding (1 participant)</P>
<P>Rash (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>
</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxacin: palpitation (1) ????</P>
<P>Ofloxacin: palpitation (2)</P>
</TD>
<TD>
<P>palpitation (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>
</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>Oral candidiasis (4)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs co-trimoxazole</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>
</P>
</TD>
<TD>
<P>Pefloxacin: Phototoxicity (1)</P>
</TD>
<TD>
<P>Rash (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>
</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs ampicillin/amoxicillin</P>
</TD>
<TD>
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>
</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs cefixime</P>
</TD>
<TD>
<P>
<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>
</P>
</TD>
<TD>
<P>Ofloxacin: Death (1)</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>
</P>
</TD>
<TD>
<P>Excessive vomiting requiring</P>
<P>intravenous therapy(1)</P>
</TD>
<TD>
<P>Death(1)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs ceftriaxone</P>
</TD>
<TD>
<P>
<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>
</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Fluoroquinolone vs azithromycin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gastrointestinal bleeding (1 participant)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gastrointestinal bleeding (1 participant)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>
</P>
</TD>
<TD>
<P>Gastrointestinal bleeding (4 participants)</P>
<P>Rash (1)</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-09-01 11:52:47 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-08-05 11:36:38 +0100" MODIFIED_BY="[Empty name]">Non-serious adverse events</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-01 11:52:47 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="29">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Comparison</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Clinical adverse events <SUP>a</SUP>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Laboratory adverse events <SUP>a</SUP>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="8" VALIGN="TOP">
<P>Fluoroquinolone vs chloramphenicol</P>
</TD>
<TD>
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD>
<P>3 reported adverse events. No specific event</P>
</TD>
<TD>
<P>4 reported adverse events. No specific event</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gottuzzo-1992-N_x002f_A" TYPE="STUDY">Gottuzzo 1992 N/A</LINK>
</P>
</TD>
<TD>
<P>Rash (1)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>leukopenia (11)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cristiano-1995-ITA" TYPE="STUDY">Cristiano 1995 ITA</LINK>
</P>
</TD>
<TD>
<P>Nausea (3), mild and transient epigastric pain (3), transient skin rash (1)</P>
</TD>
<TD>
<P>Mild and transient epigastric pain (5)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morelli-1992-ITA" TYPE="STUDY">Morelli 1992 ITA</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxacin: Skin rash (2), dizziness (4), flushing (4), epigastric pain (8)</P>
<P>Ofloxacin: Mild epigastric pain (4), flushing (4), headache (2)</P>
<P>Pefloxacin: Skin Rash (2), headache (6), epigastric pain (10)</P>
</TD>
<TD>
<P>Diarrhoea (3), Mild epigastric pain (6),</P>
<P>abdominal pain (4)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gasem-2003-IDN" TYPE="STUDY">Gasem 2003 IDN</LINK>
</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>skin rash (1)</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Phongmany-2005-LAO" TYPE="STUDY">Phongmany 2005 LAO</LINK>
</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rizvi-2007-PAK" TYPE="STUDY">Rizvi 2007 PAK</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxcin: Nausea/vomiting (10), diarrhoea (1), heartburn (2), headache/dizziness (3), anorexia (1), palpitation (1).</P>
<P>Ofloxacin: Nausea/vomiting (6), abdominal pain (1), heartburn (4), headache (2), palpitation (2)</P>
</TD>
<TD>
<P>Chloramphenicol: Nausea/vomiting(4), abdominal pain (1), cough (1), palpitation(1), anaemia(2)</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Arjyal-2011" TYPE="STUDY">Arjyal 2011</LINK>
</P>
</TD>
<TD>
<P/>
<P>Number of patients with events (59/426)</P>
<P>Abdominal pain (8), acne (0),<BR/>anorexia (1), diarrhoea (5),<BR/>dizziness (2), nausea (9), oral candidiasis (0), vomiting (35),<BR/>weakness (0)</P>
</TD>
<TD>
<P>Number of patients with events(99/418)</P>
<P>Abdominal pain (11), acne (2), anorexia (9), diarrhoea (24), dizziness (11), nausea (26), oral candidiasis (4), vomiting (36),<BR/>weakness (4)</P>
<P/>
<P/>
</TD>
<TD>
<P>Dysglycaemia<SUP>b</SUP>
</P>
<P>Hyperglycaemia: 1/400</P>
<P>Hypoglycaemia: 2/400</P>
<P>Leucopenia<SUP>c</SUP>
</P>
<P>Grade 1:1/188</P>
<P>Grade 2: 1/188</P>
</TD>
<TD>
<P>Dysglycaemia<SUP>b</SUP>
</P>
<P>Hyperglycaemia: 0/402</P>
<P>Hypoglycaemia: 2/402</P>
<P>Leucopenia<SUP>c</SUP>
</P>
<P>Grade 1:4/403</P>
<P>Grade 2: 3/403</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs cotrimoxazole</P>
</TD>
<TD>
<P>
<LINK REF="STD-Hajji-1988-MAR" TYPE="STUDY">Hajji 1988 MAR</LINK>
</P>
</TD>
<TD>
<P>Photosensitivity (1)</P>
</TD>
<TD>
<P>Generalized rash (1)</P>
</TD>
<TD>
<P>Mild and transient rise in transaminases (2)</P>
</TD>
<TD>
<P>Mild and transient rise in transaminases (3)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Limson-1989-PHL" TYPE="STUDY">Limson 1989 PHL</LINK>
</P>
</TD>
<TD>
<P>Ciprofloxacin</P>
<P>Abdominal discomfort/diarrhoea (1)</P>
<P>Dizziness (1)</P>
</TD>
<TD>
<P>Cotrimoxazole: nausea or abdominal discomfort (5)</P>
<P>Pruritus (1)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs ampicillin/amoxicillin</P>
</TD>
<TD>
<P>
<LINK REF="STD-Yousaf-1992--PAK" TYPE="STUDY">Yousaf 1992 PAK</LINK>
</P>
</TD>
<TD>
<P>3 reported adverse events. No specific event</P>
</TD>
<TD>
<P>11 events reported to be mostly diarrhoea, pruritus and rashes</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Flores-1994-MEX" TYPE="STUDY">Flores 1994 MEX</LINK>
</P>
</TD>
<TD>
<P>Moderate nausea (1)</P>
</TD>
<TD>
<P>Epigastric pain (1)</P>
</TD>
<TD>
<P>None reported</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs cefixime</P>
</TD>
<TD>
<P>
<LINK REF="STD-Phuong-1999-VNM" TYPE="STUDY">Phuong 1999 VNM</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pandit-2007-NPL" TYPE="STUDY">Pandit 2007 NPL</LINK>
</P>
</TD>
<TD>
<P>Nausea/occasional vomiting (23)</P>
</TD>
<TD>
<P>Erythematous skin rash(1)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fluoroquinolone vs ceftriaxone</P>
</TD>
<TD>
<P>
<LINK REF="STD-Wallace-1993-BHR" TYPE="STUDY">Wallace 1993 BHR</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Smith-1994-VNM" TYPE="STUDY">Smith 1994 VNM</LINK>
</P>
</TD>
<TD>
<P>Pruritus (1)</P>
</TD>
<TD>
<P>skin rashes (2)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Fluoroquinolone vs azithromycin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-2000-VNM" TYPE="STUDY">Chinh 2000 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ofloxacin: nausea (1); vomiting (3); abdominal pain (4); skin rash (0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: nausea (5); vomiting (5); abdominal pain (4); skin rash (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ofloxacin: mild elevation in mean transaminase levels</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: mild elevation in mean transaminase levels</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dolecek-2008-VNM" TYPE="STUDY">Dolecek 2008 VNM</LINK>
</P>
</TD>
<TD>
<P>Gatifloxacin: vomiting (1); Diarrhoea (1)</P>
</TD>
<TD>
<P>Azithromycin: jaundice (2)</P>
</TD>
<TD>
<P>Gatifloxacin: mild elevations in median transaminase levels</P>
</TD>
<TD>
<P>Azithromycin: mild elevations in median transaminase levels</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Girgis-1999-EGY" TYPE="STUDY">Girgis 1999 EGY</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ciprofloxacin: nausea or vomiting (4); lightheadedness (2); dry throat or mouth (4); loose stools (3); constipation (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: nausea or vomiting (6); lightheadedness (2); dry throat or mouth (3); loose stools (3); constipation (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ciprofloxacin: thrombocytosis (1); mild increases in aspartate transaminases levels (3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: thrombocytosis (4); mild increase in aspartate amino transaminase levels (2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parry-2007-VNM" TYPE="STUDY">Parry 2007 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ofloxacin: joint discomfort</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: joint discomfort (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Ofloxacin: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Azithromycin: none</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Fluoroquinolones 2days vs 3days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chinh-1997-VNM" TYPE="STUDY">Chinh 1997 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2D: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3D: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2D: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3D: none</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vinh-1996-VNM" TYPE="STUDY">Vinh 1996 VNM</LINK>
</P>
</TD>
<TD>
<P>2D: none</P>
</TD>
<TD>
<P>3D: none</P>
</TD>
<TD>
<P>2D: none</P>
</TD>
<TD>
<P>3D: none</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vinh-2005-VNM" TYPE="STUDY">Vinh 2005 VNM</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2D: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3D: none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2D: no significant increases in liver enzymes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3D: no significant increases in liver enzymes</P>
</TD>
</TR>
<TR>
<TD>
<P>Fluoroquinolone 3days vs 5days</P>
</TD>
<TD>
<P>
<LINK REF="STD-Tran-1995-VNM" TYPE="STUDY">Tran 1995 VNM</LINK>
</P>
</TD>
<TD>
<P>3D: Insomnia (5), dizziness (5) epigastric pain (2), nausea (1), headache (1)</P>
</TD>
<TD>
<P>5D: Insomnia (5), dizziness (1) vomiting (1), rash (1)</P>
</TD>
<TD>
<P>3D: none</P>
</TD>
<TD>
<P>5D: none</P>
</TD>
</TR>
<TR>
<TD>
<P>Fluoroquinolone 5days vs 7days</P>
</TD>
<TD>
<P>
<LINK REF="STD-Unal-1996-TUR" TYPE="STUDY">Unal 1996 TUR</LINK>
</P>
</TD>
<TD>
<P>5D: Nausea and vomiting (3)</P>
</TD>
<TD>
<P>7D: Nausea and vomiting (3)</P>
</TD>
<TD>
<P>5D: None</P>
</TD>
<TD>
<P>7D: Increased transaminase levels (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Fluoroquinolone 7days vs 10days</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kalo-1997-ALB" TYPE="STUDY">Kalo 1997 ALB</LINK>
</P>
</TD>
<TD>
<P>7D Nausea/abdominal discomfort</P>
</TD>
<TD>
<P>10D: Nausea/ abdominal discomfort<SUP>d</SUP>
</P>
</TD>
<TD>
<P>7D: None</P>
</TD>
<TD>
<P>10D:None</P>
</TD>
</TR>
<TR>
<TD>
<P>Fluoroquinolone 10days vs 14 days</P>
</TD>
<TD>
<P>
<LINK REF="STD-Alam-1995-BGD" TYPE="STUDY">Alam 1995 BGD</LINK>
</P>
</TD>
<TD>
<P>10D: Eleven events occurred in four patients namely headache, malaise, dizziness, insomnia, skin rash, pruritus, lethargy, weakness</P>
</TD>
<TD>
<P>14D: Eighteen events occurred in nine patients namely headache, malaise, abdominal pain, dizziness, nausea, oral mucosal pain, insomnia, photosensitivity, vomiting, vertigo, joint pain palpitation, restlessness.</P>
</TD>
<TD>
<P>10D: Moderate eosinophilia (5)</P>
</TD>
<TD>
<P>14D: Transient elevation of urea and creatinine (1)</P>
<P>Moderate eosinophilia (3)</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Number of participants with adverse event.</P>
<P>
<SUP>b</SUP>Hyperglycaemia grade 2 defined as non-fasting plasma glucose level between 161 and 250 mg/dL; hypoglycaemia grade 2 defined as non-fasting plasma glucose between 40 and 54 mg/dL</P>
<P>
<SUP>c</SUP>Leucopenia GRADE 1:WBC count 2000-2500/mm<SUP>3 </SUP>and GRADE 2: WBC count 1500-1999/mm<SUP>3</SUP>
</P>
<P>
<SUP>d</SUP>Total number with listed adverse events was four but no specific number for each group</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2011-02-24 00:04:17 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>